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Introduction
Worldwide, the highest priorities for tuberculosis control are comprehensive case finding 
and case holding. This is how patients are cured of tuberculosis. Besides saving the lives 
and the productivity of the individuals who have tuberculosis, society gains an additional 
benefit: when the patients are cured, transmission is interrupted. Case finding and case 
holding in the United States are monitored through the national surveillance system, 
which is explained in separate guidance from the Division of Tuberculosis Elimination 
(DTBE) of the Centers for Disease Control and Prevention (CDC).
The Aggregate Reports for Tuberculosis Program Evaluation (ARPEs), the subject of these 
instructions, help you to evaluate some other activities that have a different approach. In 
the United States, resources for tuberculosis control are available for going beyond curing 
cases by preventing them in the first place. Examples of prevention activities are contact 
tracing, targeted tuberculin testing, and treating latent tuberculosis infection (LTBI). These 
activities accelerate tuberculosis elimination, but they are labor intensive and offer mainly 
remote return for the investment. Therefore, careful evaluation of these activities is critical 
for assessing their validity in your setting. ARPEs are the national summary tools for 
confirming the merit of these activities for you. 
This manual will help you in three general tasks for ARPEs. The first task is collecting the 
best data that is feasible in your setting. The second is assembling the data, storing and 
combining the reports, and submitting them efficiently. The third is the most important: 
interpreting the results of your reports while considering their limitations. This final task 
creates the opportunities for improvements in your tuberculosis-prevention activities. 
Who can use ARPEs 
Tuberculosis control starts at the local level, at each health department and with each 
provider who cares for the patients who have tuberculosis or who are exposed to it. 
Everyone who undertakes prevention activities and contributes to the data collection 
should be empowered to understand the results of ARPEs and to respond with ideas for 
improvements. Within a local health department, the principal user of ARPEs is the 
tuberculosis program manager. Other workers in tuberculosis control, such as public 
health nurses, outreach workers, and physicians, should be kept aware of the results of 
ARPEs so that they can recognize their contribution to the overall efforts. 
Within a state health department, the principal users of ARPEs are the regional 
supervisors, the program manager, and the tuberculosis controller. The reports are a 
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communication tool—the common language for evaluating and coordinating tuberculosis-
prevention activities statewide. For policymakers, the reports are the documented 
summary of the work that has been accomplished and the improvements that are still 
needed. Epidemiologists also can take advantage of the reports, although they should be 
cautioned that the reports are not designed for epidemiological studies. 
At CDC in Atlanta, the principal users of ARPEs are the DTBE program consultants, who 
administrate the Federal tuberculosis cooperative agreements with states, large cities, and 
U. S. Trust Territories and Protectorates. The DTBE program consultants use ARPEs to 
study program operations and progress toward the national objectives. DTBE as a whole 
uses the national ARPE results as documentation of progress toward program objectives 
and as a corroboration of nationwide funding needs. 
Who should use this manual 
If you generate or collect ARPE data, you should use this manual as a reference for 
defining these data. Also, if you need to assemble, submit, or interpret ARPEs, you will 
find useful hints in this guide. 
At workshops, DTBE trains state ARPEs coordinators, and these coordinators should refer 
to this manual as a refresher or as a template for their own training workshops. The 
manual also can be used as stand-alone instructions for persons who are learning about 
ARPEs on their own or who need an explanation of the reporting instructions. 
Administrative structure of tuberculosis control in the United States 
Authority for tuberculosis control in the United States rests with state governments; some 
states devolve authority to local jurisdictions, such as districts, counties, townships, or 
cities. Public health officials are responsible for certain actions, which include gathering 
information about selected hazards and diseases and taking action to protect their citizens 
from these conditions. 
With few exceptions, CDC does not have the authority to undertake public health 
activities directly unless it is invited to act on the behalf of a state or other jurisdiction. In 
its usual role, DTBE facilitates tuberculosis control by monitoring epidemiology, 
formulating strategy, offering consultation, promulgating guidance, and disbursing funds. 
Other components of CDC contribute to epidemiologic response, program development, 
laboratory services, training, and tuberculosis screening of international migrants. 
Most CDC funding for tuberculosis control is distributed through cooperative 
agreements, a non-contractual mechanism. DTBE and the local or state health jurisdiction 
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set expectations for working together on the shared tasks of tuberculosis
control. The health jurisdiction is obliged to carry out recipient activities that are outlined 
in the agreement—reporting with ARPEs is one of these recipient activities. 
Federal approval for CDC to collect ARPEs 
The U.S. Office of Management and Budget (OMB) approved a CDC application to collect 
and use ARPEs under OMB #0920-0457. OMB requires renewal of this approval every 3 
years. CDC must seek additional OMB approval, subject to a public comment period, for 
any ARPEs amendments. Respondents have the option of commenting to OMB about the 
reports at any time. Please see the report form for instructions on how to do this. 
Under the OMB approval, DTBE may request, collect, and use ARPEs from public health 
officials for the jurisdictions that receive federal tuberculosis cooperative agreements. 
ARPEs are stipulated in the cooperative agreements, but the reports are classified as 
voluntary/optional. Nonetheless, DTBE interprets a failure to submit ARPEs as evidence 
of potential program problems, possibly caused by insufficient resources or unbalanced 
priorities.
Strategies for finding and treating latent tuberculosis infection 
Experienced tuberculosis controllers are keenly aware of the discrepancies between the 
theory and the reality of finding and treating latent tuberculosis infection (LTBI). 
Although the guidelines about LTBI appear to be straightforward on the surface, in truth 
the tasks are challenging, and efficiency and effectiveness are difficult to achieve. In this 
section, we review the general principles that influence the success of your prevention 
activities.
The success of your prevention activities is governed by three elements that we all need to 
balance simultaneously in order to have successful public health interventions. These 
elements are: (1) finding and accurately diagnosing LTBI, (2) determining the urgency of 
treatment, and (3) completely treating the patients who have LTBI. Problems in any of 
these three areas will detract from the success of your activities. For example, if you start a 
project that finds dozens of at-risk patients who have LTBI but none of the patients start or 
complete treatment, the project does not contribute to tuberculosis prevention. ARPEs 
give you a broad overview that helps you to find problems and to strike a balance among 
the three elements. 
Finding and accurately diagnosing LTBI 
Finding and accurately diagnosing LTBI depends on the prevalence rate of LTBI in the 
population that is under consideration. The prevalence rate refers to how common LTBI is, 
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and it is a population characteristic that reflects the tuberculosis history of the population. 
The prevalence rate controls how many infected individuals you will discover by testing. 
This is your yield of LTBI. The minimum prevalence rate for a successful strategy is 
unknown, but you need to take a critical look at the balance of the three elements if you 
are testing in a population having an LTBI prevalence rate less than 10 percent. 
The LTBI prevalence rate also influences the accuracy of the tuberculin skin test.1 This is 
because the predictive value of a positive test result depends on the prevalence rate. When 
the prevalence rate is low, the predictive value of a positive result is also low. For 
example, when the LTBI prevalence rate falls below 10 percent, most of the patients with 
positive results from the skin test actually will have false-positive results. Therefore, when 
the prevalence rate of LTBI is low, most of the patients who are being treated for LTBI are 
actually not at risk for tuberculosis because they do not even have LTBI. This is wasteful of 
resources and possibly hazardous to the patients. 
Determining the urgency of treatment 
The urgency of treatment for LTBI patients depends on how likely they are to get sick with 
active tuberculosis. If the likelihood of active tuberculosis is high, then the urgency of 
treatment is high. One example is the patients who have been recently exposed to 
contagious tuberculosis (i.e., contacts). We also worry about patients who have medical 
problems that change their immune capacity: co-infection with the human 
immunodeficiency virus (HIV) is a very serious example. 
The urgency of treatment is relative. No one can predict which patients with LTBI are 
going to become sick with tuberculosis. The risk of tuberculosis might be high, medium, 
or low, and this determines the urgency of treatment. The current medical condition and 
the tuberculosis exposure history are factors to consider when determining the urgency of 
treatment for an individual. The final decision to treat rests with the individual patient 
and the prescribing provider. 
Sometimes the urgency of treatment offsets the concerns about testing a population with a 
low LTBI prevalence rate. For example, infants who might have been exposed to 
contagious tuberculosis should be tested even if the exposure was minimal because
infection could be very dangerous for them. In this example, the concern about the danger 
of tuberculosis overrides the low yield of testing. 
1 Recent developments in blood tests for infection with M. tuberculosis offer the possibility 
that they might perform better than the tuberculin skin test. DTBE will send an 
amendment to these ARPEs instructions if these blood tests are implemented and if they 
substantially alter the way that contact investigations and targeted testing are done. 
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Completely treating the patients who have LTBI 
Finally, LTBI patients who are good treatment candidates must start and complete 
treatment if prevention activities are to be effective. Activities for finding LTBI must be 
followed by decisions about treating patients (based on the urgency of treatment) and 
monitoring them for adverse effects and completion of therapy. This does not mean that 
every single instance of LTBI should be managed with medical treatment. It does mean 
that activities for finding LTBI should be undertaken with (1) a goal of finding patients 
who are most likely to benefit form treatment and (2) a strategy and support systems for 
getting patients all the way through treatment. 
Targeted testing 
You start targeted testing by choosing a population that has either a high prevalence rate 
of LTBI or a high risk of disease if infection is present. Having both conditions present 
gives maximal potential public health impact. The results of targeted testing are reported 
in the ARPE: Targeted Testing and Treatment for Latent Tuberculosis Infection. 
Your activities for targeted testing often will be adapted to fit the population you have 
chosen. When the individuals can be tested as a group, your activities take the form of a 
project. For example, you might go to a nursing home twice a year to test any new 
residents.
Under different circumstances, you might be testing some individuals who are at risk for 
tuberculosis and who come to your clinic, perhaps for reasons besides tuberculosis. For 
example, you might test persons who attend prenatal clinic at your health department if 
they come from countries where tuberculosis is common. These activities are still targeted 
testing because you are selecting the individuals who should be tested. However, these 
activities are not a project, because you have not set up a system for finding and reaching 
the populations at risk for tuberculosis. The distinction is subtle, and it does not always 
have practical significance. When the distinction is vague for your situation, you and your 
colleagues should make a decision about how to count the data and then follow that 
decision consistently. 
Contact investigations 
One very special type of targeted testing, and the highest priority, is a contact 
investigation. In a contact investigation, you test a population that you selected because of 
recent exposure to a contagious tuberculosis patient. The prevalence rate of LTBI for 
contacts is likely to be greater than average. Also, the recent exposure means that some 
contacts might be sick already with tuberculosis disease at the time that they are 
evaluated, and the contacts who have LTBI are at a relatively high risk for tuberculosis 
5  
disease. The structure and the issues of a contact investigation are so distinctive that they 
have to be evaluated as a specific system of activities, separate from other types of
targeted testing. The results of contact investigations are reported in the ARPE: Contact 
Follow-up and Treatment. 
Accountability is different from responsibility 
Health departments have responsibilities to protect their communities from certain threats 
to public health, as laid out in state and local laws. One of these threats is tuberculosis. 
Health departments also have general responsibilities to evaluate their effectiveness and to 
account for their work. ARPEs are accounting tools designed for evaluating selected 
prevention activities. ARPEs help you to account for key processes that are important for 
monitoring tuberculosis-prevention activities. 
You might feel reluctant to report on activities that make your program or your health 
department appear unsuccessful. Most of us would prefer to gather and classify data in a 
way that puts the emphasis on success. However, ARPEs cannot serve you unless they 
realistically reflect what happens with your activities. The only way to evaluate the 
prevention activities of your tuberculosis program is to account for the processes as 
accurately and consistently as possible. 
Some of the events that appear in ARPEs are beyond your immediate control. Example: a 
patient who has LTBI after recent exposure seeks advice from a healthcare provider who 
advises against treatment for LTBI. This is problematic for tuberculosis control. You are 
responsible to count this event, even though you were not responsible for what happened. 
In this instance, the health department is accountable for an event but not immediately 
responsible for it. At least, you learned that you need to build a collaboration with the 
healthcare provider who does not like to treat LTBI, but in this instance, the purpose of 
reporting is more to keep track of important outcomes and less to measure the 
performance of the health department. 
Structure of the ARPE Forms and Data 
The report forms follow a common-sense flow of information from left to right and from 
top to bottom. The activities with higher priority are grouped in the left-most columns on 
each of the two forms. The sequence of outcomes flows from top to bottom, with the initial 
process steps recorded in the top rows of both forms and the later steps listed in lower 
rows. The bottom-line results for both reports are the absolute number and the percentage 
of LTBI patients who complete treatment for their infection. 
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You begin the ARPE reporting process with data for individuals and events, and you 
finish with the data in an aggregate format. This means that the data are lumped together, 
and you cannot study any factors separately without returning to the original records for 
those individuals and events. Sometimes you can overcome the limitations of aggregate 
data by keeping separate records and sub-reports that you predefine in accordance with 
your needs. This refinement is described in “How to Interpret and Use the ARPE Results” 
on page 99. 
At the bottom of the reports, the calculated indices are listed. These indices are the rates 
and ratios that are calculated from the aggregate data, and they are an aid in comparing 
overall results with program objectives. 
Data required for these reports 
The specific minimum data elements that are required for ARPEs are listed in appendix 2 
for the contact report and in appendix 4 for the targeted-testing report. With these data, 
you have all the information for filing representative reports and monitoring the 
prevention activities of your program. 
For the contact reports, the data about source cases, that is, the tuberculosis cases that are 
at the center of contact investigations, are coded in the Report of a Verified Case of 
Tuberculosis (RVCT) in tuberculosis registries. Case registers are different from place to 
place, and you need to be familiar with your registry so that you can assemble essential 
data (unless automated links between case and contact data are available to you already). 
Data about contacts are managed differently from site to site in accordance with local and 
state program needs. Routine contact-investigation flow sheets (i.e., tables showing the 
outcome of contacts when they are listed and evaluated) usually include all the data 
needed for the contact reports except for the treatment completion data and the reasons 
treatment is not completed. For contacts numbering fewer than approximately 200, 
original medical records are a feasible option for retrieving contact data, but data for 
greater numbers of contacts can be cumbersome when original medical records are the 
main source. For greater numbers of contacts, you probably need an automated tracking 
system, which also can help in many other ways. 
Data for targeted testing are similar to data for contact investigations, but the absolute 
numbers of patients who are included in counts could be greater. Therefore, you need as 
much simplification and automation as possible to improve accuracy, efficiency, and 
feasibility.
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For the targeted-testing report, the risk classification of patients who have LTBI is the most 
distinctive feature. Although the data are collapsed into two general risk categories (i.e., 
medical risks and population risks), each of these categories includes multiple conditions. 
Therefore, you might prefer a data worksheet that has check boxes related to the 
conditions listed on pages 21 and 22. 
ARPEs are relatively simple tools, and they might not encompass all the data that you 
need. You and your colleagues might determine that more detailed information is needed 
for assessing certain aspects of your prevention activities. DTBE encourages collection of 
additional data for state and local program purposes if (1) the extra effort that you invest 
in data collection is balanced by the potential value of the data and (2) the results of the 
evaluation ultimately are used to improve the effectiveness and efficiency of prevention 
activities. As with any data collection, the challenge is to validate the extra work by 
showing a benefit for the program. The collection of additional data should be planned 
carefully with clear goals for program evaluation and improvement. Any of your 
personnel who are responsible for gathering or generating the data should be consulted 
about proposals for data elements that go beyond the minimum required for ARPEs. 
How to classify data for these reports: motivation, uniformity, and 
coordinators
You will discover that the Basic Instructions for the Aggregate Reports for Tuberculosis 
Program Evaluation (pp. 13–26) do not include all possible situations and outcomes that 
you encounter. This is because the instructions and the reports were designed for 
simplicity and for ordinary day-to-day operations. Simple reports such as these cannot 
accommodate all the details of either your tuberculosis program activities or your 
individual patients. 
The classification of most patients and most outcomes is straightforward after you are 
comfortable with the reporting instructions. Still, you will come across events that are not 
covered by the reporting instructions. For these situations, someone will need to move 
beyond the confusion and decide how to count the patients or events—this might seem
arbitrary at first. In this section, we outline some general concepts to make this process 
more transparent. 
By stepping back from the details, you often can answer your own questions by asking 
yourself and your colleagues, “Why are we collecting these data in the first place? What 
do the data mean? How will the results help us describe our program activities?” These 
are the justifications for collecting the data, and in most instances they will help resolve a 
dilemma.
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On the other hand, the reason for having definitions in the first place is to explain how the 
data elements (e.g., patients, results, outcomes) should be classified. The goal is to have 
everyone in your program and in other programs classify specific data elements 
identically. This is uniformity, and uniformity should be guarded when making 
adjustments in the definitions for local purposes. ARPEs, the same as other data collection 
tools, require a careful, consistent balance between flexibility and uniformity. 
ARPE coordinators should supervise the uniformity of reporting. For most jurisdictions, 
the coordinator is a member of the state tuberculosis program who has attended one of the 
ARPE workshops sponsored by DTBE. If local jurisdictions designate their own ARPE 
coordinators, then the state tuberculosis program should link the local coordinators with 
each other and with the state program so that everyone contributes to uniformity. The 
administrative details of how the coordinators work together should be determined. 
Coordinators can monitor uniformity through routine communication with program 
personnel who are engaged in prevention activities and data collection. Keeping track of 
questions and answers in a simple log book allows a quick summary of the common 
problems plus a list of rare problems for future reference. This method makes the entire 
ARPEs process smoother. 
At the national level, DTBE seeks overall uniformity of reporting. To this end, the DTBE 
program consultants work with ARPE coordinators in each state program. When state 
coordinators are considering variations on the standard definitions, they should contact 
their DTBE program consultant for a national perspective. The program consultants can 
offer helpful suggestions, and they can share solutions that the ARPE coordinators in 
other states have discovered. 
The Basic Instructions and Definitions for Reporting 
This section contains copies of the basic definitions for both reports, as approved by the
U. S. Office of Management and Budget under package #0920-0457. CDC cannot change 
these instructions without an amendment approved by the Office of Management and 
Budget, which requires an extensive process of public comment and official review. 
However, individual jurisdictions within the U. S. Trust Territories and Protectorates may 
adjust or expand the definitions to accommodate local or regional needs, as described in 
the previous section. Any changes to the definitions should be consistent with the 
intentions of the report, and if the revised definitions are printed for local use, they should 
be labeled as different from the national ones so that they are not misinterpreted.  
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Proposed changes should be discussed and coordinated with the corresponding program 
consultant, Field Services and Evaluation Branch, DTBE.2
The instructions and definitions generally follow the order of elements in the reports, from 
top to bottom and left to right. The instructions for the two reports are as similar as 
possible. However, the instructions are slightly different between the two reports in a few 
ways because contact investigations and targeted testing are different from each other. 
These differences are explained in Extended Definitions: Understanding the Concepts.
In Extended Definitions: Understanding the Concepts (see page 26), which is the section 
right after The Basic Instructions and Definitions for Reporting, the instructions and 
definitions are repeated and expanded one point at a time. Extended Definitions explains 
the definitions in a way that is helpful for meeting challenges of unusual situations. 
2 The TB controllers of each cooperative agreement site are familiar with the program 
consultants and can facilitate communications. 
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Basic Instructions for the Aggregate Reports for Tuberculosis Program Evaluation: 
Follow-up and Treatment for Contacts to Tuberculosis Cases 
Note: The instructions for this report are not a substitute for guidelines about TB 
diagnosis, treatment, or control. Any contradictions between the implied content of these 
instructions and the health department’s policies and practices should be discussed, 
according to the context, with a consultant from the local or state TB program or the 
Division of Tuberculosis Elimination (DTBE). 
This report is an annual summary of the core activities of eliciting and evaluating contacts 
to TB cases and treating the contacts who have LTBI. The health department also may 
include results that are provided by partner or contract healthcare entities if the health 
department has assurance that the data are satisfactory. Generally, this means that the 
other entities have cooperated with the health department in confirming the results from 
contact evaluations and in managing the treatment of contacts who have LTBI. 
For two special circumstances, contact-related data can be reported in the other aggregate 
report: Targeted Testing and Treatment for Latent Tuberculosis Infection. 
1. If a health department is compelled to evaluate contacts who probably have not 
been exposed to the index case of TB that is under investigation, the results of this 
excess testing may be reported in the targeted-testing report instead of in the 
contact report. Then, the testing category is likely to be Administrative in Part I of 
the targeted-testing report unless some of the individuals have TB risk factors, and 
then these individuals usually will be grouped under Targeted Testing and 
Individual.
2. If the contacts having previous records of TB disease (now inactive) or latent 
infection are treated for LTBI, the data about treatment can be recorded in Part III. 
Referral Counts of the targeted-testing report. The contact report does not have 
categories to record the diagnosis and treatment of these contacts. However, these 
contacts are still included in the counts for the Number of Contacts and Evaluated
(see below) in the contact report. 
Cohort Year. The data are accumulated into a cohort over 1 calendar year. The contacts are 
assigned to the same count-year as the TB cases being investigated. A person who is 
included in more than one contact investigation in a year should be counted for each 
event, but exposures to multiple TB cases that are connected to a single contact 
investigation should be counted as one event only. 
Closure Date for Follow-up. A preliminary report should be tabulated by August 15 
following the cohort year (i.e., before all the completion-of-therapy data are available) and, 
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depending on the context, shared with the program consultant at the state health 
department or DTBE. The final results, including the completion-of-therapy data, are due 
at DTBE by August 15, 1 year later. 
Total TB Cases Reported. This is the surveillance result for TB morbidity for the count-
year.
Part I. Cases and Contacts 
Cases for Investigation. The TB cases, their contacts, and all the subsequent results are 
grouped into three categorical columns according to the types of TB cases that led to the 
contact investigations. 
Sputum smear +. All of the following criteria must be met for counting cases under this 
category:
1. Inclusion in the overall surveillance count, 
2. a disease site in the respiratory system including the airways, and 
3. a positive acid-fast bacilli (AFB) sputum-smear result, whether or not any culture 
result is positive. 
Cases should be counted under this category even if contacts could not be elicited for any 
reason (e.g., the patient left the area or died before an interview could be done). 
Sputum smear - culture +. All of the following criteria must be met for counting cases 
under this category: 
1. Inclusion in the overall surveillance count, 
2. a disease site in the respiratory system including the airways, 
3. negative AFB sputum-smear results, and 
4. sputum culture result positive for Mycobacterium tuberculosis. 
Cases should be counted under this category even if contacts could not be elicited for any 
reason.
Other. This category includes contact investigations that were done because of any 
circumstances not included in the other two categories. Example: Associate-contact or 
source-case investigations done because of TB in a child. The number of contacts is 
counted, but the number of cases for investigation is not. 
Cases with No Contacts. Cases that are counted under one of the first two columns 
(Sputum smear + or Sputum smear - culture +, see above) are counted here if no contacts 
were elicited, regardless of the reason that contacts were not elicited. 
Number of Contacts. All of the following criteria must be met for counting a person who 
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has been exposed to TB as a contact for this report: 
1. The health department believes that the person was exposed, warranting an 
evaluation for TB disease or latent infection; 
2. the exposure was caused by a TB case that was counted by the reporting 
jurisdiction; and 
3. enough identifying and locating information is available for a reasonable 
opportunity to contact the person, regardless of whether the person is in the 
jurisdiction of the health department. 
The follow-up of out-of-jurisdiction contacts usually requires the assistance of the health 
departments in those other jurisdictions. 
Note: Persons should not be included in the contact count if they do not need to be 
evaluated as judged by the health department. For example, this happens when the model 
of concentric circles is used. After evaluating some of the contacts who had more exposure 
(i.e., close contacts), the health department determines that the other contacts who had less 
exposure do not need to be evaluated. The remaining contacts should not be included in 
the reported count of contacts because the health department believes that an evaluation is 
not warranted for them. 
Note: Sometimes contact investigations are done because of a suspected TB case before the 
diagnosis of TB is confirmed. If TB is excluded (i.e., ruled out), then the persons who 
initially were listed as contacts should still be counted as contacts, although a TB case is 
not counted. These persons and their test results are reported under the case category 
Other, which does not include a TB case denominator. 
Note: The contacts that are associated with TB cases in other jurisdictions are not counted 
by the jurisdiction with the contacts; they are counted by the jurisdictions that are 
reporting the TB cases. 
Evaluated. This is the count of contacts who have been tested and examined, as part of a 
contact investigation, to the point where a final determination can be made about two of 
the potential diagnostic outcomes: LTBI or TB disease (see below for reporting definitions 
of these outcomes). Most contacts will receive a tuberculin skin test unless their medical 
history indicates otherwise (see following note). Contacts who receive a skin test should 
not be counted under Evaluated until the skin test has been read. Contacts who need a 
second skin test because of recently ended exposure should not be counted under 
Evaluated until the second skin test has been read. Contacts who have a positive skin test 
result should not be counted under Evaluated until active TB disease has been excluded 
by any further tests as indicated. (Skin tests with other antigens, for cutaneous anergy, 
should not be considered for classifying outcomes for this report.) 
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Note about contacts having prior TB disease or latent infection: This contact report only 
includes the contact evaluation results that are determined through contact investigations. 
Contacts who already have known TB disease or latent infection already diagnosed before 
they are investigated are counted under Number of Contacts, but the diagnostic outcomes 
are not counted in the contact report. Generally, these contacts can be counted under 
Evaluated even if further tests and examinations are not done because enough history is 
already available to determine their TB status and therefore they have been evaluated in 
the context of the contact investigation. If such contacts will be treated, then the treatment 
should be counted only in the other aggregate report, Targeted Testing and Treatment for 
Tuberculosis Infection, in the section headed Part III. Referral Counts. (These contacts are 
counted on both reports. They are counted on this report as contacts and then on the other 
form as referrals for treatment.) 
TB Disease. Contacts should be counted under this outcome if they have TB disease (i.e., 
active TB) initially discovered as part of the contact investigation. Cases should fit the 
CDC RVCT definition, and they should be referred for morbidity surveillance according to 
the reporting requirements. Active TB that develops after latent infection was diagnosed 
during the contact investigation should not be counted here. Old TB cases that have been 
treated already or that have spontaneously healed, and TB disease discovered 
coincidentally (i.e., not because of the contact investigation), should not be counted in this 
category. (These instructions differ slightly from the ones for the report of Targeted 
Testing and Treatment for Latent Tuberculosis Infection.) 
Note about DNA fingerprinting [i.e., restriction fragment length polymorphism (RFLP) or 
strain typing]: The results of DNA fingerprinting of M. tuberculosis isolates should be 
ignored for counting contacts under TB Disease, even if the fingerprinting results 
disprove a transmission link. The count for TB Disease should be tabulated for this report 
as though DNA fingerprinting were unavailable. 
LTBI. This is the count of contacts who have LTBI (not TB disease) diagnosed because of 
current contact investigations. Both of the following criteria are required: 
1. A positive result of a current tuberculin skin test (as interpreted according to 
national, state, or local diagnostic guidelines) and 
2. the exclusion of active TB disease through further tests or examinations. 
Latent TB infections that have been diagnosed coincidentally or previous to the contact 
investigation should be not be included in this count. 
Note about anergy: In determining whether to count a contact under LTBI, only results 
from a tuberculin test should be considered, not from skin tests with other antigens (i.e., 
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control antigens or an anergy panel). However, if a contact with a negative tuberculin skin 
test result is being treated with a full-course regimen for suspected LTBI, then that contact 
should be counted under LTBI.
Started Treatment. A contact who has LTBI is counted in this category after the first dose 
of a planned full-treatment course for LTBI. The determination of whether the first dose 
has been taken is based on the best available information, which is often the contact’s 
statement. If a contact is lost to follow-up after treatment was prescribed and information 
is unavailable about whether any medication was taken, then treatment can be considered 
started if the contact picked up the medicine from a clinic or pharmacy. 
Note about window-period treatment: Contacts who are receiving treatment pending a 
second tuberculin skin test (i.e., window-period treatment) should not be counted under 
Started Treatment unless LTBI is diagnosed finally and counted for the report. 
Completed Treatment. (Note: This category is based partly on an arbitrary, operational 
definition of completion. It might not be equivalent to an adequate course of therapy.) The 
following criteria are required for counting under this category: 
1. The prescribing provider, believing that an adequate regimen has been received, 
discontinues treatment; 
2. the contact has taken at least 80 percent of the prescribed doses in the selected 
regimen; and 
3. the treatment is finished within a period of 150 percent of the selected duration of 
therapy.
The determination about whether the definition is met is made from the best available 
information, which is generally the provider’s records and the contact’s statements about 
adherence to treatment. 
Reasons Treatment Not Completed: This section catalogues some general reasons that the 
treatment for LTBI is not completed. 
Death. Contacts who were receiving treatment on schedule but who had treatment 
interrupted by death before completion are counted under this category. (Note: Because of 
the seriousness of this outcome and the unreliability of anecdotal reports, a verification 
check of any deaths is helpful for accuracy in reporting.) 
Contact Moved (follow-up unknown). Contacts who do not complete treatment because 
they have moved or migrated from the jurisdiction of the health department should be 
counted in this category if follow-up information is unavailable. However, if the health 
department receives specific follow-up from a receiving jurisdiction (e.g., Completed
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Treatment or Patient is Lost to Follow-up), then the outcome should be reclassified 
accordingly. 
Active TB Developed. If a contact who still is receiving treatment for LTBI has active TB 
that qualifies as a case under the standard surveillance definition (i.e., RVCT), then the 
outcome is counted in this category. However, if the treatment regimen already has been 
stopped before active TB develops because of completion or any other reason, then the 
outcome should not be changed to Active TB Developed.
Adverse Effect of Medicine. If contacts do not complete treatment because of an adverse 
effect (including drug-drug or drug-food interactions) of the anti-TB medication, they 
should be counted in this group if a healthcare provider documents the problem and 
determines that the medicine should be discontinued. If a contact stops taking the 
medicine because of an adverse effect but a provider has not recommended the 
discontinuation, then the reason for stopping treatment should be counted as Contact
Chose to Stop.
Contact Chose to Stop. Contacts should be counted in this category if they decide to stop 
taking their medicine before they have finished their regimen and a healthcare provider 
has not determined that the medicine should be discontinued for a medical reason. 
Contact is Lost to Follow-up. Contacts whose treatment status at the anticipated end of 
the treatment regimen is incomplete or indeterminate because the health department 
cannot locate them for determining a more specific outcome should be counted in this 
category.
Provider Decision. If a healthcare provider determines that the treatment for LTBI should 
be stopped because of concerns about the benefits, the safety, or the practicality of 
treatment (e.g., a contact has such erratic attendance at the clinic that the adequacy and the 
safety of the treatment cannot be monitored), then this is the reported reason. 
Part II. Evaluation Indices.
This part of the contact follow-up report is the summary statistics that are calculated from 
the aggregate data entered into Part I of the report. The indices are calculated 
automatically and presented as either ratios or percentages by TIMS. The formulae are 
shown in the paper-copy table to show the source figures for the calculations. 
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Basic Instructions for the Aggregate Reports for Tuberculosis Program Evaluation: 
Targeted Testing and Treatment for Latent Tuberculosis Infection 
Note: The instructions for this report are not a substitute for guidelines about TB 
diagnosis, treatment, or control. Any contradictions between the implied content of these 
instructions and the health department’s policies and practices should be discussed, 
according to the context, with a consultant from the local or state TB program or the 
Division of Tuberculosis Elimination (DTBE). 
This report is an annual summary of activities to find and treat LTBI through targeted and 
other testing. Testing means diagnostic tests done to find mainly LTBI. Testing and follow-
up of contacts, however, are not included in this report. Active-case finding (i.e., seeking 
mainly TB disease) should not be included in this report, either, unless the individuals also 
are being tested for LTBI. 
At its discretion, the health department may include testing activities that are carried out 
by partner or contract entities on its behalf if the health department has assurance that the 
data are satisfactory. (Generally, this means that the health department has contributed to 
the work, through training, consultation, supplies, funding, or direct assistance by health 
department personnel, and the quality of the testing, treatment, and data are monitored 
routinely and meet the expectations of the health department.) 
Systematic skin testing that is done partly for infection control and surveillance purposes 
(e.g., the annual testing of healthcare workers) generally should not be included in this 
report unless the health department determines that this testing has mixed features of 
both targeted testing and surveillance. If latently TB-infected individuals are diagnosed 
during these other types of testing programs and referred to the health department for 
other testing and for treatment, they should be counted under the second half of this 
report, Referral Counts.
The second half of this report, Referral Counts, mainly records the treatment of LTBI 
when the denominator data (i.e., the number of persons tested) are unavailable or 
inappropriate for this report. Referral Counts sums up the follow-up of persons who are 
referred to the health department because of possible latent TB infections. At its discretion, 
the health department also may include the data generated by other entities that carry out 
these same activities on its behalf if the health department somehow assists with the care 
of the patients (e.g., providing medication or monitoring adherence) and participates in 
collecting the data. 
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Cohort Year. The data are accumulated into a cohort over 1 calendar year. Depending on  
the circumstances, the year for entering an individual patient into a cohort is the date of  
registration at the health department or the date that an individual is tested, listed for  
testing, or at least sought for testing as part of a target group. A person who is included in  
testing activities more than once in a year should be counted for each event.  
Closure Date for Follow-up. A preliminary report should be tabulated by August 15  
following the cohort year (i.e., before all the completion-of-therapy data are available) and,  
depending on the context, shared with the program consultant at the state health  
department or DTBE. The final results, including the completion-of-therapy data, are due  
at DTBE by August 15, 1 year later.  
Part I. Testing Counts.  
This section includes the count of persons who are sought or enrolled for testing and the 
outcomes of testing and treatment.  
Testing Formats. The selection of a testing category [Targeted Testing (Project or  
Individual), or Administrative] is determined by the structure of the testing activities and  
the public health intentions. The data in Part I flow down the columns under these  
categories.  
Targeted Testing. This is the sum of testing projects or testing of individuals, with the  
testing focused on specific groups or individuals who should be tested for LTBI as per  
current guidelines. The groups or individuals should be at an increased risk for TB  
because of a high prevalence of latent infection, ongoing TB transmission, or a high  
prevalence of concurrent medical conditions that promote the progression of LTBI to  
active TB disease.  
Project. Usually, testing projects for groups are done at sites outside of the health  
department, as determined by the convenience or needs of the groups being tested. Such  
testing projects might be done only once during a limited period, or they can be recurrent  
(e.g., annual testing at a correctional facility) or ongoing (e.g., testing of all new admissions  
to a homeless shelter).  
Note: The targeted-testing projects that are supported by dedicated funding through a TB  
cooperative agreement should be included in the sum for the Project category. Separate  
counts for each project should be retained by the funding recipient for inclusion in the  
annual narrative for the TB cooperative agreement.  
Individual. This is the sum of testing that is done, one person at a time or group-wise but  
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outside of testing projects, when testing is in accordance with national, state, or local 
guidelines for selecting persons who are at risk for TB and who are expected to be 
candidates for treatment if they have LTBI. Often the testing is done at a health 
department clinic. 
Administrative. This is the sum of testing for LTBI that is done when the testing is a low 
public health priority because the tested persons or groups are not at risk for TB and might 
not even be candidates for treatment of LTBI. Often this testing is required by regulations 
or policies created outside of the TB control program. (Persons who are tested for 
administrative reasons should be counted under Targeted Testing and Individuals if the 
health department determines that they would fit into a TB risk category.) 
Note about overextended contact investigations: As part of a contact investigation, 
persons who are tested because of mass screening following minimal or no TB exposure 
also can be counted in the report for targeted testing (usually under Administrative)
instead of in the report for contact follow-up, at the discretion of the health department. 
Sought, Enlisted, or Registered. For Project under Targeted Testing, this is the count of 
individuals who should be tested as part of the project, whether or not they can be 
evaluated (e.g., persons who decline testing would still be counted here because they were 
sought for testing). For the other testing formats, this is the count of persons who are listed 
or registered by the health department for testing, whether or not any further testing or 
evaluation is done. 
Evaluated. This is the count of persons who have been evaluated to the point where a 
determination can be made about these outcomes: LTBI or TB disease (see the outcome 
categories, below). Most persons who are counted under Evaluated receive a tuberculin 
skin test. For persons who have a record of disease or latent infection that already has 
been diagnosed, a skin test and other examinations might not be needed and the outcome 
can be classified; therefore they are counted under Evaluated. Persons who receive a skin 
test are not counted under Evaluated until the test has been read. Persons who have a 
positive skin test result are not counted under Evaluated until active TB disease has been 
excluded by any further tests and examinations as indicated. (Tests for cutaneous anergy 
should not be considered for classifying outcomes for this report.) 
TB Disease. Persons are counted under this outcome if they have TB disease (i.e., active 
TB) at the time of the evaluation in the testing process, even if the illness has been 
previously diagnosed and reported and whether or not the person is undergoing 
treatment at the time of the evaluation. Such cases should fit the CDC RVCT definition, 
and these cases should be referred for morbidity surveillance according to the local 
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reporting requirements. Old, resolved TB cases that have been treated and cured already 
or that have spontaneously healed should be counted under LTBI even if a skin test is not 
done. (Note: In the other report, Contact Follow-up, previous TB disease is not counted as 
an evaluation outcome.) 
LTBI. Persons are counted under this outcome if they have LTBI but not TB disease. LTBI 
is determined by the result of a current tuberculin skin test (as interpreted according to 
national, state, or local diagnostic guidelines); by a known LTBI that already has been 
diagnosed from a previous skin test result, whether or not treatment has been taken; or by 
resolved prior TB disease whether or not it has been treated. Persons who are still 
receiving anti-TB medication for a TB case should be counted under TB Disease. (Note: In 
the other report, Contact Follow-up, previously known LTBI is not counted as an 
evaluation outcome.) 
Note about anergy: In making a diagnosis of LTBI, only the results from tuberculin skin 
tests should be considered, not from skin tests with other antigens (i.e., control antigens, 
or an anergy panel). However, if persons with a negative tuberculin skin test result are to 
be treated for suspected LTBI, then they should be counted in this report as TB infected. 
LTBI, (sorted by risk). Under the Project and Individual formats of Targeted Testing, the 
persons who have LTBI are divided into categories according to TB risk factors. Every 
person who is counted as latently TB infected should be classified into one of these two 
categories: Medical Risk and Population Risk. Persons who have both a medical risk and 
a population risk should be counted under Medical Risk. Persons who have no known 
risks should be counted under Population Risk.
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Medical Risk. Latently TB-infected persons are counted under this category if they have a 
condition known to predispose to TB disease, usually a concurrent medical diagnosis (see 
box, below). The treatment of LTBI has increased urgency in this target category. 
Conditions that are counted under Medical Risk  
HIV infection  
Tuberculin skin test conversion  
Fibrotic lesions (on chest x-ray) consistent with old, healed TB  
Injection drug use  
Diabetes mellitus  
Prolonged high-dose corticosteroid therapy or other intensive  
immunosuppressive therapy  
Chronic renal failure  
Some hematologic disorders, such as leukemia or lymphoma  
Specific malignant neoplasms, such as carcinoma of the head or neck  
Weight at least 10 percent less than ideal body weight  
Pulmonary silicosis  
Gastrectomy or jejunoileal bypass  
Age < 5 years  
Recent exposure to TB  
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Population Risk. Latently TB-infected persons are counted under this category if they are 
members of socially or demographically defined groups known to have a high prevalence 
rate of TB infection or a high transmission rate (see box, below). 
Circumstances that are counted under Population Risk 
Residency or occupation in high-risk congregate settings:  
Prisons and jails  
 Healthcare facilities  
Nursing homes and long-term facilities for the elderly  
Shelters for homeless persons  
Birth in a country having a high prevalence or incidence of TB: Includes 
Immigrants
 Refugees 
Students
Some migrant workers 
Socioeconomic predictors of exposure:  
 Low income  
 Inner-city residence  
 Migrant labor  
Candidates for Treatment. Latently TB-infected persons are counted in this category if 
they should receive treatment according to the treatment guidelines in effect at the time. 
Counting under this category should be determined according to medical and 
epidemiological factors, even if treatment will not be prescribed because of other factors. 
Persons who are not candidates for treatment because of temporary conditions (e.g., 
treatment will be deferred because of pregnancy) should not be counted under this 
category, even if treatment is planned for the future. When the deferred treatment is 
given, it can be counted in Part III. Referral Counts. (Note: In the other report, Contact 
Follow-up, the Candidates for Treatment category is not included.) 
Started Treatment. A person who has LTBI is counted under this category after the first 
dose of a planned full-treatment course for LTBI. The determination of whether the first 
dose has been taken is based on the best available information, which is often the person’s  
statement. If a person is lost to follow-up after treatment was prescribed and information 
22  
is unavailable about whether any medication was taken, then treatment can be considered 
started if the medicine was picked up from a clinic or pharmacy. 
Completed Treatment. (Note: This category is based partly on an arbitrary definition of 
completion. It might not be equivalent to an adequate course of therapy.) A person is 
counted under this category (1) if the prescribing provider, believing that an adequate 
regimen has been received, discontinues treatment, and (2) if the person has taken at least 
80 percent of the prescribed doses in a therapy course within a period of 150 percent of the 
selected duration of therapy. The determination about whether the definition is met is 
made from the best available information, which is generally the provider’s records and 
the person’s statements. 
Reasons Treatment Not Completed: This section catalogues some general reasons that the 
treatment for LTBI is not completed. 
Death. Persons who were receiving treatment on schedule but who had treatment 
interrupted by death before completion are counted under this category. (Note: Because of 
the seriousness of this outcome and the unreliability of anecdotal reports, a verification of 
any deaths is helpful for accuracy in reporting.) 
Patient Moved (follow-up unknown). Persons who do not complete treatment because 
they have moved or migrated from the jurisdiction of the health department should be 
counted under this category when follow-up information is unavailable. However, if the 
health department receives specific follow-up (e.g., Completed Treatment or Lost to 
Follow-up) from a receiving jurisdiction, then the outcome should be counted 
accordingly. 
Active TB Developed. If a person who still is receiving treatment for LTBI has active TB 
that qualifies as a case under the standard surveillance definition (i.e., RVCT), then the 
outcome is counted in this category. However, if the treatment regimen already has been 
stopped before active TB develops because of completion or any other reason, then the 
outcome should not be changed to Active TB Developed.
Adverse Effect of Medicine. Persons who do not complete treatment because of adverse 
effects (including drug-drug or drug-food interactions) of anti-TB medications should be 
counted in this group if a healthcare provider documents the problem and determines that 
the medicine should be discontinued. If a person stops taking the medicine because of an 
adverse effect but a provider does not recommend the discontinuation, then the reason for 
stopping treatment should be counted as Patient Chose to Stop.
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Patient Chose to Stop. Persons who do not complete treatment should be counted in this 
category if they decide to stop taking their medicine before they have received a complete 
regimen and a healthcare provider has not determined that the medicine should be 
discontinued for a medical reason. 
Patient is Lost to Follow-up. Persons whose treatment status at the end of the expected 
treatment regimen is incomplete or indeterminate because the health department cannot 
locate them for determining a more specific outcome should be counted in this category. 
Provider Decision. If a healthcare provider determines that the treatment for LTBI should 
be stopped because of concerns about the benefits, the safety, or the practicality of 
treatment (e.g., a person has such erratic attendance at the clinic that the adequacy and the 
safety of the treatment cannot be monitored), then this is the reported reason. 
Part II. Evaluation Indices for Testing. 
This section of the report is the summary statistics that are calculated from the aggregate 
data entered into Part I of the report. The indices are calculated automatically and 
presented as percentages by TIMS. The formulae are shown in the paper-copy table to 
show the source figures for the calculations. 
Part III. Referral Counts. 
Persons are included in this section when they are being evaluated for treatment of LTBI, 
usually diagnosed with a positive tuberculin skin test result, and when they cannot be 
counted as part of the testing denominators in Part I of the report. Part III also includes 
the persons with LTBI who had their treatment delayed beyond a reporting period after 
they were evaluated and it includes certain contacts who cannot be counted under the 
treatment categories in the report of contact follow-up. 
Referred. This is the number of persons who are registered for the confirmation (and often 
treatment) of presumed LTBI, whether or not TB disease has been excluded already. 
TB Disease. As defined for Part I.  
LTBI. As defined for Part I.  
Candidates for Treatment. As defined for Part I.  
Started Treatment. As defined for Part I.  
Completed Treatment. As defined for Part I.  
Reasons Treatment Not Completed: All reasons as defined for Part I.  
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Part IV. Evaluation Indices for Referrals.  
This part is similar to Part II, except that rates for evaluation and infection are not  
included.  
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Extended Instructions and Definitions: Understanding the Concepts 
This section is designed for ARPE coordinators and others who need in-depth discussions 
of the instructions. Each item from the basic instructions is quoted (in small font type) and 
then is expanded to encompass more details, the underlying concepts are reviewed, and 
practical issues are discussed. This section will help you when you encounter complex 
situations that do not fit into ARPEs in any obvious way.
When you encounter complex situations, a single question can resolve many dilemmas: 
why are we collecting this data? Or, how are we planning to use this data? The data and 
the reports are designed to serve the tuberculosis control program. If the reporting process 
itself becomes disruptive because the data are difficult to classify and interpret, then the 
issues should be resolved quickly with concise, consistent solutions. 
Consistency is an important goal when making decisions about complex data. Consistency 
means that when a similar complex situation is encountered later, a similar process will be 
followed. (In contrast, uniformity means that a similar process is followed by your 
colleagues who are working in different settings.) Two methods will improve consistency: 
team work (i.e., consensus building) and record keeping. Team work builds a clearer 
perspective on difficult data. Record keeping, such as maintaining a reporting log book, 
provides a quick reference for reviewing both recurrent problems and the solutions that 
have been used previously. 
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Extended instructions: contact report 
Basic Instructions for the Aggregate Reports for   
Tuberculosis Program Evaluation:  
Follow-up and Treatment for Contacts to Tuberculosis Cases 
Note: The instructions for this report are not a substitute for guidelines about TB diagnosis, treatment, 
or control. Any contradictions between the implied content of these instructions and the health 
department’s policies and practices should be discussed, according to the context, with a consultant 
from the local or state TB program or the Division of Tuberculosis Elimination (DTBE). 
ARPEs are a tool for program evaluation. A potential hazard of these reports is that the 
reporting instructions and the data definitions might be misconstrued as treatment 
recommendations or program guidelines. The reporting instruction and the data 
definitions are derived from national guidelines and recommendations, but they are much 
simpler.
For example, the data definitions for completion of therapy in ARPEs specify the number 
of doses and the duration of treatment. However, when therapeutic decisions are under 
discussion for individual patients, treatment recommendations and medical judgment 
must be followed instead of ARPEs instructions. Under unexpected circumstances, the 
appropriate treatment decisions might cause a problem with reporting, but patient care is 
more important than these reporting definitions. 
In another example, the ARPE results for a certain contact investigation might suggest that 
too many contacts were evaluated, with a low yield. However, the decision about how far 
to extend a contact investigation should be based on judgment derived from experience 
and program guidelines and not on results in ARPEs. 
ARPEs are not capable of accommodating all the issues that must be considered for 
making programmatic decisions. The aim of ARPEs is general results, and the ARPE 
coordinators and the program managers have to recognize how unusual circumstances 
caused peculiar results in the reports. This is critical for taking advantage of the reports. 
State and local jurisdictions should consult with each other on the reports when questions 
arise. For example, the designated ARPE coordinator in the state tuberculosis control 
program might be responsible for tracking all ARPEs-related questions and responding to 
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them. At DTBE, the program consultants for each reporting area3 are the main point of 
contact for questions that are directed to the national tuberculosis program. They have 
available a range of public health specialists to assist them. 
The contact report is an annual summary of the core activities of eliciting and evaluating contacts to 
tuberculosis cases and treating the contacts who have LTBI. The health department also may include 
results that are provided by partner or contract healthcare entities if the health department has 
assurance that the data are satisfactory. Generally, this means that the other entities are cooperating 
with the health department in confirming the results from contact evaluations and in managing the 
treatment of contacts who have LTBI. 
Contact investigations are the second most important element in the U.S. general strategy 
for tuberculosis control. Contact investigations are a direct method for finding recent 
LTBI, and they also are probably the most efficient, productive method for active-case 
finding in the United States. 
In spite of these benefits, contact investigations present some of the biggest challenges that 
a tuberculosis program routinely encounters, and some investigations require an 
intensive, long-term investment of personnel and other scarce resources. Evaluation of 
these activities is important for validating the investigations. This is the purpose of the 
contact report. 
The contact report is completely unable to detect one very serious type of problem: long-
term consequences of incomplete contact investigations. If infected contacts are missed 
(this can happen because the contacts are not elicited in the first place or because contacts 
are listed but not found, evaluated, or started on treatment), then these contacts might 
have tuberculosis disease later on. This problem can be addressed with an integrated 
epidemiological investigation, which is separate from ARPEs. 
In many jurisdictions, some or even all contacts receive their medical evaluations and 
treatments through providers besides the health department. Examples of other providers 
are private physicians; health maintenance organizations; and comprehensive systems 
such as correctional settings, military bases, and hospitals. Collecting data from other 
providers is difficult to initiate, but you should pursue the data anyway. In some settings, 
the only source of information about contacts is outside of the health department. By 
seeking the data, you become acquainted with other providers in your jurisdiction, and 
they learn about the services provided by the health department. Working with other 
3For most jurisdictions, the state TB controller or the TB nursing consultant is the point of 
contact for communications with the DTBE program consultants. 
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providers gives you an opportunity to educate them about tuberculosis control policies 
and procedures, and you can participate in decisions for individual patients. 
For the contact report, you should regard ARPE data from providers outside of the health 
department as equivalent to data that you generate from your own patient care activities, 
although you can anticipate practical differences. Separate analyses of data from different 
sources might provide important information under certain circumstances.  For example, 
you could measure the completion of therapy for contacts who go to private medical 
providers and compare the rate with that of patients who start treatment at the health 
department.
Please note that the instructions on data from other sources are slightly different for the 
targeted-testing reports because the purposes of the data collection are different. 
For two special circumstances, contact-related data can be reported in the other aggregate report:  
Targeted Testing and Treatment for Latent TB Infection.  
1. If a health department is compelled to evaluate contacts who probably have not been exposed to 
the index case of TB that is under investigation, the results of this excess testing may be reported in 
the targeted-testing report instead of in the contact report. Then, the testing category is likely to be 
Administrative in Part I of the targeted-testing report, unless some of the individuals have TB risk 
factors and then these individuals usually will be grouped under Targeted Testing and 
Individual.
2. If the contacts having previous records of TB disease (now inactive) or latent infection are 
treated for LTBI, the data about treatment can be recorded in Part III. Referral Counts of the 
targeted-testing report. The contact report does not have categories to record the diagnosis and 
treatment of these contacts. However, these contacts are still included in the counts for the 
Number of Contacts and Evaluated (see below) in the contact report. 
Sometimes the health department has to do extraneous work in a contact investigation, 
but this extra work barely is related to the basic tasks of contact investigations. This extra 
work should not be counted in the contact report because it dilutes the meaning of the 
results. This report is intended to show the results that were achieved in seeking, 
evaluating, and treating persons who were likely to be exposed to tuberculosis and thus 
likely to be infected recently. 
One example of extra work in Point 1 (above instructions) occurs when the health 
department is investigating a case of noncontagious (negative results from sputum smear 
and culture) tuberculosis in a grade-school child. Probably the initial investigation will 
find no evidence of transmission to household contacts (unless, of course, an actual 
contagious tuberculosis patient happens to be part of the household). Even though 
tuberculosis in grade-school children rarely is contagious, the health department might 
encounter pressure to test the child's schoolmates. Under these circumstances, the health 
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department is testing children who probably are not contacts, in the sense that that they 
were unlikely to have been exposed to tuberculosis. These pseudo-contacts should not be 
counted in the contact report. The health department has two main options for counting 
the grade-school contacts in this example: include them on the contact report anyway and 
later explain why the number of contacts is greater and the infection rate for contacts is 
much lower than anticipated, or report them as counts in low-priority testing on the 
targeted-testing report. The first option probably will increase the number of contacts in 
the third column of the contact report, where results from other types of contact 
investigations are counted. The second option is a better reflection of the work done by the 
health department and the reasons for doing it, but this second option does require more 
effort to sort out the data. (A third option would be not counting these contacts at all.) 
Point 2 refers to a very different situation that appears only in unusual settings. Contact 
investigations can find contacts who had previous tuberculosis disease (self-resolved or 
incompletely treated) or previously diagnosed LTBI, and after a full evaluation these 
persons might be regarded as good candidates for treatment of LTBI. However, this 
diagnosis and treatment of LTBI (or old, healed tuberculosis) is not supposed to be 
counted on the contact report because the diagnosis was made before the contact 
investigation. The steps that were attributable to the contact investigation were finding 
and evaluating the contacts, and these steps should be counted on the contact report. 
If the health department undertakes treatment of these contacts (in Point 2 of the above 
instructions) who have previously diagnosed LTBI, then the results can be counted in the 
targeted-testing report in the section called Referral Counts. The concept here is that the 
health department has referred these patients to itself for treatment. 
Under both Point 1 and Point 2, transferring the data to the targeted-testing report for 
these special purposes improves the quality of the data but also increases the clerical work 
for the health department. Therefore, these options should be undertaken only with the 
intention that the improved data will be useful in evaluating the prevention activities. 
These options increase the complexity and effort of reporting, and the ARPE coordinator 
should monitor these points for consistency and uniformity. 
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Cohort Year. The data are accumulated into a cohort over 1 calendar year. The contacts are assigned 
to the same count-year as the TB cases being investigated. A person who is included in more than one 
contact investigation in a year should be counted for each event, but exposures to multiple TB cases 
that are connected to a single contact investigation should be counted as one event only. 
This brief instruction includes several major points. First, the reports are on an annual 
cycle. The contacts who are collected for one annual cycle are counted together in a cohort, 
which means a group that is traced in aggregate through the course of all outcomes for all 
contacts (within the bounds of the closure date for reporting). The counting cycle is based 
on the calendar year. 
Next, the contacts are linked with the tuberculosis cases that are under investigation, and 
the contacts are assigned to their cohort year depending on the count-year of the index 
cases. Count-year for index cases is determined in RVCT, which is the national 
tuberculosis surveillance form. 
Next, under unusual circumstances, some contacts are exposed to more than one 
tuberculosis case in the same year. For example, within 1 calendar year, a person might be 
exposed to a tuberculosis case that is counted in March and later to another tuberculosis 
case that is counted in November. In this instance, the person is counted as a contact for 
each exposure, that is, the person is counted independently twice as a contact. However, if 
LTBI or tuberculosis disease were diagnosed in the first contact investigation, then neither 
of these diagnostic outcomes could be counted for the second investigation, although the 
contact could be counted as evaluated in the second investigation because all the work (for 
listing and checking the contact in the second investigation) was done. 
Lastly, under other unusual circumstances, one person might be a contact to two or more 
tuberculosis cases in the same investigation. This might occur during a tuberculosis 
outbreak, where one contact is connected to several different cases that are 
epidemiologically related as a case cluster. This is a dilemma because each tuberculosis 
case in the outbreak might require a separate contact investigation that should be reported 
in the contact report. The individual who potentially was exposed to several of the 
tuberculosis cases in the cluster should only be counted as a contact once, if only one 
medical evaluation is required for all the exposures. Generally, for counting purposes, 
such a contact should be assigned to the case that was being investigated at the time that 
the contact was listed first; however, these situations can be very complex, and they 
should be settled with assistance from an ARPE coordinator who can document the 
circumstances. 
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Closure Date for Follow-up. A preliminary report should be tabulated by August 15 following the 
cohort year (i.e., before all the completion-of-therapy data are available) and, depending on the 
context, shared with the program consultant at the state health department or DTBE. The final results, 
including the completion-of-therapy data, are due at DTBE by August 15, 1 year later. 
The purpose of the closure date is to establish administrative finality for processes that 
might be prolonged beyond reasonable limits. This implies that arbitrary criteria have 
been set, because what is reasonable is subject to interpretation. However, the U.S. 
tuberculosis controllers who contributed to the development of ARPEs believed that the 
closure dates were acceptable for capturing most of the important prevention work, 
because most outcomes should be available before the stated closure dates. 
Occasionally, outcome events might occur later than the closure dates. For example, a 
contact who starts treatment for LTBI much later than the contact investigation might not 
complete treatment until later than the second (i.e., final) ARPEs closure date. The contact 
reports still should be closed on August 15, and the report should not be revised for 
including this unusual completion of therapy after the closure date. In the example given, 
the contact will be counted as having started treatment but not as having completed 
treatment. You should note that this is an extreme example. If it occurred routinely, then it 
might indicate a systematic problem. 
The contact report has two closure dates. The first closure date marks the end of the 
preliminary report. The preliminary report records the cohort of contacts that are included 
for the count-year. Most if not all of the contacts that are going to be counted should be 
counted by the first closure date. In addition, most of the data about 
evaluating/diagnosing contacts and starting treatment for contacts with LTBI should be 
ready also. The second closure date marks the end of the final report, which should 
include the outcomes for contacts who received treatment. The final report focuses on 
completion of therapy. 
Even for reports that are delayed administratively, the closure dates should be observed in 
regards to classifying data for the report. Reports should not be revised for data from 
events that occur after the final closure date, because this causes inconsistencies. 
Total TB Cases Reported. This is the surveillance result for TB morbidity for the count-year. 
The total tuberculosis cases that are reported should match what is reported to DTBE in 
routine surveillance via RVCT/SURVS/TIMS. The result is included on the report as a 
reference point, and it is not used in the calculation of any of the indices. When a contact 
report is entered into TIMS, the software has a validation check to confirm that the total of 
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the cases for investigation in the first two columns of the report does not exceed the total 
for the year. However, no software automatically enters or checks the counts for cases 
reported.
Sometimes, the total cases reported by a tuberculosis program changes by a small number. 
Ideally, the contact report should show the same case count that the tuberculosis program 
does for other purposes, but this is not a critical detail. 
Please note that, within a state or big-city reporting area, the rules for counting 
tuberculosis cases (e.g., counting cases at the county level) can be different from one 
jurisdiction to the next. If this is a problem for the contact report, then the ARPE 
coordinator should discuss potential solutions with the program consultant at DTBE. 
Part I. Cases and Contacts 
Cases for Investigation. The TB cases, their contacts, and all the subsequent results are grouped into 
three categorical columns according to the types of TB cases that led to the contact investigations. 
The three columns are a distinguishing feature of the contact report. This structure reflects 
the levels of urgency for contact investigations, and it is fundamental to interpreting the 
results. The first column lists the results of investigations of respiratory tuberculosis cases 
with a positive AFB sputum smear. These cases are likely to be the most contagious; 
therefore the contact investigations take a high priority. The second column lists the 
results for respiratory cases with a negative AFB sputum smear but a positive culture 
result. These cases are likely to be less contagious, but transmission is still possible and 
therefore most tuberculosis programs undertake complete contact investigations. The 
third column includes a range of other activities with lower efficiency. The criteria for the 
three categories follow. 
The important feature to note is that the three columns establish the data structure for the 
contact report. This is because data for contacts are grouped with the cases and listed 
under them. Data do not cross between the columns, although a tuberculosis case counted 
as a contact diagnosis/outcome in one column subsequently might be a case for 
investigation in a different column. This is a reflection of standard operations and it does 
not entail any transfer of data between columns. 
Sputum smear +. All of the following criteria must be met for counting cases under this category:  
1. Inclusion in the overall surveillance count; 
2. a disease site in the respiratory system including the airways; and 
3. a positive AFB sputum-smear result, whether or not any culture result is positive. 
Cases should be counted under this category even if contacts could not be elicited for any reason (e.g., 
the patient left the area or died before an interview could be done). 
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In most ways, these instructions match the reporting instructions for RVCT. For the 
contact report, three points are listed (above) and expanded here: 
1. Only cases that are counted by the jurisdiction submitting the contact report 
should be included. In other words, the jurisdiction has to count a case before the 
contacts can be counted, and contacts from cases that are not counted for this 
column should not reported in this column. This can occur when the RVCT
criteria are not met for any reason or when the criteria are met but the case is 
counted by a different jurisdiction. 
2. For the contact report, the case should include tuberculosis disease somewhere in 
the respiratory system, which for these purposes extends from the epiglottis down 
to the alveolus and includes all the connecting airways. This is slightly different 
from the RVCT definition for pulmonary, which does not include the upper airway. 
The reason for the difference is that upper-airway tuberculosis, including laryngeal 
tuberculosis, can be a very contagious form, and this is relevant to setting priorities 
for contact investigations. In practical terms, upper-airway tuberculosis usually 
includes pulmonary disease anyway. On other points, the contact report follows the 
same reporting instructions as the RVCT. The hilum and the pleura are defined as 
extra-pulmonary structures for surveillance. Tuberculosis in these locations is 
unlikely to be directly transmissible. Therefore, pleural or hilar tuberculosis are not 
by themselves sufficient for counting in this category of a contact report, but a 
positive sputum smear or culture is not expected anyway if tuberculosis is solely in 
these sites. 
3. The positive AFB sputum smear result can be read from a direct specimen smear 
or a sputum concentrate. The central word here is “sputum.” Sputum is the 
specimen that the patient expectorates, whether it is spontaneous or induced. 
Specimens that are collected via lavage or biopsy through a bronchoscope or any 
other route are not counted with sputum. This is compatible with the RVCT 
instruction. The reason for the distinction is that the epidemiological impact of 
tuberculosis cases that are diagnosed without a sputum AFB examination is not 
known. Please note that positive smear results from sputum specimens obtained 
before or after a bronchoscopic procedure are valid for counting in this category. 
The sputum culture result can be either positive or negative for this category. The 
reason that a negative result is accepted is that the culture has imperfect sensitivity. 
In approximately 3 percent of cases reported with a positive AFB smear result, the 
culture result is negative. All that is required for this category in the contact report 
is that the case is counted by the jurisdiction and the sputum AFB smear result is 
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positive.
It is important to include all cases in this category if they fit the requirements for counting, 
even when contacts were not found. This is because cases without contacts found can have 
serious implications for tuberculosis control. Numerous operational factors go into finding 
or not finding contacts, and although the reasons for this occurring are not part of the 
contact report, they should be sought out as part of routine operations. 
Sputum smear - culture +. All of the following criteria must be met for counting cases under this 
category:  
1. Inclusion in the overall surveillance count; 
2. a disease site in the respiratory system including the airways; 
3. negative AFB sputum-smear results; and 
4. sputum culture result positive for Mycobacterium tuberculosis. 
Cases should be counted under this category even if contacts could not be elicited for any reason.  
As for the definition preceding this one, in almost every respect, this definition matches 
the reporting instruction for RVCT/SURVS tuberculosis. For the contact report, three 
points are listed (above) and expanded here: 
1. Only cases that are counted by the jurisdiction submitting the contact report 
should be included. The jurisdiction has to count a case before its contacts can be 
counted, and contacts from cases that are not counted at the head of this column 
should not be reported in this column. This can occur when the RVCT criteria are 
not met for any reason or when the criteria are met but the case is counted by a 
different jurisdiction because of local arrangements or because of details in the 
RVCT instructions. 
2. For the contact report, the case should include tuberculosis disease somewhere in 
the respiratory system, which for these purposes extends from the epiglottis down 
to the alveolus and includes all the connecting airways. This is slightly different 
from the RVCT definition for pulmonary, which does not include upper-airway 
tuberculosis, for example. The reason for the difference is that upper-airway 
tuberculosis can be the most contagious of all forms, and this is relevant to the 
purpose of the contact report. (Please note that upper-airway tuberculosis is 
uncommon without a positive sputum AFB smear result.) On other points, the 
contact report follows the same reporting conventions as the RVCT. The hilum and 
the pleura are defined as extra-pulmonary structures for surveillance. Tuberculosis 
in these locations is unlikely to be directly transmissible. Therefore, pleural or hilar 
tuberculosis are not by themselves sufficient for counting in this category of a 
contact report, but a positive sputum smear or culture is not expected anyway if 
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tuberculosis is solely in these sites. 
3. The positive sputum culture result can be derived from any culture method for 
mycobacteria. In addition, a positive result from a direct genetic amplification 
method applied to sputum, even without a positive sputum culture result to 
corroborate it, can be counted in this category for the contact report, although the 
relative degree of contagiousness is undetermined for this unusual scenario. Also, 
the term sputum is meant strictly. Sputum is the specimen that the patient 
expectorates, whether expectoration is spontaneous or induced. Specimens that are 
collected via lavage or biopsy through a bronchoscope or any other route are not 
counted as sputum. This distinction is compatible with the RVCT instruction. The 
reason for the distinction is that the general epidemiological impact of tuberculosis 
cases that are diagnosed without a sputum AFB examination or culture is not 
known. Please note that positive culture results from sputum specimens obtained 
before or after a bronchoscopic procedure are valid for counting in this category. 
All that is required for the contact report is that the case is counted by the 
jurisdiction and the sputum culture result is positive for M. tuberculosis or M.
tuberculosis complex. 
It is important to include all cases in this category if they fit the requirements for counting, 
even when contacts were not found. This is because cases without contacts found can have 
serious implications for tuberculosis control. Numerous operational factors go into finding 
or not finding contacts, and although the reasons for this occurring are not part of the 
contact report, they should be sought out as part of routine operations. 
Other. This category includes contact investigations that were done because of any circumstances not 
included in the other two categories. Example: Associate-contact or source-case investigations done 
because of TB in a child. The number of contacts is counted, but the number of cases for investigation 
is not. 
The first two columns of the contact report include the most important contact 
investigations that a health department undertakes. For a wide variety of reasons, health 
departments also undertake a number of contact investigations for the tuberculosis cases 
that they count when the cases in and of themselves are unlikely to be contagious. The 
reasons for doing these other types of contact investigations vary from jurisdiction to 
jurisdiction. The overall public health impact of doing these other investigations is 
indeterminate, but sometimes there are compelling reasons. 
“Other” is a catch-all term that captures the contact investigative results that were not 
countable in the first two columns of the contact report. Note that this category does not 
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have a case denominator. That is, the number of cases for investigation is not reported 
and, therefore, the number of contacts per case is undefined. This is because the other 
investigations are of disparate types and DTBE currently does not intend to capture these 
data systematically. On the other hand, a state or local program might gain new insight by 
reviewing these data, and if numerous contacts are being reported in this category, then 
the reasons for these investigations, and their productivity, should be monitored. 
Associate-contact investigations are done to find persons who might have been infected 
from the same source as an index case. The assumption is that the index case was caused 
by recent infection; therefore other persons who currently are associated with the index 
patient might have been exposed, too. One distinction here is that the source case and the 
site for the transmission are undetermined initially, and for this and other reasons the 
yield of associate-contact investigations is low on average. A typical example of an 
associate-contact investigation is evaluating the siblings of a child who has tuberculosis. 
The assumption is that the siblings might have been exposed and infected along with the 
sick child—not because of potential transmission from the sick child to the healthy siblings 
(i.e., pediatric tuberculosis cases usually are not contagious). Associate-contact 
investigations are similar to source-case investigations, and often these investigations are 
done in tandem. 
Source-case investigations are designed to find the source of infection for a tuberculosis 
patient who probably was recently infected. The typical reason for a source-case 
investigation is tuberculosis in a young child. Because of the child's young age, the date of 
tuberculosis infection is certainly fairly recent; therefore the odds of finding the source 
case are better than average, although still poor. 
Both associate-contact and source-case investigations sometimes are done for LTBI, 
especially if children are involved. The public health value of this work is uncertain, but 
the Other column of the contact report is available for these data. 
Another reason for counting in the Other category is explained under Number of 
Contacts in the basic instructions and definitions. If the health department undertakes a 
contact investigation around a suspected tuberculosis case, but the culture later confirms a 
diagnosis of infection with a mycobacterium besides M. tuberculosis (e.g., M. avium) or 
tuberculosis is excluded in some other way, then the health department has the option of 
counting the contacts for this non-case under the Other column. (In some instances, the 
investigation is undertaken because the index patient has a positive sputum AFB smear 
result, but tuberculosis later is excluded.) Reporting these contacts has advantages and 
disadvantages. An advantage is that the health department has a standard measure of 
how much work was undertaken, while a disadvantage is that the results generally do not 
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reflect productive activities. If your program chooses to report these data, then the reasons 
for reporting should be determined in advance and the value of the data probably should 
be reviewed critically to determine whether the program derives benefits from this 
reporting practice. 
Sometimes contact investigations are done for extrapulmonary tuberculosis cases. The 
reasons for this kind of investigation are defined poorly in most instances, but the 
concepts are related to associate-contact or source-case investigations.  If these contacts are 
to be counted in the report, then they should be included under Other.
Cases with No Contacts. Cases that are counted under one of the first two columns (Sputum smear + 
or Sputum smear - culture +, see above) are counted here if no contacts were elicited, regardless of 
the reason that contacts were not elicited. 
Sometimes tuberculosis patients who are difficult to interview transmit a great deal of 
infection before being diagnosed. Sometimes these patients cannot, for many reasons, 
assist the health department in listing contacts. 
Failure to find contacts can contribute to outbreaks. However, some of the reasons for not 
finding contacts are beyond the control of the health department. The challenge 
confronting the health department under these circumstances is to account for these 
events and to seek alternatives. 
One requirement of the contact report can cause an artifact in this category. All the 
contacts who are related to a tuberculosis case cluster might be assigned to the index case, 
which means that no unique contacts remain for other cases in the cluster. (The 
instructions stipulate that the contacts are only counted once each even if multiple cases 
exposed them to tuberculosis.) In many instances, however, additional unique contacts are 
found for the other tuberculosis cases in a cluster. 
Number of Contacts. All of the following criteria must be met for counting a person who has been  
exposed to TB as a contact for this report:  
1. The health department believes that the person was exposed, warranting an evaluation for TB 
disease or latent infection; 
2. the exposure was caused by a TB case that was counted by the reporting jurisdiction; and 
3. enough identifying and locating information is available for a reasonable opportunity to contact 
the person, regardless of whether the person is in the jurisdiction of the health department. 
The follow-up of out-of-jurisdiction contacts usually requires the assistance of the health departments 
in those other jurisdictions. 
The contact count is the essence of the contact report. It is also one of the most difficult 
numbers to determine. This is mostly because contact ascertainment is challenging in the 
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first place. Contact ascertainment is an imprecise science combining various evidence 
about a presumed source case and the resulting exposures. The completeness of contact 
investigations depends on flexible pursuit of evidence, or else important contacts can be 
missed. On the other hand, excess inclusion of contacts causes unnecessary medical 
evaluation and treatment. Full guidance about contact investigations goes beyond the 
scope of this training manual. The instructions here focus on counting contacts. 
1. The essential idea for counting a contact in this report is that someone in the 
health department has determined, from whatever evidence or rationale, that the 
person (who might have been exposed to tuberculosis) might have been infected, 
and an evaluation to exclude LTBI or active tuberculosis is justified. The contact 
report does not aid in determining how good or how poor the guess was, at least 
not directly for each contact (see How to Interpret and Use the ARPE Results). The 
evidence and the circumstances vary from contact to contact; all that is needed from 
the health department for counting in the contact report is the decision that a 
diagnostic evaluation is warranted. 
2. The tuberculosis case under investigation must be included in the count for the 
reporting jurisdiction if the contacts are going to be counted also. This requirement 
usually simplifies the reporting because the records for cases and contacts can be 
tied together in either a paper file or a computer data system. However, it also 
means that the health department sometimes cannot count all the contacts that need 
evaluation. You do not count contacts to cases counted by another jurisdiction, even 
though you evaluate the contacts. For example, if a tuberculosis case is reported in 
a neighboring state and the patient absconds from treatment and spends several 
months in your jurisdiction before being rediscovered, the additional contacts in 
your state should not be counted on your contact report because your tuberculosis 
program is not counting the case. Contacts to cases that are not counted (anywhere) 
because of an RVCT instruction/definition also should not be counted for the 
contact report. 
3. In the spirit of meaningful reporting of program activities, the contact report 
includes data only on contacts that the health department has a reasonable 
opportunity for locating and thereby evaluating. “Reasonable” is subjective. The 
idea is to collect data on contacts that are accessible within the United States. 
Verifiable data are seldom available for contacts who move abroad or for fugitives. 
Contacts who are incompletely identified (e.g., partial or inaccurate name or 
inaccurate address) cannot be confirmed to exist, and counting them for the contact 
reports would have unclear value. However, incomplete locating information can 
be pursued more or less rigorously, and the efforts that are allocated to find 
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contacts should be determined according to the circumstances and not according to 
the instructions for ARPEs. 
The contact report assigns the accountability for contacts to the jurisdiction reporting the 
tuberculosis cases under investigation. Accountability does not mean responsibility for 
evaluating and treating every single contact; it is more an insistence to find data and 
results for contacts, wherever they might be. This can happen only if health departments 
exchange essential information about contacts. In some U.S. regions, this is already the 
standard practice. With the increasing emphasis on tuberculosis prevention, contact 
tracing and reporting between jurisdictions is likely to become more standard. 
Note: Persons should not be included in the contact count if they do not need to be evaluated as 
judged by the health department. For example, this happens when the model of concentric circles is 
used. After evaluating some of the contacts who had more exposure (i.e., close contacts), the health 
department determines that the other contacts who had less exposure do not need to be evaluated. 
The remaining contacts should not be included in the reported count of contacts because the health 
department believes that an evaluation is not warranted for them. 
The concentric-circles model is an iterative process of measuring the rates of tuberculosis 
infection (both LTBI and disease) around a contagious source case. This is done by 
arranging the investigation into stages called circles. The theory is that contacts who have 
had more intensive or prolonged exposure are more likely to be infected, and these 
contacts should be evaluated before others. The circles of contacts are determined by the 
estimated degree of exposure. The data from each stage of the investigation are used as 
evidence for making decisions for the next stage, until the results show that enough 
contacts have been evaluated—that is, no more evidence of recent transmission is found. 
The concentric-circles model is a reasonable guide for planning investigations, but 
operational limitations seldom permit this approach to be followed in every detail. 
Sometimes, it cannot be used at all. In any instance, the contact report does not evaluate 
the use of the model because it does not distinguish degrees of exposure. The contact 
report makes no distinction between close and other-than-close contacts. 
On the other hand, if you are using the concentric-circles model, then this sometimes helps 
you to decide how to count contacts for reporting. The contact report only includes 
contacts that you (i.e., the health department) believe should be evaluated for possible 
LTBI or tuberculosis disease. If the concentric-circles model provides you with evidence 
that no further contacts beyond a point need to be evaluated, only the contacts up to that 
point should be counted for reporting. However, the last set of contacts who are evaluated 
should be counted, if they were evaluated because of a concern that they could have been 
infected.
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Example: You start a contact investigation in a high school because one of the students has 
culture-confirmed tuberculosis with acid-fast bacilli observed on sputum microscopy. The 
school has 600 students, but the results for 8 household contacts and 30 homeroom 
contacts at school show no evidence for transmission. Therefore, you decide that the rest 
of the high school students do not need to be tested. The best number of contacts for 
reporting is 8 + 30 = 38, which is how many persons you determined should be evaluated. 
If you reported 8 + 600 = 608 contacts, then you also would have to report that you 
evaluated 38 contacts and did not evaluate 570. This would be unhelpful information in 
the report. In fact, you determined that the 570 should not be evaluated, and the contact 
report should reflect your correct reasoning by showing only the 38 contacts. 
Note: Sometimes contact investigations are done because of a suspected TB case before the diagnosis 
of TB is confirmed. If TB is excluded (i.e., ruled out), then the persons who initially were listed as 
contacts should still be counted as contacts, although a TB case is not being counted. These persons 
and their test results are reported under the case category Other, which does not include a TB case 
denominator.
Many if not all tuberculosis programs initiate a contact investigation as soon as a 
suspected tuberculosis case is found, especially if the suspected tuberculosis patient has a 
positive result on the sputum smear for AFB. In general, this is a good idea. However, 
sometimes investigations are done for non-cases, that is, tuberculosis later is excluded as a 
diagnosis for the index patient. 
Whether or not these contacts should be counted for the contact report is controversial. 
Some tuberculosis controllers prefer to include the data because the results reflect the 
burden that is incurred with this extra work. Other tuberculosis controllers prefer to omit 
the data because the public health benefit of the extra work is uncertain. 
For tuberculosis programs where these data are included in the contact report, the report 
permits the results to be added into the Other column of the report. If this option is used, 
then the ARPE coordinator should discuss this with the DTBE program consultant and 
should review these data to determine how the results contribute to program evaluation. 
Note: The contacts that are associated with TB cases in other jurisdictions are not counted by the  
jurisdiction with the contacts; they are counted by the jurisdictions that are reporting the TB cases.  
If you did not count a tuberculosis case under investigation, then you do not count the 
contacts, either. You might have contacts from a case in a neighboring jurisdiction or from 
farther away, and although you are evaluating these contacts, you should not be counting 
them for the contact report because you are not counting the index case. Conversely, if the 
41  
contacts to a tuberculosis case that you are counting are in another jurisdiction, you count 
the contacts and all the results and outcomes. To do this, you need the data from your 
colleagues in the other jurisdiction. 
You might receive just as much contact data as you share with other jurisdictions, but a 
perfect balance is unlikely. In various tuberculosis programs, the priority assigned to 
tracing contacts between jurisdictions and then sharing data runs from high to low. One 
reason for building this type of data sharing into the contact reports is to raise the visibility 
of these activities. 
Evaluated. This is the count of contacts who have been tested and examined, as part of a contact 
investigation, to the point where a final determination can be made about two of the potential 
diagnostic outcomes: LTBI or TB disease (see below for reporting definitions of these outcomes). Most 
contacts will receive a tuberculin skin test unless their medical history indicates otherwise (see 
following note). Contacts who receive a skin test should not be counted under Evaluated until the 
skin test has been read. Contacts who need a second skin test because of recently ended exposure 
should not be counted under Evaluated until the second skin test has been read. Contacts who have a 
positive skin test result should not be counted under Evaluated until active TB disease has been 
excluded by any further tests as indicated. (Skin tests with other antigens, for cutaneous anergy, 
should not be considered for classifying outcomes for this report.) 
A truly complete definition for evaluated would be difficult because the story for each 
contact has subtleties of history, epidemiology, and test results.  The contact report is too 
simple for distinguishing all the details for each contact. Therefore, the definition for 
counting a contact as evaluated for the report is based on final diagnostic decisions that 
are in turn based on the complete story for each contact. 
A contact should be counted as evaluated for the report after all necessary tests and other 
evaluations for LTBI and tuberculosis disease are finished and the healthcare providers 
have determined a tuberculosis status for the contact. The general choices are (1) not 
infected, (2) infected with M. tuberculosis but no evidence of tuberculosis disease (i.e., 
LTBI), and (3) active tuberculosis disease. Note that the first choice, not infected, is not an 
explicitly counted category in the contact report. 
In general, the initial steps involved in the evaluation process are an interview about the 
recent exposure and any previous tuberculosis history and a tuberculin skin test (for 
contacts who are not already known to be reactive to tuberculin). 4 Because the skin test 
4 Recent developments in blood tests for infection with M. tuberculosis offer the possibility 
that they might perform better than the tuberculin skin test. DTBE will send an 
amendment to these ARPEs instructions if these blood tests are implemented and if they 
substantially alter the way that contact investigations and targeted testing are done. 
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result might not convert to positive until up to 8 weeks after initial infection with M.
tuberculosis, some contacts require a second skin test if the first result is negative. 
Contacts who have a positive tuberculin test result, or current tuberculosis symptoms 
even if the skin test result is negative, require further evaluation because they might have 
active tuberculosis. The evaluation usually starts with a chest radiograph at a minimum, 
and the healthcare providers might arrange for other tests or procedures. 
The above outline of evaluated is not a substitute for current guidelines for diagnosing 
LTBI and tuberculosis disease. For detailed information on diagnosis and case 
management, you should refer to publications by the American Thoracic Society, the 
Infectious Disease Society of America, the American Academy of Pediatrics, and CDC. 
Until the presence or absence of either infection or disease is established, a contact should 
not be counted as evaluated. Some reasons for not counting a contact as evaluated are 
listed here, although this list is not intended to be complete: 
1. A contact is never seen for evaluation, 
2. a test for M. tuberculosis infection should be done but is not, 
3. a tuberculin skin test is applied but not read, 
4. a second test for infection should be done but is not, and 
5. a positive test result is not followed by further testing for active tuberculosis 
disease.
The contact report is not a tool for determining whether contacts have been evaluated 
optimally, although you might encounter quality-of-care issues while you are collecting 
data for the report. The contact report has an implicit assumption that evaluations are 
done in accordance with local, state, and national policies or guidelines. Disagreements 
about medical evaluations for specific contacts should be resolved between your health 
department and the healthcare providers. The DTBE program consultants are available to 
assist ARPE coordinators in state or local health departments in resolving these types of 
issues.
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Note about contacts having prior TB disease or latent infection: This contact report only includes the 
contact evaluation results that are determined through contact investigations. Contacts who already 
have known TB disease or latent infection already diagnosed before they are investigated are counted 
under Number of Contacts, but the diagnostic outcomes are not counted in the contact report. 
Generally, these contacts can be counted under Evaluated even if further tests and examinations are 
not done because enough history is already available to determine their TB status; therefore they have 
been evaluated in the context of the contact investigation. If such contacts will be treated, then the 
treatment should be counted only in the other aggregate report, Targeted Testing and Treatment for 
Tuberculosis Infection, in the section headed Part III. Referral Counts. (These contacts are counted on 
both reports. They are counted on this report as contacts and then on the other form as referrals for 
treatment.) 
Generally contacts who already have had a documented positive tuberculin skin test result 
before the contact investigation would not receive another skin test. The same would hold 
for contacts who have had active tuberculosis in the past. If a healthcare provider 
determines that an evaluation is completed for such a contact, then the contact should be 
counted as evaluated for the contact report. In this scenario, historical information 
constitutes a major part of contact evaluation. 
Treatment decisions for contacts with old, previously diagnosed LTBI are made 
individually, and practices vary. Also, contacts who were treated previously for LTBI are a 
similar issue. Because the practices are variable, previously diagnosed LTBI is not 
included under LTBI in the contact report. If your health department routinely treats 
contacts under these circumstances, then the count of LTBI can be added to the targeted-
testing report in the section Referral Counts in the targeted-testing report, and the 
treatment should be counted there. 
If the targeted-testing report is used in this way, the practice is irregular because an 
individual contact is counted (1) once as a contact who has been evaluated and (2) again as
a referral for treatment of LTBI. Although this is irregular, the practice is allowed as long 
as the principles of consistency and uniformity are followed. 
This type of transfer between the two ARPEs adds complexity to the reporting process. 
The ARPE coordinator should set standards for these practices. 
TB Disease. Contacts should be counted under this outcome if they have TB disease (i.e., active TB) 
initially discovered as part of the contact investigation. Cases should fit the CDC RVCT definition, 
and they should be referred for morbidity surveillance according to the reporting requirements. 
Active TB that develops after latent infection was diagnosed during the contact investigation should 
not be counted here. Old TB cases that have been treated already or that have spontaneously healed 
and TB disease discovered coincidentally (i.e., not because of the contact investigation) should not be 
counted in this category. (These instructions differ slightly from the ones for the report of Targeted 
Testing and Treatment for Latent Tuberculosis Infection.) 
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Contact investigations are one of the better methods for active case-finding for 
tuberculosis in the United States. Active case-finding means seeking tuberculosis disease 
in a defined population. This contrasts with passive case-finding, which means waiting for 
individuals to seek medical attention because of tuberculosis symptoms. (These terms are 
not the same as active surveillance and passive surveillance, which are contrasting 
strategies for collecting tuberculosis case reports. Active and passive surveillance are not 
directly relevant to ARPEs.) 
The reason that active case-finding is efficient in contact investigations is that tuberculosis 
cases are common among recent contacts to contagious tuberculosis—an average of 1 
percent or more of these contacts have tuberculosis disease at the time they are evaluated. 
Active-case finding is a crucial component of contact investigations. 
The case definition for counting tuberculosis disease is the same as that of the national 
case definition in the RVCT instructions. However, the counting instructions are different. 
For RVCT, the determination about jurisdiction and who counts the case is connected to 
the address of the patient and several other details. For the contact report, if you counted 
the contact because you also counted the index case, then you count the secondary 
tuberculosis case (of the contact) in this section of the contact report, even if another 
jurisdiction is counting the same case for RVCT national surveillance. This happens in 
contact investigations that cross jurisdictional borders. These reporting systems, ARPEs 
and RVCT national surveillance, are functionally independent, and counting the same case 
in each of the systems causes no problems. 
The contact report is designed to show the results of contact investigations only. Findings 
from other, coincidental sources should not be counted as outcomes in this report. For 
example, if a contact has active tuberculosis and is diagnosed before the contact 
investigation starts, this is not a discovery/result of the contact investigation. At best it is a 
coincidence and at worst it is evidence that the contact investigation was delayed. Another 
example is tuberculosis that develops after a contact has been evaluated and found not to 
have tuberculosis. These kinds of data contribute to understanding the epidemiology of 
tuberculosis transmission, but the contact report is not designed for this depth of data. 
In contrast, for the targeted-testing report, some coincidental findings are accepted. The 
reason for this is that the structure and purpose of targeted-testing projects are different 
from contact investigations. 
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Note about DNA fingerprinting [i.e., restriction fragment length polymorphism (RFLP) or strain 
typing]: The results of DNA fingerprinting of M. tuberculosis isolates should be ignored for counting 
contacts under TB Disease, even if the fingerprinting results disprove a transmission link. The count 
for TB Disease should be tabulated for this report as though DNA fingerprinting were unavailable. 
DNA fingerprinting (i.e., genotyping) is a valuable tool for detecting or confirming 
tuberculosis transmission and studying its epidemiology. Examples of DNA 
fingerprinting methods are RFLP and spoligotying. Occasionally, results from these 
methods show a mismatch between a contact who has culture-confirmed tuberculosis and 
the presumed source case. From this evidence, the conclusion is that the cases are not 
linked by recent transmission. 
The contact report is designed to study the process/results of contact investigations and 
not the exact epidemiological links among cases. A primary result of contact investigations 
is that cases are discovered by active case-finding. The evidence from DNA fingerprinting 
is not relevant for making decisions about the contact report. The contact report is the 
report for showing that you sought the contacts, evaluated them, and discovered a 
tuberculosis case because you did an investigation. DNA fingerprinting results are not 
available on all cases. This is because testing was not done or culture  
results were negative. The results of DNA fingerprinting should not be considered in 
making decisions about counting cases among contacts in the contact report. 
In conclusion, DNA fingerprinting (i.e., genotyping) results for M. tuberculosis isolates
should be ignored for classifying data for the contact reports. 
LTBI. This is the count of contacts who have LTBI (not TB disease) diagnosed because of current  
contact investigations. Both of the following criteria are required:  
1. A positive result of a current tuberculin skin test (as interpreted according to national, state, 
or local diagnostic guidelines) and 
2. the exclusion of active TB disease through further tests or examinations. 
Latent TB infections that have been diagnosed coincidentally or previous to the contact investigation 
should be not be included in this count. 
For contacts, the average rate of LTBI is approximately 20 times greater than that of active 
tuberculosis disease. Sometimes more than half of contacts are infected by the time an 
investigation is undertaken. The purpose of finding LTBI is to treat it and prevent the 
progression to active tuberculosis. 
Obtaining the diagnostic outcome of LTBI requires a range of activities, although only the 
outcome itself is counted in the contact report. First is an interview to determine whether 
the patient (i.e., the contact) already has symptoms of active tuberculosis and any previous 
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history of tuberculosis disease, infection, or exposure. Next is a tuberculin skin test, and 
sometimes another one, for detecting evidence of LTBI. 5 The skin test should be 
interpreted according to local policies or guidelines. Finally, if the skin test result is 
positive, a chest radiograph (i.e., x-ray) and sometimes other tests are needed to exclude 
active tuberculosis. The selection of tests for excluding active tuberculosis depends on the 
circumstances and the healthcare providers’ judgment. 
For each contact, the determination about the LTBI diagnosis is up to the healthcare 
provider. Discrepancies between guidelines and diagnoses should be resolved by public 
health officials. The contact report is not designed to evaluate diagnostic practices for 
LTBI; the report has a built-in assumption of correct practices. 
The general rules for counting LTBI found in a contact investigation are the same as for 
active tuberculosis disease. The ARPE report is designed to capture the results of contact 
investigations. Occasionally, LTBI has been diagnosed before the contact investigation is 
undertaken, or it might be diagnosed accidentally when a contact receives a tuberculin 
skin test but the tuberculosis exposure is unknown to provider, who is unaware of the 
contact investigation. Although these events are unusual in most areas of the United 
States, when they occur, the LTBI should not be counted as such on the contact report. 
Even if the LTBI is not countable, the contact can be counted as Evaluated if enough 
information is available to confirm the LTBI diagnosis and active tuberculosis disease has 
been excluded. 
Note about anergy: In determining whether to count a contact under LTBI, only results from a 
tuberculin test should be considered, not from skin tests with other antigens (i.e., control antigens or 
an anergy panel). However, if a contact with a negative tuberculin skin test result is being treated with 
a full-course regimen for suspected LTBI, then that contact should be counted under LTBI.
Recent guidelines about finding and treating LTBI have discounted tests for cutaneous 
anergy. Cutaneous anergy is detected by various combinations of control antigens referred 
to as an anergy panel. The reasons for this trend of discontinuing anergy testing are 
beyond the scope of this manual. At present, the tuberculin skin test is the only type of test 
that is taken into consideration when counting outcomes of contact evaluation for the 
contact report, until and unless improved blood tests for M. tuberculosis change this. 
Under special circumstances, health care providers occasionally prescribe a full course of 
5 Recent developments in blood tests for infection with M. tuberculosis offer the possibility 
that they might perform better than the tuberculin skin test. DTBE will send an 
amendment to these ARPEs instructions if these blood tests are implemented and if they 
substantially alter the way that contact investigations and targeted testing are done. 
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treatment for LTBI for contacts who have persistently negative tuberculin skin test results. 
(This contrasts with window-period treatment, which is not intended to be a full course 
from the onset.) An example is full LTBI treatment of HIV-infected contacts who have 
negative tuberculin skin test results after exposure to contagious tuberculosis. For the 
contact report, such contacts can be counted as treated, but they also have to be counted as 
infected. This is because they are receiving full treatment for the reason that LTBI is 
presumed. In reality, this occurs rarely except under special circumstances, usually 
congregate settings. 
Started Treatment. A contact who has LTBI is counted in this category after the first dose of a planned 
full-treatment course for LTBI. The determination of whether the first dose has been taken is based on 
the best available information, which is often the contact’s statement. If a contact is lost to follow-up 
after treatment was prescribed and information is unavailable about whether any medication was 
taken, then treatment can be considered started if the contact picked up the medicine from a clinic or 
pharmacy. 
The two components of this instruction are (1) that the contact has been counted under 
LTBI for the evaluation outcome and (2) the contact receives at least the first dose of 
treatment. The concept for the first point is that treatment implies an LTBI diagnosis, and 
the details meet the ARPE definition for LTBI. 
The second point can be difficult to determine with certainty unless a patient is receiving 
directly observed therapy (i.e., supervised doses). Sometimes you and other providers 
have to rely on substitute methods for ascertaining the start of treatment. The best and 
simplest method is asking the contact about it in an interview; if the response from the 
contact can be validated by a pill count, this is even better. 
However, sometimes the information about starting treatment is inaccessible. For this 
circumstance, the only substitute is a confirmation that the patient filled a prescription for 
LTBI treatment. When even this information is unavailable, then treatment should not be 
counted as started. In particular, the existence of a prescription or a medical order to start 
treatment should not be considered adequate for counting under the category of Started
Treatment.
Note about window-period treatment: Contacts who are receiving treatment pending a second 
tuberculin skin test (i.e., window-period treatment) should not be counted under Started Treatment 
unless LTBI is diagnosed finally and counted for the report. 
Window-period treatment is given to a contact when the transmission rate is believed to 
be substantial, or the contact is extra vulnerable to tuberculosis, but the result from the 
first tuberculin skin test is negative. This practice is based on the assumption that the 
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contact might have acquired LTBI recently but the infection is so new that delayed 
hypersensitivity to tuberculin (e.g., the skin test) has not developed yet. Window-period 
treatment is administered until sufficient time has passed and a second tuberculin skin test 
is administered. If the second test result is negative, then treatment is stopped because the 
contact probably does not have LTBI. 
The contact report is incompatible with the intrinsic concept of window-period treatment. 
From the perspective of this report, a contact who is receiving window-period treatment 
pending a second skin test is still being evaluated, because a determination still has not 
been made about whether the contact has LTBI. If the result of the second skin test is 
negative, then LTBI would be excluded. If LTBI is not diagnosed, then the contact cannot 
be counted under LTBI, and a contact who is not counted under LTBI also cannot be 
counted under Started Treatment.
The frequency that window-period treatment is prescribed varies from place to place. 
Although the contact report cannot help in evaluating window-period treatment, the basic 
structure of the report could be adapted for studying this practice locally. A consultation 
with your ARPE coordinator or a DTBE program consultant is recommended. 
Completed Treatment. (Note: This category is based partly on an arbitrary, operational definition of  
completion. It might not be equivalent to an adequate course of therapy.) The following criteria are  
required for counting under this category:  
1. The prescribing provider, believing that an adequate regimen has been received, discontinues 
treatment; 
2. the contact has taken at least 80 percent of the prescribed doses in the selected regimen; and 
3. the treatment is finished within a period of 150 percent of the selected duration of therapy. 
The determination about whether the definition is met is made from the best available information, 
which is generally the provider’s records and the contact’s statements about adherence to treatment. 
A simplistic definition is necessary for Completed Treatment because this element is 
intrinsically difficult to describe and measure. Even with this definition, Completed
Treatment is likely to cause confusion and disagreement. Consistency should be your 
highest priority. 
One overriding factor: The definition for Completed Treatment is not a substitute for 
guidelines for treating LTBI. Treatment practices should be based on local, state, and 
national policies or guidelines, and decisions for individual patients are between 
healthcare providers and their patients. None of the ARPE definitions are intended as 
references for medical care or case management. 
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The definition for Completed Treatment includes three requirements: 
1. The provider discontinues treatment after concluding that the contact has 
completed a recommended treatment regimen. Decisions by the patient or program 
administrators are not equivalent for meeting the definition. Thus, administrative 
close-outs do not meet the definition. (An administrative close-out is a 
determination by a program administrator that enough treatment was given even 
though a prescribing provider has not discontinued it. This does not meet the 
definition for the contact report.) 
2. The reason for the “80 percent” figure is that some tuberculosis treatment studies 
have used this as an arbitrary cut-point for specifying completion of therapy. When 
intensive monitoring methods such as pill counts or directly observed therapy are 
in effect, the achievement of 80 percent of doses is measurable directly. In most 
situations where contacts are being treated, however, data are not available to 
determine how many doses have been taken. In these situations, you need a 
combination of data to make a reasonable guess about the number of doses that 
were taken (and whether or not this constitutes 80 percent of what was prescribed). 
Typical factors you might consider are the start date for treatment, the number of  
prescription refills, clinic attendance, and the adherence rate reported by the 
patient.
3. Completion within 150 percent of the planned treatment period is a pragmatic 
component of the definition. The purpose is to get the reports closed with finality. 
The contact report is no longer relevant if every single open treatment record is 
pursued to the point of final determination. Contacts who are still on treatment at 
the time point that is one-and-one-half times (i.e., 150 percent of) the intended 
duration should be regarded as not completed for the sake of the contact report, 
even if completion might be reached at a later date. 
A number of factors can complicate determinations about Completed Treatment. An 
example is contacts who require a change of regimen midway through a course. Another 
example is contacts who start and stop treatment several times. For the contact report, you 
sometimes have to make arbitrary decisions about how to count these events. As much as 
possible, you should make these decisions consistently when similar situations arise and 
uniformly across reporting sites. Consultation with your ARPE coordinator or a DTBE 
program consultant is recommended. 
Reasons Treatment Not Completed: This section catalogues some general reasons that the treatment 
for LTBI is not completed. 
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Although DTBE requests submission of information about incomplete treatment, the main 
purpose of this section of the report is to assist local and state tuberculosis control 
programs to assess the obstacles that prevent completion of therapy within their 
jurisdictions. A major shortcoming of these data is that they are peculiar to local context; 
therefore these data have uncertain meaning when combined with reports from other 
areas. In addition, tuberculosis controllers have reported that interpretations of the 
definitions vary substantially from site to site; therefore the data that are aggregated from 
multiple reporting areas consist of mixed information. The definitions used in the 
instructions still should be followed as closely as possible. 
The categories under Reasons Treatment Not Completed have a relative hierarchy: in a 
situation where several reasons for incomplete treatment might apply to one contact, the 
most specific reasons should be selected. In general, the reasons near the top of the list are 
more specific and less subjective. Some of the reasons are more serious, for example, death 
during treatment or adverse effects of treatment. These events are likely to require further 
attention; therefore they should be captured for the report whenever possible. 
You should set a goal of counting each instance of incomplete treatment under one of the 
categories of Reasons Treatment Not Completed. However, you can expect difficulties in 
doing this and accept that you might not be able to assign a reason for each contact. DTBE 
does not require that the sum of contacts who are counted under the categories of Reasons
Treatment Not Completed equal 100 percent of all the contacts who do not complete 
treatment, although a local or state tuberculosis program might decide to require this. 
TIMS automatically checks the total count under all categories and signals an error if the 
total exceeds the number of patients who did not complete treatment. 
Death. Contacts who were receiving treatment on schedule but who had treatment interrupted by  
death before completion are counted under this category. (Note: Because of the seriousness of this  
outcome and the unreliability of anecdotal reports, a verification check of any deaths is helpful for  
accuracy in reporting.)  
Death is a rare reason that contacts with LTBI do not complete treatment. As estimated 
from previous reporting systems for treatment of LTBI, death occurs in less than 0.5 
percent of contacts while they are receiving treatment. You should be alert to reports of 
death in contacts for two general reasons: (1) A report of death might be inaccurate, and 
you should verify it, and (2) if the report is accurate, you need to know whether the death 
might be somehow related to the treatment of LTBI or to active tuberculosis that escaped 
your attention. 
For counting events under this category it is important to determine whether death was 
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the reason that treatment was stopped, that is, the proximate reason. For example, if a 
contact dies while still receiving treatment after 3 months, then Death is the appropriate 
category. However, if the contact decides to stop treatment after 1 month and then dies 2 
months later (unless a complication of treatment caused a late death), the closest reason 
that treatment was incomplete was the patient's decision, which you should record in that 
category.
If the contact stops treatment because of an illness or injury that proves fatal, this outcome 
should be included under Death. Under these circumstances, the treatment of LTBI is 
likely to be suspended because of the contact’s worsening condition, but the general 
understanding is that the treatment would have been resumed if the contact had survived. 
On the other hand, if the treatment is suspended because of illness (not including an 
adverse effect of the treatment) or injury, and the contact survives but the treatment is 
discontinued permanently by a provider, this probably would be counted as Provider
decision.
Contact Moved (follow-up unknown). Contacts who do not complete treatment because they have 
moved or migrated from the jurisdiction of the health department should be counted in this category 
if follow-up information is unavailable. However, if the health department receives specific follow-up 
from a receiving jurisdiction (e.g., Completed Treatment or Patient is Lost to Follow-up), then the 
outcome should be reclassified accordingly. 
The programmatic goal for contacts who move is to obtain follow-up information 
whenever possible. Although Contact Moved (follow-up unknown) is a nonspecific 
outcome, the contact can be assumed to be unavailable for further public health 
monitoring and completion of therapy. 
Gathering follow-up information about contacts who move while being treated for LTBI 
can be difficult. You might need to decide that the additional data that you gain from 
finding out what happens to contacts after they leave your jurisdiction does not have 
enough priority relative to your other tasks. This is a realistic approach, but it entails some 
loss of information for the contact report. Also, your effort in tracing the outcome of 
contacts has intangible benefits, such as increasing the odds that a contact who started 
treatment in your jurisdiction will come to the attention of public health providers in 
another jurisdiction. 
For counting a contact in this outcome category, you should seek some form of 
confirmation that the contact indeed moved outside of your jurisdiction. One possibility 
that you want to avoid is a contact who claims to be moving (i.e., as an avoidance of public 
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health monitoring) when in fact this person is not planning to move. In this instance, the 
better category for counting would be Contact Chose to Stop because it is closer to the 
facts. Making this distinction requires extra effort, but the distinction is important. 
Contact Moved (follow-up unknown) implies that you know the destination of the 
contact who is moving. Without this information, you cannot determine a more specific 
outcome because you have no way to make a referral for continued monitoring of 
treatment for the contact. If you believe that the contact probably moved but you do not 
know the destination, then you should classify the outcome as Contact is Lost to Follow-
up because you are uncertain about what happened to the contact. 
Active TB Developed. If a contact who still is receiving treatment for LTBI has active TB that qualifies 
as a case under the standard surveillance definition (i.e., RVCT), then the outcome is counted in this 
category. However, if the treatment regimen already has been stopped before active TB develops 
because of completion or any other reason, then the outcome should not be changed to Active TB 
Developed.
Large-scale trials of LTBI treatment proved that an occasional patient becomes sick with 
active tuberculosis even while under treatment for LTBI. This occurred even with drug-
susceptible M. tuberculosis and in patients who were adherent to treatment. The reasons 
for this phenomenon are unknown; you can assume that this outcome is rare. 
On the other hand, tuberculosis is more likely to develop in a contact who stops treatment 
for LTBI, and you should attempt to determine if this is the underlying reason for the 
failure of treatment. If you determine that treatment was stopped for some reason before 
active tuberculosis developed, then you should record the proximate reason for stopping 
treatment.
After treatment for LTBI, active tuberculosis can develop. None of the treatment regimens 
for LTBI is 100-percent effective in preventing tuberculosis, and this is even more true for 
contacts who fail to complete therapy. If tuberculosis develops after treatment has been 
stopped (because it was completed or any other reason), then the original reason for 
ending treatment should be retained. 
Note: Sometimes contacts are started on treatment for LTBI before all results from medical 
evaluation are obtained. Delayed test results or reinterpretation of early results might 
change a diagnosis from LTBI to active tuberculosis. For example, a positive culture result 
for M. tuberculosis might not become available until 6 weeks after the collection of a 
specimen. Also for example, abnormalities might be noted in the review of chest 
radiographs that initially were read as normal. For these unusual instances, the initial 
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evaluation actually was not complete at the time that treatment for LTBI was undertaken. 
The contact should be classified under TB Disease instead of under LTBI. Thus, the 
treatment start itself should not be counted because the LTBI diagnosis was incorrect. The 
classification of LTBI, Started Treatment, and Active TB Developed would be incorrect in 
this scenario because the proper disposition of the contact (for counting in the report) 
would be TB Disease.
Adverse Effect of Medicine. If contacts do not complete treatment because of an adverse effect 
(including drug-drug or drug-food interactions) of the anti-TB medication, they should be counted in 
this group if a healthcare provider documents the problem and determines that the medicine should 
be discontinued. If a contact stops taking the medicine because of an adverse effect but a provider has 
not recommended the discontinuation, then the reason for stopping treatment should be counted as 
Contact Chose to Stop.
All regimens for treating LTBI cause adverse reactions in a few patients, and sometimes 
these reactions are severe or dangerous enough to end treatment. The judgment that is 
required to make this decision is beyond the scope of the contact report and these 
instructions, and in each instance the decision to stop treatment rests with a healthcare 
provider and a contact. You can reasonably assume that consistency and uniformity are 
lacking in how this decision is made, but this too is beyond the scope of the report. 
The crucial detail for counting in this category is that a healthcare provider has 
documented the decision to stop treatment because of the adverse effect. In instances 
where a contact decides to stop treatment because of the adverse effect but a healthcare 
provider has not evaluated the contact and has not decided to discontinue treatment, then 
the reported outcome should reflect the patient's decision as Contact Chose to Stop. For 
example, some anti-TB medicines cause abdominal pain, and this can prompt a patient to 
stop treatment. This would only be counted under Adverse Effect of Medicine if a 
provider evaluated the situation and recommended treatment be stopped. 
An average rate of stopping treatment because of adverse effects should be less than 
approximately five percent. If you find a higher rate, you should be concerned about the 
possibility that treatment is being stopped without sufficient reason or that information is 
being misinterpreted when it is classified for reporting purposes. 
If the adverse effect of medicine for a contact is fatal, then the outcome should be counted 
under Death rather than under Adverse Effect of Medicine. These events are of particular 
concern, and you should monitor them closely. 
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Contact Chose to Stop. Contacts should be counted in this category if they decide to stop taking their 
medicine before they have finished their regimen and a healthcare provider has not determined that 
the medicine should be discontinued for a medical reason. 
This category is almost self-explanatory, but it also has its confusing points. One example 
is a contact who moves from your jurisdiction and deliberately leaves incorrect locating 
information. You would be reasonable in believing that the contact chose to stop treatment 
because that message is implicit, but a better classification would be Lost to follow-up.
When you are counting a contact who did not complete treatment under the category of 
Contact Chose to Stop, you should be able to determine the whereabouts and the clinical 
condition of the contact. Whether or not you seek out the contact to encourage resumption 
of treatment or check on health status depends on your program resources 
and priorities. However, when you count a contact under this category, you are implying 
that you have a way to check on the person. 
Contact is Lost to Follow-up. Contacts whose treatment status at the anticipated end of the treatment 
regimen is incomplete or indeterminate because the health department cannot locate them for 
determining a more specific outcome should be counted in this category. 
When you really cannot determine what became of a contact who was on treatment for 
LTBI, Contact is Lost to Follow-up is the category. You might be concerned that this 
category depends on how much effort is spent on finding a contact, and probably it does. 
It is likely that if you had the resources and information for finding all contacts who seem 
to vanish, some of them would tell you that they prefer not to return to clinic. 
In fact, resources are limited, and you have to set priorities when it comes to tracing 
absconders. You would be correct in guessing that from place to place resource levels for 
tracing lost contacts are different, and the priority assigned to this activity varies. Also, the 
local context influences this factor. If you work in a small community where everyone 
knows everyone else, a contact is less likely to disappear than if you are in an urban 
setting with social anonymity. This shows why program-process evaluation reports such 
as ARPEs are not fully comparable from one place to the next. 
Provider Decision. If a healthcare provider determines that the treatment for LTBI should be stopped 
because of concerns about the benefits, the safety, or the practicality of treatment (e.g., a contact has 
such erratic attendance at the clinic that the adequacy and the safety of the treatment cannot be 
monitored), then this is the reported reason. 
This is a narrow category among reasons that treatment was not completed. You should 
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not expect to encounter it often. You should count a contact under Provider Decision only 
if a healthcare provider has decided in good faith, prospectively, to discontinue treatment 
because of some medical concern. (If, however, the medical concern is brought about by 
an actual adverse effect, then the contact should be counted under that category instead.) 
Provider Decision cannot be defined for every circumstance because the situation for each 
contact is different, and each healthcare provider has a different sense of judgment. 
The main problem to avoid for counting contacts under this category is the retrospective 
interpretation of data. Provider Decision should not be used as a default or an escape for 
counting outcomes when only incomplete information is available. 
The following are some reasonable examples of Provider Decision. By comparing the 
outcomes for contacts in your program against these examples, you have a frame of 
reference for typical situations that could be counted under this category: 
An elderly woman who is a contact with LTBI has alcoholism. The healthcare 
provider is concerned about liver injury associated with isoniazid, and the plan is to 
check the patient in clinic and to do blood tests every other week to monitor for 
early evidence of liver injury. However, this person does not keep clinic 
appointments and is difficult to locate when outreach workers search for her. The 
healthcare provider is concerned that she either is skipping her treatment or is in 
jeopardy from adverse effects of isoniazid. Therefore, the provider discontinues 
treatment.
A man who is a contact being treated for LTBI is found to have cancer and starts 
intensive chemotherapy, and this makes him very sick. The healthcare provider 
decides to postpone treatment of LTBI indefinitely until the more urgent medical 
issues are settled. This amounts to an indefinite discontinuation of treatment. The 
provider is concerned that this patient could become sick with tuberculosis; 
therefore careful monitoring is planned so that tuberculosis can be discovered early 
if it develops. 
A woman who is a contact being treated for LTBI becomes pregnant during the 4th 
month of isoniazid treatment. The patient and the healthcare provider agree to 
postpone treatment until well after the birth of the baby (although this is not quite 
in keeping with treatment guidelines). For practical purposes you determine that 
treatment for this contact should be counted as incomplete, and you assign the 
outcome to Provider Decision.
Part II. Evaluation Indices.
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This part of the contact follow-up report is the summary statistics that are calculated from the 
aggregate data entered into Part I of the report. The indices are calculated automatically and 
presented as either ratios or percentages by TIMS. The formulae are shown in the paper-copy table to 
show the source figures for the calculations. 
Note that some specific indices are different between the contact report and the targeted-
testing report, which reflects differences in the activities. 
The purpose of the evaluation indices is to give you a synopsis of the data flow in the 
contact report. Each index reflects the average result of a specific process that is shown in 
the report. You could regard each index as a measurement of performance, but this 
interpretation generally is overly simple. Better that you regard the indices as general 
comparators (i.e., for comparison to national averages) and as clues for determining which 
activities in contact investigation need your closer scrutiny. (See page 99, How to 
interpret and use the ARPE results, for additional suggestions about interpreting the 
indices.)
ARPEs differ from some other or previous U.S. tuberculosis program reports in that the 
indices are not adjusted for mitigating factors. For example, the treatment completion rate 
does not exclude contacts who move from your jurisdiction after starting treatment, and 
therefore the treatment rate is diminished by the departure of these contacts. This is a 
controversial point, but you have the option of calculating indices with adjustments, for 
your purposes. In the national report, no adjustments are made. 
When ARPEs are entered into TIMS, the software program will calculate indices initially 
and then will recalculate them when you edit/update the data. The formulae that appear 
in the printed ARPE forms are the basis for those built into TIMS. If you use paper-copy 
forms, or computer-screen mock-up forms, you must remember to recalculate the indices 
after counts are edited/revised in the upper sections of the forms. If you use spreadsheet 
software programs for recording ARPE data, you can incorporate the formulae that are 
shown in the paper-copy form. 
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Extended instructions: target testing report 
Basic Instructions for the Aggregate Reports for  
Tuberculosis Program Evaluation:  
Targeted Testing and Treatment for Latent Tuberculosis Infection 
Note: The instructions for this report are not a substitute for guidelines about TB diagnosis, treatment, 
or control. Any contradictions between the implied content of these instructions and the health 
department’s policies and practices should be discussed, according to the context, with a consultant 
from the local or state TB program or the Division of Tuberculosis Elimination (DTBE). 
ARPEs are a tool for program evaluation. A potential hazard of these reports is that the 
reporting instructions and the data definitions might be misconstrued as treatment 
recommendations or program guidelines. The reporting instructions and the data 
definitions are derived from national guidelines and recommendations, but they are much 
simpler.
For example, the data definitions for completion of therapy in ARPEs specify the number 
of doses and the duration of treatment. However, when therapeutic decisions are under 
discussion regarding individual patients, treatment recommendations and medical 
judgment must be followed instead of ARPEs instructions. Under unexpected 
circumstances, the appropriate treatment decisions might cause a problem with reporting, 
but patient care is more important than these reporting definitions. 
In another example, the ARPE results for a certain targeted-testing project might suggest 
that the population selected for testing is not appropriate because the prevalence rate of 
LTBI is low. However, the selection of targeted populations should be based on judgment 
derived from experience and program guidelines and not on results in ARPEs alone. 
ARPEs simply are not capable of accommodating all the issues that must be considered for 
making programmatic decisions. The aim of ARPEs is general results, and it is up to the 
ARPE coordinators and the program managers to recognize how unusual circumstances 
caused peculiar results in the reports. This is critical for taking advantage of the reports. 
State and local jurisdictions should consult with each other on the reports when questions 
arise. For example, the designated ARPE coordinator in the state tuberculosis control 
program might be responsible for tracking all ARPEs-related questions and responding to 
them. At DTBE, the program consultants for each reporting area6 are the main point of 
6For most jurisdictions, the state TB controller or the TB nursing consultant coordinates  
communications with the DTBE program consultants. 
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contact for questions that are directed to the national tuberculosis program. They have 
available a range of public health specialists to assist them. 
This report is an annual summary of activities to find and treat LTBI through targeted and other 
testing. Testing means diagnostic tests done to find mainly LTBI. Testing and follow-up of contacts, 
however, are not included in this report. Active-case finding (i.e., seeking mainly tuberculosis disease) 
should not be included in this report, either, unless the individuals also are being tested for LTBI. 
Targeted testing is the third element in the general U.S. strategy for tuberculosis control. 
The essence of targeted testing is preventing tuberculosis by selecting and evaluating 
individuals or groups who have risks for tuberculosis disease and treating individuals 
who have latent infection with M. tuberculosis. The public health impact of targeted testing 
is achieved only when individuals found to have LTBI are fully treated in order to prevent 
the emergence of active tuberculosis disease. 
In spite of the benefits of preventing future tuberculosis cases, targeted testing is prone to 
inefficiency because of the large number of persons who have to be evaluated, the low risk 
of active tuberculosis in the general population, and the difficulties of completely 
evaluating and treating persons with LTBI. Targeted testing usually requires an intensive, 
long-term investment of personnel and other scarce resources. Evaluation of targeted-
testing activities is important for validating these prevention activities. This is the purpose 
of the targeted-testing report. 
Contact investigations are a special type of targeted testing, but in almost all instances, 
data for contacts should be counted in the contact report instead of the targeted-testing 
report. The notable exception is the extensive and generally unproductive testing of 
contacts beyond the limits of what the health department authorities recommend. These 
data can be entered into the targeted-testing report, as explained under the extended 
instructions for the contact reports (page ). 
Active-case-finding refers to projects that have the primary aim of detecting tuberculosis 
disease in the selected population. The targeted-testing report was not developed with the 
intention of capturing data from projects for active-case finding. Tuberculosis cases are 
comparatively rare in most U.S. populations. On average, fewer than 1 per 10,000 persons 
has tuberculosis at a given time. In selected populations, the prevalence rate might be 
greater than 1 in 1,000, and in these populations, active case-finding might be efficient. The 
tuberculin skin test is not a sensitive or specific method for active case-finding; therefore 
targeted-testing activities that include a component of active case-finding require an 
ancillary testing method, such as chest radiography. The typical methods of active case-
finding projects are a rapid screen for tuberculosis symptoms; chest radiographs of all the 
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individuals or only of ill individuals; and sputum examinations for AFB, usually only on 
ill individuals or individuals with abnormal radiographic results. Tuberculin skin testing 
is a poor adjunct to active-case finding, but in some projects targeted testing for LTBI is 
combined with active-case finding. You can use the targeted-testing reports for tracking 
the results of projects that combine both active-case finding and targeted testing for LTBI, 
but you need to distinguish the data because the methods and motives are different from 
those of ordinary targeted testing for LTBI. 
At its discretion, the health department may include testing activities that are carried out by partner 
or contract entities on its behalf if the health department has assurance that the data are satisfactory. 
(Generally, this means that the health department has contributed to the work, through training, 
consultation, supplies, funding, or direct assistance by health-department personnel, and the quality 
of the testing, treatment, and data are monitored routinely and meet the expectations of the health 
department.)
In many jurisdictions, some or even all persons who are tested for M. tuberculosis infection
receive initial medical evaluation and treatment through providers besides the health 
department. Examples of other providers are private physicians; health maintenance 
organizations; and systems such as correctional facilities, military facilities, and hospitals. 
Collecting data from other providers is difficult, and the results you collect from those 
sources should be collected only if the data are helpful. You have to create opportunities 
for influencing practices and thus improving the efficiency and the impact of targeted 
testing, so that the data collection from outside of health department is meaningful. 
However, by seeking targeted-testing data from activities outside of health department 
projects, you become acquainted with other providers in your jurisdiction, and they learn 
about the services provided by the health department. Working with other providers gives 
you an opportunity to educate them about tuberculosis-control policies and procedures, 
and you can participate in strategy, decisions, and case management.  In some 
jurisdictions, health departments have negotiated partnerships for targeted testing and 
treatment of LTBI. Examples of partners are infirmaries in correctional settings and clinics 
of community-based organizations. Collecting data from collaborative projects enhances 
the health department’s capacity for technical consultation. For collaborative projects, data 
collection and project evaluation should be negotiated at the beginning of the 
collaboration.
For the targeted-testing report, you can regard the ARPE data accepted from providers 
outside of the health department as equivalent to data that you generate from your own 
patient care activities if data quality meets your normal standards, although you can 
anticipate differences. Separate analyses of data from different sources might provide 
important information. For example, you could measure the completion of therapy for 
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patients who go to private medical providers and compare the rate with that of patients 
who start treatment at the health department. 
Please note that the instructions on data from other sources are slightly different for the 
contact reports because the purposes of the data collection are different. 
Systematic skin testing that is done partly for infection control and surveillance purposes (e.g., the 
annual testing of healthcare workers) generally should not be included in this report unless the health 
department determines that this testing has mixed features of both targeted testing and surveillance. 
If latently TB-infected individuals are diagnosed during these other types of testing programs and 
referred to the health department for other testing and for treatment, they should be counted under 
the second half of this report, Referral Counts.
Many types of settings (e.g., hospitals, long-term convalescence homes, and hospices) have 
systematic tuberculin skin testing that sometimes is repeated at routine intervals for 
employees, clients, or both. These testing activities generally do not have primary aims of 
both finding and treating LTBI. Rather, they are implemented as epidemiological 
monitoring systems for determining the prevalence of LTBI and detecting potential 
transmission of M. tuberculosis. Sometimes the individuals undergoing testing are at very 
low risk for LTBI or tuberculosis disease. These types of testing systems generally do not 
have routine tracking of LTBI treatment because treatment is prescribed through other 
health-service systems. Therefore, the data usually are not suitable for the targeted-testing 
report.
The targeted-testing report has an implicit design assumption that individuals are only 
tested once for LTBI,7 and the report does not include a special way for counting repeated 
tests. This is another reason that the targeted-testing report is ill-suited for data from 
infection control and surveillance systems. 
In some communities, the health department administers and interprets the tuberculin 
skin tests for non-targeted-testing activities as described above. However, because these 
activities generally are not targeted toward individuals at specific current risk for LTBI or 
active tuberculosis disease, the data should not be entered into the targeted-testing report. 
If specific individuals at risk for tuberculosis are being evaluated for the purposes of both 
7In some targeted-testing projects (e.g., a project in a homeless shelter), individuals leave 
and enter the scope of the project repeatedly and sometimes are reevaluated. The targeted-
testing report regards these persons as fresh, new entrants; it does not have a way of 
tracking them differently. Because this shortcoming can bias the overall results, you 
should consider it when interpreting the report. 
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finding and treating LTBI, then these might be counted along with other targeted-testing 
data.
Sometimes the individuals who are diagnosed with LTBI during these other types of skin 
testing activities are already in the health department or are referred to the health 
department for further evaluation and possibly treatment. If so, they should be counted in 
the second half, Referral Counts. This reflects that the health department was not engaged 
in targeted testing but is providing prevention services subsequently. 
The second half of this report, Referral Counts, mainly records the treatment of LTBI when the 
denominator data (i.e., the number of persons tested) are unavailable or inappropriate for this report. 
Referral Counts sums up the follow-up of persons who are referred to the health department because 
of possible latent TB infections. At its discretion, the health department also may include the data 
generated by other entities that carry out these same activities on its behalf if the health department 
somehow assists with the care of the patients (e.g., providing medication or monitoring adherence) 
and participates in collecting the data. 
In some jurisdictions the health department does not do tuberculin skin testing except 
when evaluating contacts. In many of these jurisdictions, tuberculin tests are applied by 
providers outside of the health department for a variety of reasons. If these outside 
providers refer the patients who have positive test results to the health department, then 
you can use the second page of the targeted-testing report, Referral Counts, for recording 
counts and results. 
The major distinction between the second page (Referral Counts) and the first page of the 
targeted-testing report is the lack of target population denominator data. When you use 
the second page of the report, your starting point is the patient subset who are believed to 
have LTBI (or, rarely, active tuberculosis) when they are referred to the health department. 
You receive little or no information about the individuals who had negative test results or 
who did not return for test interpretation. 
As with the first half of the report, you may include Referral Count data from sources 
outside of the health department if these data are comparable to health department data 
and the health department is participating in the evaluation with the good-faith 
anticipation of influencing the process. Because the specialized activities counted under 
Referral Counts are unusual outside of health departments, you should verify your plan 
with your ARPE coordinator before accepting these data from outside sources. 
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Cohort Year. The data are accumulated into a cohort over 1 calendar year. Depending on the 
circumstances, the year for entering an individual patient into a cohort is the date of registration at the 
health department or the date that an individual is tested, listed for testing, or at least sought for 
testing as part of a target group. A person who is included in testing activities more than once in a 
year should be counted for each event. 
This brief instruction includes several major points. First, the reports are on an annual 
cycle. The targeted individuals, or members of a targeted population, who are collected for 
one annual cycle are counted together in a cohort, which means a group that is traced in 
aggregate through the course of all outcomes from testing through treatment (within the 
bounds of the closure date for reporting). The counting cycle is based on the calendar year. 
Next, the date of entry depends on the recruitment system, that is, how persons are 
gathered for testing. For example, if a targeted-testing project automatically enrolls an 
individual at a homeless shelter when he or she registers in the shelter for the first time, 
then the shelter registration date determines the entry date for inclusion in the targeted-
testing cohort, even though the tuberculin skin test will not be administered until the 
county nurse makes a routine visit several days later. The strategy for dating patient entry 
should be determined by local policy and evaluation needs, but the strategy should be 
recorded and followed consistently for optimal reporting. In general, you need to 
determine the date rules for each targeted-testing system or project. Consultation with 
your ARPE coordinator is recommended. 
Under special circumstances, individuals are recruited into the same or more than one 
testing system during 1 year. For example, within 1 calendar year, a person might be 
enrolled in a testing project at a homeless shelter in March, leave the shelter in May, and 
return in November. In this instance, the person is counted for each evaluation, that is, 
counted independently, twice, as though two different persons entered the project. 
However, if LTBI or tuberculosis disease were diagnosed in the first evaluation, then this 
influences the methods for the second evaluation because a test for infection probably will 
not be helpful or necessary. Note that the instructions for classifying persons who have 
previously diagnosed LTBI or tuberculosis are different from those of the contact report. 
See the definitions of TB Disease and LTBI for the contact reports and contrast these with 
the definitions of the targeted-testing report. 
Note, however, that in jurisdictions where computerized tracking is used for individuals 
entering and leaving targeted-testing projects, the tracking programs might not be 
compatible with multiple counts reflecting multiple entries. Under these circumstances, 
only initial evaluations might be counted. This is not contrary to successful reporting as 
long as you and everyone who uses the reports understands the differences in counting 
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procedures.
Closure Date for Follow-up. A preliminary report should be tabulated by August 15 following the 
cohort year (i.e., before all the completion-of-therapy data are available) and, depending on the 
context, shared with the program consultant at the state health department or DTBE. The final results, 
including the completion-of-therapy data, are due at DTBE by August 15, 1 year later. 
The purpose of the closure date is to establish administrative finality for processes that 
otherwise might be prolonged beyond reasonable bounds. This implies that arbitrary 
criteria are have been set, because what is reasonable is subject to interpretation. However, 
the U.S. tuberculosis controllers who contributed to the development of ARPEs believed 
that the closure dates were acceptable for capturing most of the important prevention 
work, because most outcomes should be available before the closure dates. 
Occasionally, outcome events might occur later than the closure dates. For example, a 
patient who starts treatment for LTBI much later than the initial evaluation might not 
complete treatment until later than the second (i.e., final) ARPEs closure date. The 
targeted-testing reports still should be closed on August 15, and the report should not be 
revised for including this unusual completion of therapy after the closure date. In the 
example given, the patient will be counted as having started treatment but not as having 
completed treatment. You should note that this is an extreme example. If it occurred 
frequently, then it might indicate a systematic problem. 
The targeted-testing report has two closure dates (that are the same as the ones for the 
contact report). The first closure date marks the end of the preliminary report. The 
preliminary report records the cohort of individuals that are included for the count-year. 
Most if not all of the individual patients that are going to be counted should be counted by 
the first closure date. In addition, most of the data about evaluating/diagnosing these 
patients and starting treatment for those with LTBI should be ready also. The second 
closure date marks the end of the final report, which records the outcomes for patients 
who received treatment. The final report focuses on completion of therapy. 
Even for reports that are delayed administratively, the closure dates should be observed. 
Reports should not be revised for data from events that occur after the final closure date, 
because this causes inconsistencies. 
Part I. Testing Counts.  
This section includes the count of persons who are sought or enrolled for testing and the outcomes of  
testing and treatment.  
These counts set the fundamental denominator for each testing activity/project. For each 
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activity/project, a definition for counting is required. Three factors can help in setting the 
definition:
1. mission of the testing activity/project, 
2. use of the data, and 
3. local practices for similar situations. 
Setting the definition for testing counts should be part of the design for a new testing 
activity or project. In general, the testing counts should be a reflection of your intentions in 
undertaking the activity/project, that is, the mission. For example, if your mission for a 
testing project at a shelter for homeless persons is “to test every new entrant to the 
shelter,” then the testing count should be matched to the number of new registrations at 
the shelter. However, after assessing the turnover of residents at the shelter, you might 
learn that less than half of the new registrants stay for longer than 2 days. Counting all 
new registrants would not give meaningful information because few of them would be 
available for diagnostic evaluation. You even might alter your mission to fit the situation: 
“To test every new entrant who plans to stay in the shelter for at least 1 week.” 
The purposes for collecting the data, that is, the uses of the data, also can guide your 
decisions about counting. If the data are used only by the health department, then you 
might decide on a narrow definition for the testing count, such as persons who are tested. 
If you have collaborators in a testing project, you might want to count persons who 
somehow miss being tested so that you can bring attention to increasing the number of 
persons who are tested. 
Within your jurisdiction or in nearby jurisdictions, activities/projects similar to yours 
might be underway already. When a comparison of similar projects is desired, the 
counting definitions should be matched as closely as possible. Consistency of definitions 
increases the comparability of the results. 
Testing Formats. The selection of a testing category (Targeted Testing [Project or Individual], or 
Administrative) is determined by the structure of the testing activities and the public health  
intentions. The data in Part I flow down the columns under these categories.  
The Testing Formats determine how data are grouped for the targeted-testing report. The 
grouping of the data then determines the structure and the flow of the data in each of the 
columns in this report. After you group the data into a particular column, the results move 
down that column to their final outcome, completion of therapy. You can transfer data 
from column to column if you decide to change testing categories for some of the data, but 
this could be very difficult if you are doing the tabulations by hand. Therefore, you should 
try to assign data to the best-fitting categories for Testing Formats at the start of data 
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collection. The notes that follow this one describe each testing category, [Targeted Testing 
(Project or Individual) and Administrative], in detail. 
When you are deciding about how to group data under Testing Formats, you should seek 
input from collaborators and others who have a stake in the projects/activities and the 
evaluation of the activities. You also should strive for consistency between projects and 
within your jurisdiction or region so that results are comparable as much as possible. 
Consultation with the ARPE coordinator is advised. 
Targeted Testing. This is the sum of testing projects or testing of individuals, with the testing focused 
on specific groups or individuals who should be tested for LTBI as per current guidelines. The groups 
or individuals should be at an increased risk for TB because of a high prevalence of latent infection, 
ongoing TB transmission, or a high prevalence of concurrent medical conditions that promote the 
progression of LTBI to active TB disease. 
Targeted testing is a strategy for increasing the yield, the efficiency, and the benefit-to-risk 
ratio of these types of tuberculosis-prevention activities. The populations or individuals 
who are selected for targeted testing are likely to have at least one of two characteristics: 
(1) a likelihood of LTBI because of an exposure history or historical markers for exposure 
to tuberculosis, and (2) health conditions that promote the progression from LTBI to active 
tuberculosis. The greater the fraction of persons who have both characteristics, the greater 
the prevention impact that the testing activity is likely to have, that is, if patients with 
LTBI start and complete treatment. 
The initial yield of a testing activity depends on the prevalence rate of LTBI in the 
population. The prevalence rate, in turn, depends on the population’s exposure history. 
The prevalence rate of LTBI also influences the predictive positive value of tuberculin skin 
test results. With greater rates of LTBI, positive skin test results are more likely to indicate 
LTBI instead of nonspecific reactions (i.e., false-positive reactions). If the predictive value 
of skin test results is greater, then more patients who truly have LTBI receive treatment, 
and this increases both the efficiency of the activities and the benefit-to-risk ratio. 
Generally, persons who have health conditions that increase the likelihood of tuberculosis 
disease (if they are infected with M. tuberculosis) receive the most potential benefit from 
treatment of LTBI. Probably the most important health condition in this class is HIV 
infection. Treating these persons can give a good benefit-to-risk ratio because the 
likelihood of tuberculosis disease, without treatment, is greater than average.
Guidelines for targeted testing occasionally change, and the changes might affect whom 
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you include for targeted testing. However, you should not apply the guideline changes 
retroactively to data derived from activities that you already completed. Mid-year 
guideline changes can be accommodated by changes in data collection at that point in 
time.
Project. Usually, testing projects for groups are done at sites outside of the health department as 
determined by the convenience or needs of the groups being tested. Such testing projects might be 
done only once during a limited period or they can be recurrent (e.g., annual testing at a correctional 
facility) or ongoing (e.g., testing of all new admissions to a homeless shelter). 
Note: The targeted-testing projects that are supported by dedicated funding through a TB cooperative 
agreement should be included in the sum for the Project category. Separate counts for each project 
should be retained by the funding recipient for inclusion in the annual narrative for the TB 
cooperative agreement. 
Under the broader heading of Targeted Testing, you need to distinguish between Project
and Individual. The distinction is somewhat arbitrary for some situations, but usually you 
will be able to distinguish between the two and assign testing activities to one or the other. 
As for other ARPEs sections, consistency in how you classify data is an important 
consideration. You can improve consistency by working with an ARPE coordinator and 
documenting the decision process. 
Testing in the Project format involves a strategy that captures a group of persons because 
of their similar risks of tuberculosis. In some targeted-testing projects, you can skip the 
person-by-person initial screening for tuberculosis risks because most persons in the 
group have increased tuberculosis risk. 
For many targeted-testing projects, the targeted group has mutual social characteristics 
that link the individuals to specific locations where you can reach many of them at one 
time. For example, many of them might work at the same factory. Thus, targeted-testing 
projects often take place outside of health department clinics because it is more sensible to 
deliver the services to the targeted group at a common setting. 
One common feature of targeted-testing projects is that they should include collaborators 
for achieving optimal effectiveness. For example, a project at a prison would include the 
correctional system health care workers. For some settings, the collaborators are the 
unique advocates or guardians for the targeted group, for example, a volunteer agency for 
homeless services. Collaborations with groups like these are necessary for effective 
interactions with the targeted populations. They have a stake in the results of targeted-
testing projects for preventing tuberculosis, and they should be included in discussions 
about how data are collected, interpreted, and shared. 
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Individual. This is the sum of testing that is done, one person at a time or group-wise but outside of 
testing projects, when testing is in accordance with national, state, or local guidelines for selecting 
persons who are at risk for TB and who are expected to be candidates for treatment if they have LTBI. 
Often the testing is done at a health department clinic. 
If the predominant strategy for targeted testing is selecting individuals who should be 
tested and then treated if they have LTBI, then this category, Individual, is the choice for 
the testing data. For this category, an individual risk assessment is done for each person 
before the testing is done. 
Individual risk assessments sometimes are built into targeted-testing projects, but in a 
targeted-testing project, you start with the assumption that the targeted group members 
are candidates for testing and possibly for treatment, and you do the individual risk 
assessment for refining the risk information and perhaps for excluding those persons who 
should not be included. Contrast this with the individual testing format, wherein you do 
the individual risk assessments for deciding whom to include in targeted testing. 
In the individual testing format, the individual risk assessment is the starting point for 
selecting targeted individuals who have characteristics that make them good candidates 
for testing and possibly treatment. Someone outside of the health department might be 
doing the initial risk assessment and then sending the patient to the health department for 
testing. For example, a physician at a private clinic might send patients who have diabetes 
to the health department for a tuberculin skin test. Testing these patients probably would  
be in keeping with guidelines. At the health department, a provider can confirm whether 
the patient has tuberculosis risks. 
Administrative. This is the sum of testing for LTBI that is done when the testing is a low public health 
priority because the tested persons or groups are not at risk for TB and might not even be candidates 
for treatment of LTBI. Often this testing is required by regulations or policies created outside of the TB 
control program. (Persons who are tested for administrative reasons should be counted under 
Targeted Testing and Individuals if the health department determines that they would fit into a TB 
risk category.) 
This category of testing for LTBI, Administrative, is representative of low-priority testing 
activities that usually are required because of policies not directly related to public health 
or tuberculosis control. For example, mandatory tuberculin testing of all child day-care 
providers probably prevents very few tuberculosis cases; it mainly addresses a general 
public perception that children might be endangered if the testing is not done, whether or 
not this is true. The Administrative category represents this extra public health 
expenditure that is probably not in the public’s best interest, in spite of perceptions. 
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On the other hand, some child day-care providers (for example) might have characteristics 
that put them at risk for tuberculosis; therefore the testing might be valid from the public 
health perspective. If it is feasible and helpful, you have the option of reclassifying data 
from the Administrative category to the Individual category. If you consider this practice, 
you should determine whether the extra paperwork is likely to improve the utility of the 
data and whether the idea is appropriate for your jurisdiction. If you decide to reclassify, 
then you should do it consistently. 
Note about overextended contact investigations: As part of a contact investigation, persons who are 
tested because of mass screening following minimal or no TB exposure also can be counted in the 
report for targeted testing (usually under Administrative) instead of in the report for Contact Follow-
up, at the discretion of the health department. 
Occasionally tuberculosis control programs cannot avoid including excessive numbers of 
contacts in an investigation. From a public health perspective, you might not consider 
some of the “contacts” to be contacts at all because evidence shows that they were not 
exposed to tuberculosis or that they had trivial exposure. You have the option of 
reclassifying the data off of the contact report and onto the targeted-testing report, usually 
in the Administrative category, although individual contacts might have tuberculosis risk 
factors that might justify classification under the Individual category. 
For example, if a child has scrofula, you realize that the contacts of this child are not at risk 
of infection (unless they share a common source case with this child, which is a different 
type of investigation). If many so-called contacts of the child are included in an 
investigation anyway, for example because of misplaced public concern, you have some 
options about how to classify the data for reporting. You can decide whether or not these 
data should be counted in the first place, and if you count them, you should decide 
whether they should be on the contact report (in the Other category for this example) or 
on the targeted-testing report. Consultation with an ARPE coordinator is advised. 
Note: The instructions for TB Disease and LTBI are different for the targeted-testing 
report than for the contact report. If the data are reclassified from contact investigation to 
targeted testing, the definitions for the targeted-testing report should be used when 
classifying the results for counting in the reports. 
Sought, Enlisted, or Registered. For Project under Targeted Testing, this is the count of individuals 
who should be tested as part of the project, whether or not they can be evaluated (e.g., persons who 
decline testing would still be counted here because they were sought for testing). For the other testing 
formats, this is the count of persons who are listed or registered by the health department for testing, 
whether or not any further testing or evaluation is done. 
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For a targeted-testing project, the count in this category should be the total number of 
persons who would be included if the project could meet its full potential. For example, if 
your project is designed to include all new employees at a factory in your jurisdiction, 
then the count of new employees defines your count for this category. This reinforces the 
need for determining data systems while the project is being designed. If you discover that 
the number of persons who are evaluated is far fewer than the number of persons who are 
sought, then you know either that the project itself is unfeasible or that you need new 
strategies.
The counting of persons in the Individual category usually is simpler. If you register 
someone for testing, you should count that person, whether or not the evaluation proceeds 
any further. 
Within your jurisdiction or in nearby jurisdictions, activities/projects similar to yours 
might be under way already. When a comparison of similar projects is sensible, the 
conventions for counting should be matched as closely as possible. Consistency of 
definitions increases the comparability of the results. 
Evaluated. This is the count of persons who have been evaluated to the point where a determination 
can be made about these outcomes: LTBI, or TB disease (see the outcome categories, below). Most 
persons who are counted under Evaluated receive a tuberculin skin test. For persons who have a 
record of disease or latent infection that already has been diagnosed, a skin test and other 
examinations might not be needed and the outcome can be classified; therefore they are counted 
under Evaluated. Persons who receive a skin test are not counted under Evaluated until the test has 
been read. Persons who have a positive skin test result are not counted under Evaluated until active 
TB disease has been excluded by any further tests and examinations as indicated. (Tests for cutaneous 
anergy should not be considered for classifying outcomes for this report.) 
A truly complete definition for evaluated would be difficult because the story for each 
person has subtleties of history, epidemiology, and test results.  The targeted-testing 
report is too simple for distinguishing all the details for each person who is included. 
Therefore, the definition for counting persons as evaluated for the report is based on final 
diagnostic decisions that are in turn based on the story for each person. 
A person should be counted as evaluated for the report after all necessary tests and other 
evaluations for LTBI and tuberculosis disease are finished and the healthcare providers 
have determined the tuberculosis status of the person. The general choices are (1) not 
infected, (2) infected with M. tuberculosis but no evidence of tuberculosis disease (i.e., 
LTBI), and (3) active tuberculosis disease. Note that the first choice, not infected, is not a 
counting category in the targeted-testing report. 
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Until healthcare providers have determined the tuberculosis status of a person, the person 
should not be counted as evaluated for the contact report. In general, the initial steps 
involved in this process are an interview about tuberculosis exposure and any previous 
tuberculosis history and a test for infection with M. tuberculosis, such as a tuberculin skin 
(for persons who are not already known to be reactive to the skin test). 8 
Persons who have a positive test for infection or current tuberculosis symptoms, even if 
the test result is negative, require further evaluation because they might have active 
tuberculosis. Although the evaluation for disease usually starts with a chest radiograph at 
a minimum, the healthcare providers might arrange for other tests or procedures. 
The above outline of evaluated is not a substitute for current guidelines for diagnosing 
LTBI and tuberculosis disease. For detailed information on diagnosis and case 
management, you should refer to publications by the American Thoracic Society, the 
Infectious Disease Society of America, the American Academy of Pediatrics, and CDC. 
Until the presence or absence of either tuberculosis infection or disease is established, a 
person should not be counted as evaluated. Some reasons for not counting a person as 
evaluated are listed here, although this list is not intended to be complete: 
1. the person is never seen for evaluation, 
2. a test for infection should be done but is not, 
3. a tuberculin skin test is administered but not read, and 
4. a positive test result is not followed by further evaluation for active tuberculosis 
disease.
The targeted-testing report is not a tool for determining whether persons have been 
evaluated optimally, although you might encounter quality-of-care information while you 
are collecting data for the report. The targeted-testing report has an implicit assumption 
that evaluations are done in accordance with local, state, and national policies or 
guidelines. Disagreements about medical evaluations for specific persons should be 
resolved between your health department and the healthcare providers. The DTBE 
program consultants are available to assist ARPE coordinators in state or local health 
departments in resolving these types of issues. 
8 Recent developments in blood tests for infection with M. tuberculosis offer the possibility 
that they might perform better than the tuberculin skin test. DTBE will send an 
amendment to these ARPEs instructions if these blood tests are implemented and if they 
substantially alter the way that contact investigations and targeted testing are done. 
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TB Disease. Persons are counted under this outcome if they have TB disease (i.e., active TB) at the 
time of the evaluation in the testing process, even if the illness has been previously diagnosed and 
reported and whether or not the person is undergoing treatment at the time of the evaluation. Such 
cases should fit the CDC RVCT definition, and these cases should be referred for morbidity 
surveillance according to the local reporting requirements. Old, resolved TB cases that have been 
treated and cured already or that have spontaneously healed should be counted under LTBI even if a 
skin test is not done. (Note: In the other report, Contact Follow-up, previous TB disease is not counted 
as an evaluation outcome.) 
Note that this definition for TB Disease is different than the one used for the contact 
report. The main difference is that you also should count prevalent cases, that is, cases that 
already have been diagnosed, as TB Disease in the targeted-testing report. 
Targeted testing is not designed for active case-finding for tuberculosis. Active case-
finding means evaluating the individuals in a defined population for tuberculosis disease. 
This contrasts with passive case-finding, which means waiting for individuals to seek 
medical care because of tuberculosis symptoms. (These terms are not the same as active 
surveillance and passive surveillance, which are contrasting strategies for collecting 
tuberculosis case reports.) 
Active case-finding usually is not efficient as a part of targeted-testing activities because 
tuberculosis cases are comparatively rare in most U.S. populations. On average, fewer 
than 1 per 10,000 persons has tuberculosis at a given time. In selected populations, the 
prevalence rate might be greater than 1 in 1,000, and in these populations, active case-
finding might be efficient. The tuberculin skin test is not a sensitive or specific method for 
active case-finding; therefore targeted-testing activities that include a component of active 
case-finding require an ancillary testing method, such as chest radiography. The targeted-
testing report is not designed for evaluating active case-finding projects. However, 
projects that combine targeted testing with active case-finding can be evaluated with the 
targeted-testing report. 
The case definition for TB Disease is the same as that of the national case definition in the 
RVCT instructions. However, the counting instructions are different. For RVCT, the 
determination about jurisdiction and who counts the case is connected to the address of 
the patient and several other details. For the targeted-testing report, if you counted the 
person for the report, then you count the tuberculosis case under TB Disease, even if 
another jurisdiction is counting the case for RVCT national surveillance. This happens in 
targeted-testing projects that include persons who reside in different jurisdictions. 
The targeted-testing report is designed to include prevalent tuberculosis disease and LTBI. 
Therefore, findings from sources apart from the targeted testing can be counted as 
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outcomes in this report. For example, if a person who is included in a testing project has 
active tuberculosis and the case was diagnosed before the person was enrolled in the 
testing project, this case should be counted in the targeted-testing report. However, if a 
person is initially diagnosed as having LTBI after the complete diagnosis but active 
tuberculosis develops in that person later, then the classification should remain as LTBI 
because that was the determination of the targeted testing. 
If a person who is included in targeted testing has a history of resolved tuberculosis 
disease, treated or not, and if the history for tuberculosis disease is documented to the 
extent that meets local standards, then this person should be classified as having LTBI 
after the diagnostic evaluation is completed. Depending on the circumstances and the 
judgment of the healthcare providers, a test for M. tuberculosis infection might not be 
necessary for the evaluation because it would it would not be helpful. Such a person also 
might be classified as a candidate for treatment of LTBI if the tuberculosis was not treated 
before or was not treated completely. 
LTBI. Persons are counted under this outcome if they have a LTBI but not TB disease. LTBI is 
determined by the result of a current tuberculin skin test (as interpreted according to national, state, 
or local diagnostic guidelines); by a known LTBI that already has been diagnosed from a previous 
skin test result, whether or not treatment has been taken; or by resolved prior TB disease whether or 
not it has been treated. Persons who are still receiving anti-TB medication for a TB case should be 
counted under TB Disease. (Note: In the other report, Contact Follow-up, previously known LTBI is 
not counted as an evaluation outcome.) 
The goals of targeted testing are finding LTBI and getting it treated in order to prevent 
future tuberculosis cases. For these activities to be efficient, the prevalence rate of latent 
infection should be greater than the national average, which might be on the order of one 
to five percent (averaged) for adults in the United States. The efficiency of the prevention 
activities is increased even more if the infected individuals also have risk factors for 
progression to active TB. 
Obtaining the diagnostic outcome of LTBI requires a range of activities, although only the 
outcome itself is counted in the targeted-testing report. First is an interview to determine 
whether the patient already has symptoms of active tuberculosis or a history of 
tuberculosis exposure, infection, or disease. Next is a tuberculin skin test to detect 
evidence of LTBI. 9 The skin test should be interpreted according to local policies or 
9 Recent developments in blood tests for infection with M. tuberculosis offer the possibility 
that they might perform better than the tuberculin skin test. DTBE will send an 
amendment to these ARPEs instructions if these blood tests are implemented and if they 
substantially alter the way that contact investigations and targeted testing are done. 
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guidelines. Finally, if the skin test result is positive, a chest radiograph (i.e., x-ray) and 
sometimes other tests are needed to exclude active TB. The selection of tests for excluding 
active tuberculosis depends on the circumstances and the healthcare provider’s judgment. 
A two-step skin test is not recommended for targeted testing. Two-step testing is 
necessary for initial testing upon entry to infection-control surveillance programs, with the 
individuals being retested according to a routine schedule, e.g., annually. The targeted-
testing report is not recommended for tracking surveillance systems. 
For each individual, the determination about the LTBI diagnosis is up to the healthcare 
provider. Discrepancies between guidelines and diagnoses should be resolved by 
jurisdictional public health officials. The targeted-testing report is not designed to evaluate 
diagnostic practices for LTBI; the report has a built-in assumption of correct practices. 
This counting category (LTBI) can include individuals who did not have LTBI diagnosed 
directly as part of a current testing activity. This instruction is different from that for the 
contact report. For the targeted-testing report, individuals who have historical information 
about tuberculosis infection can be counted under LTBI (as having possible prevalent 
infection). The two examples are 
1. Previous positive skin test result, whether or not LTBI was treated 
2. Previous tuberculosis disease that is healed now, whether or not it was treated 
You and other ARPEs contributors who work with you should set the documentation 
standards for counting under these instructions. For example, you might require that each 
claim of a previous positive skin test result be backed by documentation before it is 
counted under LTBI in the report. With so many subtleties to counting prevalent infection 
from historical information, you should strive for consistency by working with your 
colleagues and establishing the counting criteria for your jurisdiction. 
Probably a small fraction of individuals who are counted under LTBI because of historical 
information will turn out to be candidates for treatment of LTBI. You should take this into 
account when interpreting results from the targeted-testing report. 
Note about anergy: In making a diagnosis of LTBI, only the results from tuberculin skin tests should 
be considered, not from skin tests with other antigens (i.e., control antigens, or an anergy panel). 
However, if persons with a negative tuberculin skin test result are to be treated for suspected LTBI, 
then they should be counted in this report as TB infected. 
Recent guidelines about finding and treating LTBI have discounted tests for cutaneous 
anergy. Cutaneous anergy is detected by various combinations of control antigens referred 
to as an anergy panel. The reasons for this trend of discontinuing anergy testing are 
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beyond the scope of this manual. At present, the tuberculin skin test is the only type of test 
that is taken into consideration when counting outcomes for the targeted-testing report. 
(However, the discovery of improved blood tests for diagnosing M. tuberculosis infection is 
likely to change this practice.) 
Occasionally persons who have a negative tuberculin skin test result are prescribed a full 
course of treatment for LTBI. If such persons are to be counted as treated for the targeted- 
testing report, they also have to counted as infected under LTBI, because they are 
receiving full treatment for presumed LTBI. In reality, this hardly ever happens in
connection with targeted testing. It is more likely with contact investigations, especially 
with HIV-infected contacts. 
LTBI, (sorted by risk). Under the Project and Individual formats of Targeted Testing, the persons 
who have LTBI are divided into categories according to TB risk factors. Every person who is counted 
as latently TB infected should be classified into one of these two categories: Medical Risk and 
Population Risk. Persons who have both a medical risk and a population risk should be counted 
under Medical Risk. Persons who have no known risks should be counted under Population Risk.
This stratification (i.e., branch point) is a distinctive feature of the targeted-testing report. 
All persons who have LTBI are grouped into one of two categories. Although some 
preliminary information about tuberculosis risks usually is collected as part of initial 
screening for infection, complete information usually is collected after a diagnosis of LTBI 
has been made. This is why the LTBI (sorted by risk) section is located at this point in the 
report.
Usually you can classify individuals who have LTBI into one of the two categories from 
information on hand, and the records for targeted-testing activities should include 
tuberculosis risks as routine information. For instances where the information is 
incomplete, then the default assignment should be to Population Risk because this is the 
more common reason for targeted-testing activities. 
Sometimes an individual has multiple risk factors for LTBI or tuberculosis disease. If any 
of the reasons fits under Medical Risk, then this should be the classification. For example, 
if targeted testing is done at a county jail, where the general reason for testing is the 
population-based tuberculosis risk associated with correctional facilities, but an individual 
inmate who has LTBI also has diabetes, which is a medical risk for tuberculosis disease, 
then the individual should be counted under Medical Risk. This category is at higher 
priority because the indication for treatment generally is clear and the opportunity for 
preventing cases is greater. 
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Medical Risk. Latently TB-infected persons are counted under this category if they have a condition 
known to predispose to TB disease, usually a concurrent medical diagnosis (see box, below). The 
treatment of LTBI has increased urgency in this target category. 
Conditions that are counted under Medical Risk 
HIV infection 
Tuberculin skin test conversion 
Fibrotic lesions (on chest x-ray) consistent with old, healed TB 
Injection drug use 
Diabetes mellitus 
Prolonged high-dose corticosteroid therapy or other intensive immunosuppressive 
therapy 
Chronic renal failure 
Some hematologic disorders, such as leukemia or lymphoma 
Specific malignant neoplasms, such as carcinoma of the head or neck 
Weight at least 10 percent less than ideal body weight 
Pulmonary silicosis 
Gastrectomy or jejunoileal bypass 
Age < 5 years 
Recent exposure to TB 
Each of the conditions listed in the box has been reported to promote the progression from 
M. tuberculosis infection to tuberculosis disease. (The conditions that could be included 
under the categories in the list are numerous, and consultation with medical experts is 
necessary for including all possibilities.) Sometimes the conditions that qualify for 
counting under this category are noted before the diagnostic evaluation for LTBI because 
the information is helpful for interpreting the tuberculin skin test results. The information 
always should be pursued after the diagnosis of LTBI has been made. Record-keeping 
systems that routinely include this information will facilitate reporting. 
The presence of any of these medical risks increases the likelihood of tuberculosis 
developing and thus increases the potential benefit of treating LTBI. In general, the 
completion of treatment for these individuals is a higher priority than it is for the other 
risk category, Population risk, although other factors come into setting priorities. 
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Population Risk. Latently TB-infected persons are counted under this category if they are members of 
socially or demographically defined groups known to have a high prevalence rate of TB infection or a 
high transmission rate (see box, below). 
Circumstances that are counted under Population Risk 
Residency or occupation in high-risk congregate settings: 
 Prisons and jails 
 Healthcare facilities 
Nursing homes and long-term facilities for the elderly 
Shelters for homeless persons 
Birth in a country having a high prevalence or incidence of TB: Includes 
 Immigrants  
 Refugees 
 Students  
Some migrant workers  
Socioeconomic predictors of exposure:  
 Low income  
 Inner-city residence  
 Migrant labor  
The social situations that are grouped under Population Risk are highly heterogeneous. 
Each has been associated with increased incidence rates of tuberculosis or prevalence rates 
of LTBI. The reason in each example is the particular likelihood of exposure to contagious 
tuberculosis. 
On average, more persons are included in targeted-testing activities because of population 
risks than because of medical risks. The heterogeneous content of this category means that 
the interpretation of aggregated data is limited. The local interpretation of data, when the 
content can be described specifically, is more meaningful. Specific local data should be 
studied for assessing whether a testing activity is productive, because the social situations 
listed in the box (above) are for general guidance purposes only and do not predict the 
risk of infection equally well in every setting. 
Sometimes an individual is included in a targeted-testing project, but after the diagnosis of 
LTBI has been made, the determination about risk category is impossible or unfeasible. 
For reporting purposes, the individual should be counted in the Population Risk category 
as a default. 
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Candidates for Treatment. Latently TB-infected persons are counted in this category if they should 
receive treatment according to the treatment guidelines in effect at the time. Counting under this 
category should be determined according to medical and epidemiological factors, even if treatment 
will not be prescribed because of other factors. Persons who are not candidates for treatment because 
of temporary conditions (e.g., treatment will be deferred because of pregnancy) should not be counted 
under this category, even if treatment is planned for the future. When the deferred treatment is given, 
it can be counted in Part III. Referral Counts. (Note: In the other report, Contact Follow-up, the 
Candidates for Treatment category is not included.) 
This category is an important part of the targeted-testing report. It is not part of the contact 
reports because all contacts who have LTBI are assumed to be candidates for treatment. In 
successful targeted-testing activities, most persons who are found to have LTBI are also 
candidates for treatment. However, in any circumstance, some persons who have LTBI are 
not candidates for treatment for various reasons, such as previous tuberculosis treatment, 
contraindications against specific medicines, high risk of adverse effects from treatment, or 
a very low risk for active TB. 
The guidelines for selecting candidates for treatment of LTBI are context sensitive, and 
they are dependent on judgment; ultimately someone has to make a determination about 
whether an individual should be considered a candidate, at least for counting purposes. 
This ambiguity creates the possibility for inconsistency in reporting, which is a reflection 
of the uncertainty in the recommendations for treatment of LTBI. For reporting purposes, 
you should seek optimal consistency by working with an ARPE coordinator. 
In some jurisdictions, the guidelines for selecting treatment candidates are different from 
the national guidelines. The operational treatment guidelines are the ones that should be 
used for counting Candidates for Treatment. If treatment guidelines change during the 
course of a reporting year, then the guidelines in effect at the particular moment can be 
used for counting purposes. (The distinction has little effect in most instances, and a 
decision can be made to consider all the patients under one set of guidelines or the other 
for efficiency, as long as the potential discrepancy is noted.) 
In contrast, sometimes a provider will recommend against treating LTBI because that 
patient has unstable circumstances or expresses reluctance to participate. This decision not 
to treat is up to the provider and the patient; however it is different from the criteria for 
Candidates for Treatment. Candidates for Treatment is based on the medical and 
epidemiological criteria for deciding when to recommend treatment to a patient, and a 
reluctance to prescribe or to be treated should not be considered for reporting purposes. 
Possibly patients could be started on treatment for LTBI when they are not actually, by 
guidelines or recommendations, candidates for treatment. If the treatment is to be counted 
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on the targeted-testing report, then the individuals also should be counted as treatment 
candidates in order to maintain flow of data. Such events represent a potentially inefficient 
use of resources and also a risk to patients, and therefore further inquiry is warranted. 
Started Treatment. A person who has LTBI is counted under this category after the first dose of a 
planned full-treatment course for LTBI. The determination of whether the first dose has been taken is 
based on the best available information, which is often the person’s statement. If a person is lost to 
follow-up after treatment was prescribed and information is unavailable about whether any 
medication was taken, then treatment can be considered started if the medicine was picked up from a 
clinic or pharmacy. 
The two components of this instruction are (1) that the patient has been counted under 
LTBI for the evaluation outcome and (2) the patient receives at least the first dose of 
treatment. (The patient also has to be counted as a candidate for treatment.) The concept 
for the first point is that treatment implies that LTBI has been diagnosed, and the details 
meet the ARPE definition for LTBI. 
The counting requirement about the first dose of treatment can be difficult to determine 
with certainty unless a patient is receiving directly observed therapy, which is provided 
more often for contacts than for TB-infected persons found during targeted testing. 
Sometimes you and other providers have to rely on substitute methods for ascertaining 
the start of treatment. The best and simplest method is asking the patient about it in an 
interview, and if the response from the contact can be validated by a pill count, this is even 
better.
However, sometimes the information about starting treatment is inaccessible. For this 
circumstance, the only substitute is a confirmation that the patient filled a prescription for 
treatment of LTBI. When even this information is unavailable, then treatment should not 
be regarded as started. In particular, the existence of a prescription or a medical order to 
start treatment should not be considered adequate for counting under the category of 
Started Treatment.
Completed Treatment. (Note: this category is based partly on an arbitrary definition of completion. It 
might not be equivalent to an adequate course of therapy.) A person is counted under this category (1) 
if the prescribing provider, believing that an adequate regimen has been received, discontinues 
treatment, and (2) if the person has taken at least 80 percent of the prescribed doses in a therapy 
course within a period of 150 percent of the selected duration of therapy. The determination about 
whether the definition is met is made from the best available information, which is generally the 
provider’s records and the person’s statements. 
A simplistic definition is necessary for Completed Treatment because this element is 
intrinsically difficult to describe and measure. Even with this definition, Completed
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Treatment is likely to cause confusion and disagreement. Consistency should be your 
highest priority. The instructions here are the same as for the aggregate report of contacts, 
but you should be aware that the circumstances of targeted-testing projects are different 
from contact investigations, and the information that is available to you in determining 
completion of treatment is likely to be different. 
One overriding factor: The definition for Completed Treatment is not a substitute for 
guidelines for treating LTBI. Treatment practices should be based on local, state, and 
national policies or guidelines, and decisions for individual patients are between 
healthcare providers and their patients. None of the ARPE definitions are intended as 
references for medical care or case management. 
The definition for Completed Treatment includes three requirements: 
1. The provider discontinues treatment after conclusing that the patient has 
completed a recommended treatment regimen. Decisions by the patient or program 
administrators are not equivalent for meeting the definition. Thus, administrative 
close-outs do not meet the definition. (An administrative close-out is a 
determination by a program administrator that enough treatment was given and 
therefore the treatment is being classified as Completed Treatment even though a 
provider has not discontinued it. This does not meet the definition for the targeted-
testing report.) 
2. The reason for the “80 percent” figure is that some tuberculosis treatment studies 
have used this as an arbitrary cut-point for specifying completion of therapy. When 
intensive monitoring methods such as pill counts or directly observed therapy are 
in effect, the achievement of 80 percent of doses is measurable. In most situations of 
targeted testing, however, data are not available to determine how many doses the 
patients have taken. In these situations, you need a combination of data to make a 
reasonable guess about the number of doses that were taken (and whether or not 
this constitutes 80 percent of what was prescribed). Typical factors you might 
consider are the start date for treatment, the number of prescription refills, clinic 
attendance, and the adherence rate reported by the patient. 
3. Completion within 150 percent of the planned treatment period is a pragmatic 
component of the definition. The purpose is to get the reports closed with finality. 
The targeted-testing report is no longer relevant if every single open treatment 
record is pursued to the point of final determination. Patients who are still on 
treatment at the time point that is one-and-one-half times (i.e., 150 percent of) the 
intended duration should be regarded as not completed for the sake of the contact 
report, even if completion might be reached at a later date. 
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A number of factors can complicate determinations about Completed Treatment. An 
example is patients who require a change of regimen midway through a course. Another 
example is patients who start and stop treatment several times. For the targeted-testing 
report, you sometimes have to make arbitrary decisions about how to count these events. 
As much as possible, you should make these decisions consistently when similar 
situations arise and uniformly across reporting sites. Consultation with your ARPE 
coordinator or your DTBE program consultant is recommended. 
Reasons Treatment Not Completed: This section catalogues some general reasons that the treatment 
for LTBI is not being completed. 
The instructions here are nearly to identical those for the aggregate report of contacts, with 
the exception of the omission of the word “contact” here. However, in the broader 
perspective, you should be aware that the circumstances of targeted-testing projects are 
different from contact investigations, and the information that is available to you is likely 
to be different. Also, the priority that is placed on treating LTBI found during targeted 
testing sometimes is lower than the priority placed on treating LTBI found during contact 
investigations. Therefore, less energy will be spent on tracing these patients if, for 
example, they appear to be nonadherent to a treatment regimen. 
Although DTBE encourages submission of this information about incomplete treatment to 
the national tuberculosis program, the main purpose of this section of the report is to 
assist local and state tuberculosis control programs to assess the obstacles that prevent 
completion of therapy within their jurisdictions. A major shortcoming of these data is that 
they are peculiar to local context; therefore these data have uncertain meaning when 
combined with reports from other areas. In addition, tuberculosis controllers have 
reported that interpretations of the definitions vary substantially from site to site; 
therefore the data that are aggregated from multiple reporting areas consist of mixed 
information. The definitions used in the instructions should be followed as closely as 
possible under the circumstances. 
The categories under Reasons Treatment Not Completed have a relative hierarchy: in a 
situation where several reasons for incomplete treatment might apply to one patient, the 
most specific reasons should be selected. In general, the reasons near the top of the list are 
more specific and less subjective. Some of the reasons are more serious, for example, death 
during treatment or adverse effects of treatment. These events are likely to require further 
attention; therefore they should be captured whenever possible. 
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You should set a goal of counting each instance of incomplete treatment under one of the 
categories of Reasons Treatment Not Completed. However, you can expect difficulties in 
doing this and accept that you might not be able to assign a reason for each patient. DTBE 
does not require that the sum of patients who are counted under the categories of Reasons
Treatment Not Completed equal 100 percent of all the patients who do not complete 
treatment, although a local or state tuberculosis program might decide to do so.
Death. Persons who were receiving treatment on schedule but who had treatment interrupted by 
death before completion are counted under this category. (Note: Because of the seriousness of this 
outcome and the unreliability of anecdotal reports, a verification of any deaths is helpful for accuracy 
in reporting.) 
Death is a rare reason that patients with LTBI do not complete treatment. As estimated 
from previous reporting systems for treatment of LTBI, death occurs in less than 0.5 
percent of patients while they are receiving treatment. You should be alert to reports of 
death in patients for two general reasons: (1) The report might be inaccurate and you 
should verify it and (2) if the report is accurate, you need to know whether the death 
might be somehow related to the treatment of LTBI or to active tuberculosis that escaped 
your attention. 
For counting events under this category it is important to determine whether death was 
the reason that treatment was stopped, that is, the proximate reason. For example, if a 
patient dies while still receiving treatment after 3 months, then Death is the appropriate 
category. However, if the patient decides to stop treatment after 1 month and then dies 2 
months later (unless a complication of treatment caused a late death), the closest reason 
that treatment was incomplete was the patient's decision, which you should record in that 
category.
If the patient stops treatment because of an illness or injury that proves fatal, this outcome 
should be included under Death. Under these circumstances, the treatment of LTBI is 
likely to be suspended because of the events events, but the general understanding is that 
the treatment would have been resumed if the patient had survived. On the other hand, if 
the treatment is suspended because of illness (not including an adverse effect of the 
treatment) or injury, and the patient survives but the treatment is discontinued 
permanently by a provider, this would be counted as Provider decision.
Patient Moved (follow-up unknown). Persons who do not complete treatment because they have  
moved or migrated from the jurisdiction of the health department should be counted under this  
category when follow-up information is unavailable. However, if the health department receives  
specific follow-up (e.g., Completed Treatment or Lost to Follow-up) from a receiving jurisdiction,  
then the outcome should be counted accordingly.  
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The programmatic goal for patients who move is to obtain follow-up information as often 
as possible, although treating patients who are found through targeted testing usually has 
lower priority than treating contacts. Although Patient Moved (follow-up unknown) is a 
nonspecific outcome, the patient can be assumed to be unavailable for further public 
health monitoring and completion of therapy. 
Gathering follow-up information about patients who move while being treated for LTBI 
can be difficult. You might need to decide that the additional data that you gain from 
finding out what happens to patients after they move from your jurisdiction does not have 
enough priority relative to your other tasks. This is a realistic approach, but it entails some 
loss of information for the report. Also, your effort in tracing the outcome of patients has 
intangible benefits, such as increasing the odds that a patient who started treatment in 
your jurisdiction will come to the attention of public health providers in another 
jurisdiction.
For counting a patient in this outcome category, you should seek some form of 
confirmation that the patient indeed moved outside of your jurisdiction. One possibility 
that you want to avoid is a patient who claims to be moving (i.e., as an avoidance of public 
health monitoring) when in fact this person is not planning to move. In this instance, the 
correct category for counting would be Patient Chose to Stop because it is closer to the 
facts. Making this distinction requires extra effort, but the distinction is important. 
Patient Moved (follow-up unknown) implies that you know the destination of the person 
who is moving. Without this information, you cannot determine a more specific outcome 
because you have no way to make a referral for continued monitoring of treatment. If you 
believe that the person probably moved but you do not know the destination, then you  
should classify the outcome as Patient is Lost to Follow-up because you are uncertain 
about what happened to the patient. 
Active TB Developed. If a patient who still is receiving treatment for LTBI has active TB that qualifies 
as a case under the standard surveillance definition (i.e., RVCT), then the outcome is counted in this 
category. However, if the treatment regimen already has been stopped before active TB develops 
because of completion or any other reason, then the outcome should not be changed to Active TB 
Developed.
Large-scale trials of LTBI treatment proved that an occasional patient becomes sick with 
active tuberculosis even while under treatment for LTBI. This occurred even with drug-
susceptible M. tuberculosis and in patients who were adherent to treatment. The reasons 
for this phenomenon are unknown; for purposes of ARPEs you should assume that this 
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outcome is rare. 
On the other hand, tuberculosis is more likely to develop in a patient who stops treatment 
for LTBI, and you should attempt to determine if this is the underlying reason for the 
failure of treatment. If you determine that treatment was stopped for some reason before 
active tuberculosis developed, then you should record the proximate reason for stopping 
treatment.
After incomplete or even complete treatment for LTBI, active tuberculosis can develop. 
None of the treatment regimens for LTBI is 100-percent effective in preventing TB, and 
this is even more true for patients who fail to complete therapy. If tuberculosis develops 
after treatment has been stopped (because it was completed or any other reason), then the 
original reason for ending treatment should be retained. 
Note: Sometimes patients are started on treatment for LTBI before all results from medical 
evaluation are obtained. Delayed test results or reinterpretation of early results might 
change a diagnosis from LTBI to active TB. For example, a positive culture result for M.
tuberculosis might not become available until 6 weeks after the collection of a specimen. 
Also for example, abnormalities might be found in the review of chest radiographs that 
initially were interpreted as normal. For these unusual instances, the initial evaluation 
actually was not complete at the time that treatment for LTBI was undertaken. The patient 
should be classified under TB Disease instead of under LTBI. Thus, the treatment start 
itself should not be counted because the LTBI diagnosis was incorrect. The classification of 
LTBI, Started Treatment, and Active TB Developed would be incorrect in this scenario 
because the proper disposition of the patient (for counting in the report) would be TB
Disease.
Adverse Effect of Medicine. Persons who do not complete treatment because of adverse effects 
(including drug-drug or drug-food interactions) of anti-TB medications should be counted in this 
group if a healthcare provider documents the problem and determines that the medicine should be 
discontinued. If a person stops taking the medicine because of an adverse effect but a provider does 
not recommend the discontinuation, then the reason for stopping treatment should be counted as 
Patient Chose to Stop.
All regimens for treating LTBI cause adverse reactions in a few patients, and sometimes 
these reactions are severe or dangerous enough to end treatment. The judgment that is 
required to make this decision is beyond the scope of the targeted-testing report, and in 
each instance the decision to stop treatment rests with a healthcare provider and a patient. 
You can reasonably assume that consistency and uniformity are lacking in how this 
decision is made, but this too is beyond the scope of the report. 
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The crucial detail for counting in this category is that a healthcare provider has 
documented the decision to stop treatment because of the adverse effect. In instances 
where a patient decides to stop treatment because of the adverse effect but a healthcare 
provider has not evaluated the patient and has not decided to discontinue treatment, then 
the reported outcome should reflect the patient's decision as Patient Chose to Stop. For 
example, many anti-TB medicines cause abdominal pain, and this can prompt a patient to 
stop treatment. This would only be counted under Adverse Effect of Medicine if a 
provider evaluated the situation and recommended treatment be stopped. 
An average rate of stopping treatment because of adverse effects should be less than 
approximately five percent. If you find a higher rate, you should be concerned about the 
possibility that treatment is being stopped without sufficient reason or that information is 
being misinterpreted as it is being classified for reporting. 
If the adverse effect of medicine for a patient is fatal, then the outcome should be counted 
under Death rather than under Adverse Effect of Medicine. These events are of particular 
concern, and you should monitor them closely. 
Patient Chose to Stop. Persons who do not complete treatment should be counted in this category if 
they decide to stop taking their medicine before they have received a complete regimen and a 
healthcare provider has not determined that the medicine should be discontinued for a medical 
reason. 
This category is almost self-explanatory, but it also has its confusing points. One example 
is a patient who moves from your jurisdiction and deliberately leaves incorrect locating 
information. You would be reasonable in believing that the patient chose to stop treatment 
because that message is implicit, but a better classification would be Lost to follow-up.
When you are counting a patient who did not complete treatment under the category of 
Patient Chose to Stop, you should be able to determine the whereabouts and the clinical 
condition of the patient. Whether or not you seek out the patient to encourage resumption 
of treatment or check on health status depends on your program resources and priorities. 
However, when you count a patient under this category, you are implying that you have a 
way to check on the person. 
Patient is Lost to Follow-up. Persons whose treatment status at the end of the expected treatment  
regimen is incomplete or indeterminate because the health department cannot locate them for  
determining a more specific outcome should be counted in this category.  
When you really cannot determine what became of a patient who was on treatment for 
LTBI, Patient is Lost to Follow-up is the category. You might be concerned that this 
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category depends on how much effort is spent on finding a patient, and probably it does. 
It is likely that if you had the resources and information for finding all patients who seem 
to vanish, some of them would tell you that they prefer not to return to clinic. 
In fact, resources are limited, and you have to set priorities when it comes to tracing 
absconders. You would be correct in guessing that from place to place resource levels for 
tracing lost patients are different, and the priority assigned to this activity varies. Also, the 
local context influences this factor. If you work in a small community where everyone 
knows everyone else, a patient is less likely to disappear than if you are in an urban 
setting with social anonymity. This shows why program-process evaluation reports such 
as ARPEs are not fully comparable from one place to the next. 
Provider Decision. If a healthcare provider determines that the treatment for LTBI should be stopped 
because of concerns about the benefits, the safety, or the practicality of treatment (e.g., a person has 
such erratic attendance at the clinic that the adequacy and the safety of the treatment cannot be 
monitored), then this is the reported reason. 
This is a narrow category among reasons that treatment was not completed. You should 
not expect to encounter it often. You should count a patient under Provider Decision only 
if a healthcare provider has decided in good faith, prospectively, to discontinue treatment 
because of some medical concern. (If, however, the medical concern is brought about by 
an actual adverse effect, then the patient should be counted under that category instead.) 
Provider Decision cannot be defined for every circumstance because the situation for each 
patient is different, and each healthcare provider has a different sense of judgment. 
The main problem to avoid for counting patients under this category is the retrospective 
interpretation of data. Provider Decision should not be used as a default or an escape for 
counting outcomes when only incomplete information is available. 
The following are some reasonable examples of Provider Decision. By checking the 
outcomes for patients in your program against these examples, you have a frame of 
reference for typical situations that could be counted under this category: 
An elderly woman with LTBI has alcoholism. The healthcare provider is concerned 
about liver injury associated with isoniazid, and the plan is to check the patient in 
clinic and to do blood tests every other week to monitor for early evidence of liver 
injury. However, this patient does not keep clinic appointments and is difficult to 
locate when outreach workers search for her. The healthcare provider is concerned 
that the patient either is skipping her treatment or is in jeopardy from adverse 
effects of isoniazid. Therefore, the provider discontinues treatment. 
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A man who is being treated for LTBI is found to have cancer and starts intensive 
chemotherapy, and this makes him very sick. The healthcare provider decides to 
postpone treatment of LTBI indefinitely until the more urgent medical issues are 
settled. This amounts to an indefinite discontinuation of treatment. The provider is 
concerned that this patient could become sick with TB; therefore careful monitoring 
is planned so that tuberculosis can be discovered early if it develops. 
A woman who is being treated for LTBI becomes pregnant during the 4th month of 
isoniazid treatment. She and the healthcare provider agree to postpone treatment 
until well after the birth of the baby (although this is not quite in keeping with 
treatment guidelines). For practical purposes you determine that treatment for this 
patient should be counted as incomplete, and you assign the outcome to Provider
Decision.
Part II. Evaluation Indices for Testing.
This section of the report is the summary statistics that are calculated from the aggregate data entered 
into Part I of the report. The indices are calculated automatically and presented as percentages by 
TIMS. The formulae are shown in the paper-copy table to show the source figures for the calculations. 
The instructions here are identical to those for the contact report, except that the terms are 
changed to reflect the different purposes of the reports. Note also that some specific 
indices are different between the two reports, which reflects the different activities. 
The purpose of the evaluation indices is to give you a synopsis of the data flow in the 
targeted-testing report. Each index reflects the average result of a specific process that is 
shown in the report. You could regard each index as a measurement of performance, but 
that interpretation generally is overly simple. Better that you regard the indices as general 
comparators (i.e., for comparison to national averages) and as clues for determining which 
activities in targeted-testing projects need your closer scrutiny. (See page 99, How to 
interpret and use the ARPE results, for additional suggestions about interpreting the 
indices.)
ARPEs differ from some other or previous U.S. tuberculosis program reports in that the 
indices are not adjusted for mitigating factors. For example, the treatment completion rate 
does not exclude patients who move from your jurisdiction after starting treatment, and 
therefore the treatment rate is diminished by the departure of these patients. This is a 
controversial point, but you have the option of calculating indices with adjustments, for 
your purposes. In the national report, no adjustments are made. 
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When ARPEs are entered into TIMS, the software program will calculate indices initially 
and then will recalculate them when you edit/update the data. The formulae that appear 
in the printed ARPE forms are the basis for those built into TIMS. If you use paper-copy 
forms, or computer-screen mock-up forms, you must remember to recalculate the indices 
after counts are edited/revised in the upper sections of the forms. If you use spreadsheet 
software programs for recording ARPE data, you can incorporate the formulae that are 
shown in the paper-copy form. 
Part III. Referral Counts.
Persons are included in this section when they are being evaluated for the treatment of LTBI, usually 
diagnosed with a positive tuberculin skin test result, and when they cannot be counted as part of the 
testing denominators in the Part I of the report. Part III also includes the persons with LTBI who had 
their treatment delayed beyond a reporting period after they were evaluated and it includes the 
certain contacts who cannot be counted under the treatment categories in the report of contact follow-
up.
You can use this section of the targeted-testing report for many purposes, but all the uses 
are related to one general concept: data are initiated with the diagnosis of LTBI, and not 
with enrollment into screening or testing. Ideally, the number of persons who were sought 
for testing or who were tested would be recorded, because this information is vital to 
determining the validity of prevention activities. However, circumstances sometimes do 
not allow this. 
Health care providers outside of the public health system offer tuberculin skin testing. In 
some settings or jurisdictions, these other providers even do most or all testing. If they 
refer the patients who have positive skin test results to the health department for 
additional diagnostic tests and treatment, then this section of the report, Part III Referral 
Counts, can be used for keeping track of the activities and the results. (If the health 
department arranges with the other providers to keep track of the number of persons 
sought for testing and the number tested, then the first page, Part I Testing Counts, of the 
targeted-testing report is a more comprehensive way of recording the information.) 
Particular details in the definitions for other sections of both the contact report and the 
targeted-testing report allow for unusual events (that do not fit into those other sections) 
to be recorded in this part of the targeted-testing report. The typical example is a contact 
who has a previously recorded diagnosis of LTBI before the current contact investigation. 
The previous LTBI diagnosis is not counted as LTBI for the contact report; the contact is 
considered evaluated, but the data flow for that individual ends at that point (i.e., 
treatment for LTBI should not be recorded on the contact report because infection is not 
being counted there). If treatment is recommended for that contact, then the process steps 
can be recorded in the targeted testing report, in Part III Referral Counts. Whether or not 
88  
these activities warrant the extra effort of using the targeted-testing report is a decision for 
local and state health tuberculosis control officials, in consultation with the DTBE program 
consultant.
Referred. This is the number of persons who are registered for the confirmation (and often treatment) 
of presumed LTBI, whether or not TB disease has been excluded already. 
In general, the persons who are referred to the health department already have had a skin 
test for M. tuberculosis infection and sometimes further evaluation for TB. Some arrive after 
full evaluation for LTBI, but a more common scenario is arriving with a positive 
tuberculin skin test result and no other medical evaluation yet. In some settings, even the 
reading of the skin test can be questionable. 
The count for Referred depends on how the local systems are arranged. If health care 
providers (external to the health department) are notifying the health department before 
sending patients, then the notifications can trigger counting. Alternatively, if providers ask 
patient to make their own arrangements with the health department, then the initial 
communication (e.g., telephone request for appointments) with patients can trigger 
counting. Another method would be counting patients when they actually arrive and 
register. You should select the method for counting that fits the circumstances and the 
needs for evaluation. Feasibility/efficiency of data collection is another factor you should 
take into account. DTBE does not recommend any specific method, but the DTBE program 
consultants can offer suggestion for your specific circumstances. 
One factor you can consider is the loss rate in the referral process. For example, if an HIV 
clinic refers its patients that have positive skin test results for further tests and treatment, 
but only 50% of the patients come to the health department for the tuberculosis evaluation, 
then this loss rate might be important statistically. The targeted-testing report does not 
have a way to do this because it does not include an evaluation rate. In contrast, if the 
referrals are for food service workers who have pre-employment testing, and the urgency 
to provide treatment for LTBI is comparatively minor, then the loss rate might not be such 
an important number. The decision really depends on what you are trying to measure, 
and of what value could the statistics be to your program. 
TB Disease. As defined for Part I.
The description presented here is identical to that for Part I. In general, patients who are 
referred because of positive tuberculin skin test results rarely have tuberculosis disease. 
Therefore, if a substantial fraction (e.g., > 1%) have tuberculosis disease, then this alerts 
you of a need for further exploration. 
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Note that this definition for TB Disease is different than the one used for the contact 
report. The main difference is that you also should count prevalent cases, that is, cases that 
already have been diagnosed, as TB Disease in the targeted-testing report. 
Targeted testing is not designed for active case-finding for TB. Active case-finding means 
evaluating the individuals in a defined population for tuberculosis disease. This contrasts 
with passive case-finding, which means waiting for individuals to seek medical care 
because of tuberculosis symptoms. (These terms are not the same as active surveillance 
and passive surveillance, which are contrasting strategies for collecting tuberculosis case 
reports.)
Active case-finding usually is not efficient as a part of targeted-testing activities because 
tuberculosis cases are comparatively rare in most U.S. populations. On average, fewer 
than 1 per 10,000 persons has tuberculosis at a given time. In selected populations, the 
prevalence rate might be greater than 1 in 1,000, and in these populations, active case-
finding might be efficient. The tuberculin skin test is not a sensitive or specific method for 
active case-finding; therefore targeted-testing activities that include a component of active 
case-finding require an ancillary testing method, such as chest radiography. The targeted-
testing report is not designed for evaluating active case-finding projects. However, 
projects that combine targeted testing with active case-finding can be evaluated with the 
targeted-testing report. 
The case definition for TB Disease is the same as that of the national case definition in the 
RVCT instructions. However, the counting instructions are different. For RVCT, the 
determination about jurisdiction and who counts the case is connected to the address of 
the patient and several other details. For the targeted-testing report, if you counted the 
person for the report, then you count the tuberculosis case under TB Disease, even if 
another jurisdiction is counting the case for RVCT national surveillance. This happens in 
targeted-testing projects that include persons who reside in different jurisdictions. 
The targeted-testing report is designed to include prevalent tuberculosis disease and LTBI. 
Therefore, findings from sources apart from the targeted testing can be counted as 
outcomes in this report. For example, if a person who is included in a testing project has 
active tuberculosis and the case was diagnosed before the person was enrolled in the 
testing project, this case should be counted in the targeted-testing report. However, if a 
person is initially diagnosed as having LTBI after the complete diagnosis but active 
tuberculosis develops in that person later, then the classification should remain as LTBI 
because that was the determination of the targeted testing. 
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If a person who is included in targeted testing has a history of resolved tuberculosis 
disease, treated or not, and if the history for tuberculosis disease is documented to the 
extent that meets local standards, then this person should be classified as having LTBI 
after the diagnostic evaluation is completed. Depending on the circumstances and the 
judgment of the healthcare providers, a test for M. tuberculosis infection might not be 
necessary for the evaluation because it would it would not be helpful. Such a person also 
might be classified as a candidate for treatment of LTBI if the tuberculosis was not treated 
before or was not treated completely. 
LTBI. As defined for Part I.
The description presented here is identical to that in Part I. In general, patients who are 
referred because of positive tuberculin skin test need further diagnostic history and tests 
before the LTBI determination can be made. The history should include questions about 
tuberculosis risks, as pertains to the risk categories used in the targeted-testing report, and 
the tests usually include a chest radiograph at a minimum for excluding tuberculosis 
disease. In some instances you might need to recheck the skin test reading or even repeat 
the skin test, and these details would be part of the evaluation process. The decisions 
about how to diagnose or verify LTBI in referred patients are dependent on numerous 
factors that are beyond the scope of ARPEs. 
The goals of targeted testing are finding LTBI and getting it treated in order to prevent 
future tuberculosis cases. For these activities to be efficient, the prevalence rate of latent 
infection should be greater than the national average, which might be on the order of one 
to five percent (averaged) for adults in the United States. The efficiency of the prevention 
activities is increased even more if the infected individuals also have risk factors for 
progression to active TB. 
Obtaining the diagnostic outcome of LTBI requires a range of activities, although only the 
outcome itself is counted in the targeted-testing report. First is an interview to determine 
whether the patient already has symptoms of active tuberculosis or a history of 
tuberculosis exposure, infection, or disease. Next is a tuberculin skin test (generally this 
has been done already for patients referred to the health department) to detect evidence of 
LTBI. The skin test should be interpreted according to local policies or guidelines. Finally, 
if the skin test result is positive, a chest radiograph (i.e., x-ray) and sometimes other tests 
are needed to exclude active TB. The selection of tests for excluding active tuberculosis 
depends on the circumstances and the healthcare provider’s judgment. 
A two-step skin test is not recommended for targeted testing. Two-step testing is 
necessary for initial testing upon entry to infection-control surveillance programs, with the 
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individuals being retested according to a routine schedule, for example, annually.  
However, the targeted-testing report usually is not suitable for these types of surveillance 
data.
For each individual, the determination about the LTBI diagnosis is up to the healthcare 
provider. Discrepancies between guidelines and diagnoses should be resolved by 
jurisdictional public health officials. The targeted-testing report is not designed to  
evaluate diagnostic practices for LTBI; the report has a built-in assumption of correct 
practices.
This counting category (LTBI) can include individuals who did not have LTBI diagnosed 
directly as part of a current testing activity. This instruction is different from that for the 
contact report. For the targeted-testing report, individuals who have historical
information about tuberculosis infection can be counted under LTBI (as having possible 
prevalent infection). The two examples are 
1. Previous positive skin test result, whether or not LTBI was treated 
2. Previous tuberculosis disease that is healed now, whether or not it was treated 
You and the other ARPE contributors should set the documentation standards for 
counting under these instructions. For example, you might require that each claim of a 
previous positive skin test result be backed by documentation before it is counted under 
LTBI in the report. With so many subtleties to counting prevalent infection from historical 
information, you should strive for consistency by working with your colleagues and 
establishing the counting criteria for your jurisdiction. 
Probably only a small fraction of individuals who are counted under LTBI because of 
historical information will turn out to be candidates for treatment of LTBI. You should 
take this into account when interpreting results from the targeted-testing report. 
Candidates for Treatment. As defined for Part I.
The description presented here is identical to that for Part I. For referred patients, the 
likelihood that they will be candidates for treatment depends on the reasons that they are 
being tested. Patients who are referred after “routine” (i.e., non-targeted) testing are less 
likely to be candidates for treatment. 
This category is an important part of the targeted-testing report. It is not even part of the 
contact reports because all contacts who have LTBI are assumed to be candidates for 
treatment. In successful targeted-testing activities, most persons who are found to have 
LTBI are also candidates for treatment. However, in any circumstance, some persons who 
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have LTBI are not candidates for treatment for various reasons, such as previous 
tuberculosis treatment, contraindications against specific medicines, high risk of adverse 
effects from treatment, or a very low risk for active TB. 
The guidelines for selecting candidates for treatment of LTBI are context sensitive, and 
they are dependent on judgment; ultimately someone has to make a determination about 
whether an individual should be considered a candidate, at least for counting purposes. 
This ambiguity creates the possibility for inconsistency in reporting, which is a reflection 
of the uncertainty in the recommendations for treatment of LTBI. For reporting purposes, 
you should seek optimal consistency by working with an ARPE coordinator. 
In some jurisdictions, the guidelines for selecting treatment candidates are different from 
the national guidelines. The operational treatment guidelines are the ones that should be 
used for counting Candidates for Treatment. If treatment guidelines change during the 
course of a reporting year, then the guidelines in effect at the particular moment can be 
used for counting purposes. (The distinction has little effect in most instances, and a 
decision can be made to consider all the patients under one set of guidelines or the other 
for efficiency, as long as the potential discrepancy is noted.) 
In contrast, sometimes a provider will recommend against treating LTBI because that 
patient has unstable circumstances or expresses reluctance to participate. This decision not 
to treat is up to the provider and the patient; however it is different from the criteria for 
Candidates for Treatment. Candidates for Treatment is based on the medical and 
epidemiological criteria for deciding when to recommend treatment to a patient, and a 
reluctance to prescribe or to be treated should not be considered for reporting purposes. 
Possibly patients would be started on treatment for LTBI when they are not actually, by 
guidelines or recommendations, candidates for treatment. If the treatment is to be counted 
on the targeted-testing report, then the individuals also should be counted as treatment 
candidates in order to maintain flow of data. Such events represent a potentially inefficient 
use of resources and also a risk to patients, and therefore further inquiry for program 
evaluation is warranted. 
Started Treatment. As defined for Part I.
The description presented here is identical to that for Part I.
The two components of this instruction are (1) that the patient has been counted under 
LTBI for the evaluation outcome and (2) the patient receives at least the first dose of 
treatment. (The patient also should be counted as a candidate for treatment.) The concept 
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for the first point is that treatment implies that LTBI has been diagnosed, and the details 
meet the ARPE definition for LTBI. 
The point about the first dose of treatment can be difficult to determine with certainty 
unless a patient is receiving directly observed therapy, which is provided more often for 
contacts than for TB-infected persons found during targeted testing. Sometimes you and 
other providers have to rely on substitute methods for ascertaining the start of treatment. 
The best and simplest method is asking the patient about it in an interview, and if the 
response from the contact can be validated by a pill count, this is even better. 
However, sometimes the information about starting treatment is inaccessible. For this 
circumstance, the only substitute is a confirmation that the patient filled a prescription for 
treatment of LTBI. When even this information is unavailable, then treatment should not 
be regarded as started. In particular, the existence of a prescription or a medical order to 
start treatment should not be considered adequate for counting under the category of 
Started Treatment.
Completed Treatment. As defined for Part I.
The description presented here is identical to that for Part I.
A simplistic definition is necessary for Completed Treatment because this element is 
intrinsically difficult to describe and measure. Even with this definition, Completed
Treatment is likely to cause confusion and disagreement. Consistency should be your 
highest priority. The instructions here are the same as for the aggregate report of contacts, 
but you should be aware that the circumstances of targeted-testing projects are different 
from contact investigations, and the information that is available to you in determining 
completion of treatment is likely to be different. 
One overriding factor: The definition for Completed Treatment is not a substitute for 
guidelines for treating LTBI. Treatment practices should be based on local, state, and 
national policies or guidelines, and decisions for individual patients are between 
healthcare providers and their patients. None of the ARPE definitions are intended as 
references for medical care or case management. 
The definition for Completed Treatment includes three requirements: 
1. The provider discontinues treatment after concluding that the patient has 
completed a recommended treatment regimen. Decisions by the patient or program 
administrators are not equivalent for meeting the definition. Thus, administrative 
close-outs do not meet the definition. (An administrative close-out is a 
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determination by a program administrator that enough treatment was given and 
therefore the treatment is being classified as Completed Treatment even though a 
provider has not discontinued it. This does not meet the definition for the targeted-
testing report.) 
2. The reason for the “80 percent” figure is that some tuberculosis treatment studies 
have used this as an arbitrary cut-point for specifying completion of therapy. When 
intensive monitoring methods such as pill counts or directly observed therapy are 
in effect, the achievement of 80 percent of doses is measurable. In most situations of 
targeted testing, however, data are not available to determine how many doses the 
patients have taken. In these situations, you need a combination of data to make a 
reasonable guess about the number of doses that were taken (and whether or not 
this constitutes 80 percent of what was prescribed). Typical factors you might 
consider are the start date for treatment, the number of prescription refills, clinic 
attendance, and the adherence rate reported by the patient. 
3. Completion within 150 percent of the planned treatment period is a pragmatic 
component of the definition. The purpose is to get the reports closed with finality. 
The targeted-testing report is no longer relevant if every single open treatment 
record is pursued to the point of final determination. Patients who are still on 
treatment at the time point that is one-and-one-half times (i.e., 150 percent of) the 
intended duration should be regarded as not completed for the sake of the contact 
report, even if completion might be reached at a later date. 
A number of factors can complicate determinations about Completed Treatment. An 
example is patients who require a change of regimen midway through a course. Another 
example is patients who start and stop treatment several times. For the targeted-testing 
report, you sometimes have to make arbitrary decisions about how to count these events. 
As much as possible, you should make these decisions consistently when similar 
situations arise and uniformly across reporting sites. Consultation with your ARPE 
coordinator or your DTBE program consultant is recommended. 
Reasons Treatment Not Completed: All reasons as defined for Part I.
The description presented here matches that for Part I. However, the specific reasons are 
not defined separately here. Their definitions should be the same here as there. 
The instructions here are nearly identical to those for the aggregate report of contacts, with 
the exception of the omission of the word “contact” here. However, in the broader 
perspective, you should be aware that the circumstances of targeted-testing projects are 
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different from contact investigations, and the information that is available to you is likely 
to be different. Also, the priority that is placed on treating LTBI found during targeted 
testing sometimes is lower than the priority placed on treating LTBI found during contact 
investigations. Therefore, less energy will be spent on tracing these patients if, for 
example, they appear to be nonadherent to a treatment regimen. 
Although DTBE encourages submission of this information about incomplete treatment to 
the national tuberculosis program, the main purpose of this section of the report is to 
assist local and state tuberculosis control programs to assess the obstacles that prevent 
completion of therapy within their jurisdictions. A major shortcoming of these data is that 
they are peculiar to local context; therefore these data have uncertain meaning when 
combined with reports from other areas. In addition, tuberculosis controllers have 
reported that interpretations of the definitions vary substantially from site to site; 
therefore the data that are aggregated from multiple reporting areas consist of mixed 
information. The definitions used in the instructions should be followed as closely as 
possible under the circumstances. 
The categories under Reasons Treatment Not Completed have a relative hierarchy: in a 
situation where several reasons for incomplete treatment might apply to one patient, the 
most specific reasons should be selected. In general, the reasons near the top of the list are 
more specific and less subjective. Some of the reasons are more serious, for example, death 
during treatment or adverse effects of treatment. These events are likely to require further 
attention; therefore they should be captured whenever possible. 
You should set a goal of counting each instance of incomplete treatment under one of the 
categories of Reasons Treatment Not Completed. However, you can expect difficulties in 
doing this and accept that you might not be able to assign a reason for each patient. DTBE 
does not require that the sum of patients who are counted under the categories of Reasons
Treatment Not Completed equal 100 percent of all the patients who do not complete 
treatment, although a local or state tuberculosis program might decide to do so.
Part IV. Evaluation Indices for Referrals.  
This part is similar to Part II, except that rates for evaluation and infection are not included.  
These instructions are similar to the analogous indices instruction for other ARPEs parts. 
Because the testing denominators are not included, the indices for evaluation and infection 
cannot be calculated. A greater potential difference lies in the interpretation of results, 
because the public health issues of referral counts are likely to be different than those for 
contact investigations or targeted testing. 
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The purpose of these evaluation indices is to give you a synopsis of the data flow in the 
referral section of the targeted-testing report. Each index reflects the average result of a 
specific process that is shown in the report. You could regard each index as a 
measurement of performance, but that interpretation generally is overly simple. Better 
that you regard the indices as general comparators (e.g., for comparison to national 
averages) and as clues for determining which activities need your closer scrutiny. (See 
page 99, How to interpret and use the ARPE results, for additional suggestions about 
interpreting the indices.) 
ARPEs differ from some other or previous U.S. tuberculosis program reports in that the 
indices are not adjusted for mitigating factors. For example, the treatment completion rate 
does not exclude patients who move from your jurisdiction after starting treatment, and 
therefore the treatment rate is diminished by the departure of these contacts. This is a 
controversial point, but you have the option of calculating indices with adjustments, for 
your purposes. In the national report, no adjustments are made. 
When ARPEs are entered into TIMS, the software program will calculate indices initially 
and then will recalculate them when you edit/update the data. The formulae that appear 
in the printed ARPE forms are the basis for those built into TIMS. If you use paper-copy 
forms, or computer-screen mock-up forms, you must remember to recalculate the indices 
after counts are edited/revised in the upper sections of the forms. If you use spreadsheet 
software programs for recording ARPE data, you can incorporate the formulae that are 
shown in the paper-copy ARPEs forms. 
ARPEs and TIMS 
The Tuberculosis Information Management System (TIMS) initially had a design 
requirement that it should be able to generate reports, such as ARPEs, for program 
evaluation. However, technical problems in the overall system ultimately precluded any 
capacity to generate reports. Even if data on individual contacts are saved in TIMS in the 
Client Module, the system cannot generate a contact report by itself. Generating a report 
would require exporting the data and designing a system to analyze them. 
However, the Evaluation Module in TIMS has programs for recording, storing, combining, 
and transmitting ARPEs. In general, you will find that these programs are straightforward 
if you already are fluent in both ARPEs and TIMS, but if you are not, you should consider 
contacting DTBE for user support. 
The TIMS version of ARPEs is an electronic facsimile of the paper forms. You enter 
aggregate counts of your data directly into the data fields. You can complete a report 
partially and save it for editing/updating later. When you save a report, TIMS initiates the 
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calculated indices if the report is new, and it recalculates the indices if you saved the 
report before and returned to edit it. TIMS assigns a unique number to a report the first 
time that you save it, but the program also prompts you to name the report. You should 
adopt a naming convention that makes sense to you and others who look at the report. For 
example, you could include your state, a particular district within your state, and the 
cohort year. 
In general, the more distinct reports that you save for your overall jurisdiction, the more 
flexibility you will get in return for the extra effort. At the extreme, you can save a 
separate contact report for each contact investigation. Later, you can combine any or all 
reports representing a given year. The disadvantage of saving a greater number of reports 
is the work burden and the administrative complexity. Approaches, needs, and 
capabilities differ from place to place, and you should use a team approach to determine a 
strategy for saving reports in your overall jurisdiction. One practical system is reporting 
separately for each county within a state. 
You can combine reports (a contact report with a contact report; a targeted-testing report 
with a targeted-testing report) from the same cohort year by selecting them and using the 
combine-report function. When combined, a new report is created, but the component 
reports remain. You will be prompted to name the combined report. You can edit the 
component reports, which automatically revises the combined report, but you cannot edit 
the combined report. The indices are calculated automatically in the combined report. The 
system does not set a limit on the number of reports that you can combine. 
You can submit ARPEs in TIMS to DTBE by using the same data transmission rules that 
apply to case surveillance data. When you submit a summary (i.e., combined) report, it 
“drags along” all of the component reports that you combined into it. For example, if you 
set up separate reports for each county in your state, and you add them together for the 
state report, all of the county reports remain distinct and transmit with the state report. 
Someone who is reviewing your state report also can view all the county reports. Again, 
you should name each report with reference to its origins so that an unfamiliar reader will 
be able to determine its source. 
Also, you can print the reports from TIMS at any point during their creation. You can use 
printed reports for discussions, for paper-copy files, and for submission. 
Reporting schedule: the preliminary and final reports 
The National Tuberculosis Controllers Association and DTBE negotiated the reporting 
dates for ARPEs, which represent a compromise between administrative constraints and 
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practical utility. The main administrative concerns are (1) the time required to gather and 
collate information from numerous sources and (2) the other administrative priorities, 
such as preparation of annual reports, which compete with ARPEs for staff time. The 
practical utility of the reports, however, decreases when they are delayed for 
administrative purposes. Therefore, DTBE and the National Tuberculosis Controllers 
Association recommend that you review information in the reports as soon as it becomes 
available to learn more about the issues in your tuberculosis control programs. 
Each of the reports has a 2-year reporting cycle. The cycle is based on the calendar year, 
and it is prolonged by the long duration of treatment for LTBI. During the first year in the 
life of a report, you delimit and document the cohort of patients who are included in the 
report, and by August 15 of the following year, you submit the “preliminary” report to 
DTBE through your routine reporting routes (e.g., the state epidemiologist or tuberculosis 
control official). Data on the number of patients who started treatment should be 
available to you by that time, but not on the final number of patients who completed. 
Therefore, you and your team have the option of deciding how much, if any, treatment 
completion results you enter in the preliminary report. 
You should submit the “final” report on August 15 of the year following the preliminary 
report, that is, in the second year after the cohort period. The final report should include 
all treatment completion results and the reasons that treatment was not completed, if your 
program is collecting these. If you were unable to submit a preliminary report before the  
final report comes due, then a single report, the final report, is sufficient. 
DTBE anticipates that jurisdictional programs can submit reports on schedule if reliable 
program systems are in place. DTBE will contact state or big city program officials if 
reports have not been received by August 15. The DTBE program consultants are 
authorized to work with jurisdictional program officials in negotiating alternative 
reporting schedules if deadlines cannot be met. 
How to Interpret and Use the ARPEs Results 
The reports that you generate in the ARPE systems are tools—they are only inert 
collections of numbers until you put them to work for you. How you do this will define 
their worth and simultaneously will strengthen your reporting systems, because after you 
apply the ARPE results to program evaluation, you will imagine better ways to collect the 
data and coordinate the reports. 
The counts 
The actual numbers of persons or events that are included in your system have several 
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implications. These numbers give a general indication of how much work was done or is 
underway. For example, listing a thousand contacts in a single year gives an idea of 
substantial work, and if a quarter of those contacts have latent infection, you have an 
overview of the commitment of resources required for completion of therapy. Knowing 
how much work has been done, you have an indirect indication of costs.  Monitoring the 
counts from year to year, you have an opportunity to note changes. Although the reports 
do not show the reasons for change, they notify you of potential problems that might 
require closer review. 
You should also look at the counts for assessing the statistical strength of your calculated 
indices, because small denominators or numerators can cause unstable estimates. For an 
example of a small denominator, if three of four contacts who started treatment for latent 
infection completed it, then the completion of therapy rate is 75%, but if only one less 
contact had completed treatment, the completion rate would have been 50%. For an 
example of a small numerator, if two contacts out of two hundred (total) has active 
tuberculosis disease diagnosed in contact investigations in one year, then the disease rate 
is 1%, but if four contacts out of two hundred have tuberculosis disease in the following 
year, then the disease rate is 2%—a doubling and yet possibly not a meaningful change. 
The counts are the starting point for calculating the indices, and relatively minor errors in 
the counts can generate misleading indices. Errors can creep into your reporting systems 
at each step along the way to completed reports. Although the reports themselves are very 
simple, the events and all the many steps in counting the events are very complex, which 
requires many detailed operations along the way to a completed report, and any 
unreliable details can have “ripple effects” that cause errors to propagate into your 
reports. The definitions for counting/including events can be misunderstood, events can 
be missed, and systematic bias can influence counts. Although ARPEs are not scientific 
tools, you should invest constant, steady effort in maintaining the accuracy of the reports. 
This effort includes training yourself and your colleagues about the reporting process and 
monitoring it regularly. 
Idiosyncratic details in the reporting definitions can affect the counts in frustrating ways. 
If you notice patterns that seem to be specific to your jurisdiction or problematic in any 
way, you should record the details as part of your operational information and refer back 
to these issues when interpreting the results and sharing the reports. 
The indices 
The calculated indices in the reports are not adjusted for any operational contingencies. 
For example, the calculation of completion of therapy does not deduct patients who move 
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out of your jurisdiction, even though you might not be able to influence treatment after the 
individuals leave. This serves to underscore the simplicity of the indices and the necessity 
of looking at many issues when interpreting them. 
The order of the indices in the reports reflect the data flow of the processes in contact 
investigations or targeted testing. Thus, they show the relative losses at each of the steps, 
for example, from contact evaluation through treatment initiations to completion. 
You can compare between the indices for two or more regions within a jurisdiction and for 
two or more jurisdictions. You also can compare the indices of a jurisdiction and the 
average for the United States. Although the comparisons provide perspective and should 
raise questions, they should not be overly interpreted as indicative of “performance.” The 
results in a report are reflective of the entire context that was the source for the data, and 
the context is unique to each site. For example, a treatment completion rate of 40% in one 
site does not imply worse performance than in a jurisdiction that achieved 60%, because 
the situations probably are completely different. 
You should take advantage of longitudinal (year-to-year) comparisons for your own 
programs. Even these comparisons need to be interpreted carefully, because changes in 
the indices reflect many influences beyond program performance. However, you should 
determine the likely causes of the changes, because the causes might require 
programmatic interventions. 
Each index is a simple average that reflects only the aggregate data and none of the details 
that are embedded in the aggregate data. As such, an index can either conceal extreme 
results or it can be deviated by extreme results. For example, if some contact investigations 
include far too many contacts and others include too few, the average contact-to-case ratio 
can appear unremarkable. This is why the reports are most informative when they are 
subdivided to the basic operational unit, usually the local health department. Even at the 
local health department, the averaging effect can obscure significant issues, and 
subdividing the data as much as possible improves utility. 
The indices are dependent on correct counts, especially when the numerators or 
denominators are small. Correct interpretation of the indices requires understanding the 
reliability of the source data, and the first step for investigating an index that appears out 
of range is verifying the data. 
Process and outcomes 
Most of the ARPE data items reflect processes and not outcomes. The long-term purpose 
101  
of both contact investigations and targeted-testing projects is prevention of tuberculosis 
cases, and this is the best outcome measurement for these activities, but neither report 
measures prevention or failure of prevention. The only major outcome that is measured in 
the reports is completion of treatment for latent infection, which at least is an indirect 
indication of cases prevented. 
Besides completion of therapy, finding tuberculosis cases is another true outcome that 
sometimes takes on greater consequence. Generally, cases are found as part of contact 
investigations; targeted-testing projects rarely focus on active case finding. On average, 1% 
of contacts to contagious tuberculosis have tuberculosis disease at the time of the contact 
investigation, but when transmission is intense or the contacts are more susceptible than 
usual, the rate of disease can be larger. 
Productivity and efficiency 
From an ARPEs perspective, productivity is indicated by the aggregate counts. For 
example, if you list 1,000 contacts and evaluate 900 of them, this implies a substantial 
investment of resources and a substantial amount of work that your team accomplished. 
This shows productivity. However, if the jurisdiction with 1,000 contacts only had two 
contact investigations, this raises concern over the efficiency of the activities. Even though 
you accomplished a large amount of work, the number of contacts per case far exceeded 
the typical number of 10 to 15 contacts for each contagious case. Listing, finding, and 
evaluating too many contacts is inefficient because many contacts who are unlikely to be 
infected are being included. (However, some scenarios have great numbers of contacts 
who are large odds of being infected, and the epidemiological evidence should guide the 
size of a contact investigation.) 
For another example, suppose you start a targeted-testing program that enrolls 1,500 
persons in its first year. Later, when you are reviewing the final data, you notice that only 
3 persons completed treatment for latent infection.  The end-point productivity was small, 
and the efficiency might be poor, but you have to analyze the step-by-step flow of data for 
the project before you commit to any conclusions. 
Sometimes productivity and efficiency are apposing goals that you have to balance as 
elements of program management. The measurements and principles of productivity and 
efficiency are undefined for tuberculosis program managements, but ARPEs provide you 
with a convenient descriptive overview for exploring these factors. 
Going back to the source and subsets of the data 
The broad overview that ARPEs give you is you starting point for more focused 
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exploration of the data and its sources. You should look to the results recorded in the 
ARPE system as the source of questions instead of answers. Finding the answers requires 
that you trace back the ARPE data to its sources, the daily operations of the programs in 
your jurisdiction. The sources vary from situation to situation. In one scenario, you might 
find answers by reviewing patient records in a clinic. In another, you might find answers 
in the flow sheets being used for contact investigations. Finally, you should coordinate 
with your colleagues, the persons who work in your programs. They have perspectives 
that go beyond ordinary paperwork. 
The reports are easier to trace back if the data are grouped into subsets by local 
jurisdiction or whatever administrative divisions fit the context of your area. For example, 
if you notice that (overall) a large fraction of tuberculosis patients with positive sputum-
smear results do not have contacts, you need to know where to search first for the 
underlying problems. If you have a separate report for each public health clinic, you can 
select the one with the largest fraction and begin your exploration there. 
ARPEs as a medium and a catalyst for communication 
Your reports are a tool for sharing. One of the advantages of a standard report for all U.S. 
jurisdictions is that program officials from quite different jurisdictions can discuss their 
ARPE results and have confidence that they are discussing the same types of results, 
measured with the same definitions, albeit under different conditions. 
You are encouraged to pay attention to the extremes in the ARPE results (e.g., a great 
completion-of-therapy rate or a poor evaluation rate) to initiate communications within 
your system and with your colleagues in other jurisdictions. Raising questions is a critical 
step toward finding answers. 
Providing feedback to program personnel 
The data for ARPEs start with the daily tuberculosis control activities of local programs. In 
some places, the personnel who carry out these activities also have to gather the data for 
ARPEs; in other places, separate administrative personnel gather these data. Regardless, 
you should provide each contributor to ARPEs with routine opportunities to discuss 
results and solve problems. When each worker understands how his or her contribution 
affects the reported results, then the reports are serving their best role. 
Limitations
ARPEs are the first steps for evaluating your key activities for tuberculosis prevention: 
contact investigations, targeted testing, and treatment of LTBI. The reports do not, 
however, provide comprehensive insight into any of these activities, which should be 
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evaluated in the context of local communities, tuberculosis programs, and epidemiology. 
In addition, the intrinsic limitations of the report have to be taken into account. 
Limitations of aggregate data 
Aggregate data tend to conceal extreme ratios because diverse results are likely to 
converge on an overall average result, and in the calculation of indices, the result is a
mean (i.e., simple average) instead of a median, which generally is a better representation 
of non-randomly distributed data. 
Limitations of the definitions 
For ARPEs to have broad utility, they have to be relatively simple, yet the realities that 
they encompass, that is, contact investigations and targeted-testing projects, are 
extensively complex, with layers of details that are distributed over extended time 
periods. Because of this tension between simplicity and complexity, the reports fail to 
capture nuances. The simplistic approach to reporting is most obvious in the definitions, 
which fail to reflect many subtleties. Another source of limitations in the definitions is the 
need for consistency with other data systems, especially the national tuberculosis case 
surveillance RVCT system. 
Inexact results for epidemiological study 
ARPEs were not designed for epidemiological study and analysis. The data definitions 
favor operational factors over epidemiological ones, and the data collection should not be 
subjected to the intensive quality control and review that is necessary for epidemiological 
studies, because this would be very inefficient.  However, you can use ARPEs as a starting 
point for focused investigations using more stringent definitions and data collection. 
Inaccuracies of reporting 
With the many complex activities covered by the reports, and the number of steps 
required for data collection, opportunities for misinterpretations are numerous. You 
should check any extreme results in ARPEs for potential misconceptions/errors before 
searching for programmatic problems. 
Inconsistency of reporting from site to site 
From jurisdiction to jurisdiction, and from site to site within a jurisdiction, inconsistencies 
of reporting are likely because of different contexts and different interpretations of 
instructions. The inconsistencies also can arise from intentional modifications of ARPEs 
instructions for meeting local needs. 
104  
Appendix 1 
Aggregate Reports for Tuberculosis Program Evaluation: 
Follow-up and Treatment for Contacts to Tuberculosis Cases 
Appendix 1 
Aggregate Reports for Tuberculosis Program Evaluation: 
Follow-up and Treatment for Contacts to Tuberculosis Cases 
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Appendix 2. Recommended minimal data for contact reporting, items listed in 
approximate order of appearance in report and logical sequence. See instructions for 
explanations of terms. 
For the jurisdiction 
Name of jurisdiction 
Cohort (calendar) year of the report 
Total number of tuberculosis cases for the cohort year 
Preliminary or final report 
User-assigned label for the report 
For the individual case 
Count year and count status (counted or not) 
Anatomical sites of tuberculosis disease 
Sputum smear results for acid-fast bacilli 
If smear results negative, results for sputum culture  
Whether or not any contacts were listed for the case  
For the individual contact 
Linkage to specific case counted by the jurisdiction 
ARPE category of the specific case 
Medical/diagnostic evaluation final determination (or lack thereof):  
Latent tuberculosis infection  
Active tuberculosis disease  
Both above conditions excluded  
Prior or coincidental tuberculosis  
Treatment started or not 
For the contact starting treatment 
For the infected contact 
Completion of treatment or not (number of doses, duration of treatment) 
For the contact not completing treatment 
Disposition: reasons treatment not completed 
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Appendix 3 
Aggregate Reports for Tuberculosis Program Evaluation: 
Appendix 3 
Aggregate Reports for Tuberculosis Program Evaluation: 
Targeted Testing and Treatment for Latent Tuberculosis Infections 
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Appendix 4. Recommended minimal data for targeted-testing reporting, items listed in 
approximate order of appearance in report and logical sequence. See instructions for 
explanations of terms. 
For the jurisdiction 
Name of jurisdiction 
Cohort (calendar) year of the report 
Preliminary or final report 
Types of testing activities for inclusion in report 
User-assigned label for the report 
For the individual patient 
Reason for inclusion  
Targeted testing project  
One-by-one (individual) enrollment  
No risks for infection; inclusion in administrative testing  
Medical/diagnostic evaluation final determination (or lack thereof):  
Latent tuberculosis infection  
Active tuberculosis disease  
Both above conditions excluded  
Prior tuberculosis and testing history  
For the infected patient 
Medical risks for progression of infection to disease 
Social/historical risks for latent infection 
Treatment recommended by guidelines and provider judgment (candidate) 
For the treatment candidate 
Treatment started or not 
For the patient starting treatment 
Completion of treatment or not (number of doses, duration of treatment) 
For the patient not completing treatment 
Disposition: reasons treatment not completed 
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